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Type II nephronophthisis (NPHP2) is an autosomal recessive renal cystic disorder 
characterized by mutations in the inversin gene.  Humans and mice with mutations in 
inversin have enlarged cystic kidneys.   Increased kidney size in NPHP2 may involve 
altered cell growth, apoptosis, electrolyte transport and fluid accumulation in the cysts.  
To test this hypothesis, histology and transcriptome analysis were performed on one-day 
old wild-type and inv/inv mice to uncover molecular pathways altered in the mutant mice.   
Histology of inv/inv mice kidneys showed dilated cystic tubules compared to wild type. 
Pathway analysis of transcriptome data showed that inversin exerts its effects on kidneys, 
at least in part, through the transcriptional regulation of genes implicated in 
inflammation, immune response, cellular metabolism, cell cycle and ion transport.   
Genes involved in inflammation or immune response were upregulated whereas the genes 
involved in cell cycle progression and ion transport were downregulated.  To validate the 
array findings from inv/inv mice kidneys, functional consequence of inversin loss on 
transepithelial ion transport was measured by electrophysiological techniques in shRNA 
mediated inversin-depleted renal cell type isolated from mouse cortical collecting duct 
(mCCD). Depletion of inversin decreased vasopressin-induced Na
+
 absorption, but did 
not alter Cl
-
 secretion in mCCD cells.  Addition of amiloride, a specific blocker of the 
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epithelial sodium channel (ENaC), abolished basal ion transport in both inversin 
knockdown and control cells indicating ENaC involvement. Loss of inversin decreased 
Na
+
 absorption and this effect, in part, was mediated by transcriptional and post-
translational regulation of ENaC mediators.  To better understand inversin function in 
renal cells, transcriptome analysis was performed in control and inversin-depleted mCCD 
cells.  Pathway analysis showed that inversin-depletion altered the genes represented in 
cell cycle, cellular assembly and organization, DNA replication, cell proliferation and ion 
transport in this isolated renal cell type.  In concordance with the array data from inv/inv 
mice kidneys, a decrease in the expression of cell cycle, ion transport and apoptotic genes 
were observed accompanied by an upregulation of genes implicated in inflammatory or 
immune response indicating a direct effect of inversin on renal cells.  Together, this study 
utilized a combination of transcriptome and functional analyses to unravel the role of 
inversin in renal cells.  These data demonstrate that loss of inversin can cause a delay in 
cell cycle progression with a decrease in cell proliferation and apoptosis which in turn 
can perturb the development of the renal tubule.  Also, a decrease in Na
+
 reabsorption 
together with differential regulation of other ion transporters can result in altered 
electrolyte transport contributing to cystogenesis, cyst growth, fluid accumulation and 
cyst expansion in NPHP2. 
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CHAPTER1: INTRODUCTION 
An overview of renal cystic diseases  
Renal cystic disease (RCD) represents a broad spectrum of diseases that share a 
common feature i.e., the development of multiple renal cysts. RCDs have multiple 
etiologies that include developmental, acquired, unilateral and inherited (Bisceglia et al, 
2006).  Developmental RCD exhibits multicystic dysplastic kidneys that are thought to 
arise from abnormal development of metanephros (Kalyoussef et al, 2006).  In acquired 
RCD the development of renal cysts is usually in patients who are on dialysis for end 
stage renal disease and is a consequence of prolonged uremia (Choyke, 2000).  Unilateral 
RCD is characterized by the development of multiple cysts with intervening normal 
parenchyma in one kidney, a benign entity which is not associated with malformation or 
cysts in other organs (Baradhi & Abuelo, 2012).  The inherited forms of RCD can be 
broadly classified into autosomal dominant and recessive forms.  The dominant forms 
include autosomal dominant polycystic kidney disease (type I and type II), medullary 
cystic kidney disease (type I and type II), von Hippel-lindau and tuberous sclerosis.  
Recessive forms of renal cystic disease include autosomal recessive polycystic kidney 
disease, Bardet-Biedl syndrome, Meckel-Gruber syndrome and nephronophthisis (Kim et 
al, 2016).  Characteristics and inheritance pattern of different forms of renal cystic 
diseases are shown in Table 1.  
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Table 1: Types of inherited renal cystic diseases in humans 
*ADPKD, autosomal dominant polycystic kidney disease; MCKD, medullary cystic 
kidney disease; TS, tuberous sclerosis; VHL, von Hippel-Lindau; ARPKD, autosomal 
recessive polycystic kidney disease; BBS, Bardet-Biedl syndrome; MKS, Meckel-Gruber 
syndrome; NPHP familial nephronophthisis  
 
a
(Torres et al, 2007) 
b
(Hateboer et al, 2001) 
c
(Bonsib, 2009) 
d
(Lonser et al, 2003) 
e
(Zerres et al, 1998) 
f
(Iannello et al, 2002) 
g
(Salonen & Norio, 1984) 
h
(Hildebrandt et al, 2009; Potter et al, 1980) 
 
Disease* Chromosome Gene Protein Frequency 
Autosomal dominant forms 
ADPKD type I 16p13.3 PKD1 Polycystin-1 
1:1000
a
 
ADPKD type II 4q22.1 PKD2 Polycystin-2 
MCKD type I 1q21 MUC1 Mucin Rare
b
 
MCKD type II 16p12.3 UMOD Uromodulin Rare
b
 
TS1 9q34.13 TSC1 Hamartin 
1:10,000
c
 
TS2 16p13.3 TSC2 Tuberin 
VHL 3p25-26 VHL pVHL 1:35,000
d
 
Autosomal recessive forms 
ARPKD 6p12.2 PKHD1 Fibrocystin/ 
polyductin 
1:20,000
e
 
BBS 20 genes are associated with this phenotype 1:13,500 to 
1:160, 000
f
 
MKS 11 genes are associated with this phenotype 1:13,000 to 
140,000
g
 
Familial NPHP 16 genes are associated with this phenotype   
(see Table 2) 
1:1 million
h
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Dominant forms of inherited renal cystic diseases 
Autosomal dominant polycystic kidney disease (ADPKD):  Autosomal dominant 
polycystic kidney disease is the most common monogenic disorder in the human 
population (Torres et al, 2007).  ADPKD is characterized by the progressive bilateral 
development of fluid-filled cysts derived from renal tubular epithelial cells (Chang & 
Ong, 2008; Torres et al, 2007).  Nearly 50% of patients with ADPKD reach end stage 
renal failure by 60 years of age (Bardet, 1995; Harris & Torres, 2009; Ravine et al, 1992).  
ADPKD is caused by mutations in two genes; PKD1 located on chromosome 16p13.3 
accounts for up to 85-90% of the cases and PKD2 located on chromosome 4q22 accounts 
for 10-15% of the cases (Peters & Breuning, 2001).  A small number of patients exhibit 
ADPKD with mutations at a loci distinct from PKD1 or PKD2 suggesting a yet 
unidentified gene (Ariza et al, 1997; Daoust et al, 1995; Turco et al, 1996).  PKD1 and 
PKD2 encode polycystin (PC-1and PC-2) proteins.   
PC-1 is a large membrane-bound >600 kDa glycoprotein (Hughes et al, 1995).  
PC-2 is a 110 kD membrane protein with 6 membrane-spanning domains with both N-
and the C-termini in the cytosol (Mochizuki et al, 1996).  PC-1 localizes to the epithelial 
cells of the distal nephron and vascular endothelial cells in fetal nephrons and normal 
adult kidney, ductal epithelia of liver and pancreas and in smooth muscle cells (Geng et 
al, 1997; Geng et al, 1996; Ibraghimov-Beskrovnaya et al, 1997; Ward et al, 1996). The 
subcellular localization of PC-1 includes endoplasmic reticulum, plasma membrane, and 
membranes of the primary cilium (Boletta et al, 2001; Newby et al, 2002).  PC-2 is 
expressed in cell membrane, pre-medial golgi and endoplasmic reticulum membranes and 
to the primary cilium (Cai et al, 1999; Koulen et al, 2002; Li et al, 2005; Luo et al, 2003; 
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Nauli et al, 2003; Yoder et al, 2002).  PC-1 has multiple binding partners and links the 
extracellular environment to the intracellular cytoskeleton (Retailleau & Duprat, 2014).  
PC-2 is a non-selective cation, Ca
++ 
permeable channel that interacts with PC-1 (Hanaoka 
et al, 2000; Mochizuki et al, 1996; Newby et al, 2002).  The PC-1/PC-2 complex is 
thought to participate in calcium-mediated signaling.  The cystic cells have been shown 
to have lower intracellular Ca
++
 that can affect multiple cellular processes contributing to 
cyst growth and expansion in ADPKD.   
 
Medullary cystic kidney disease (MCKD):  Two distinct types of autosomal 
dominant MCKD have been reported in humans.  MCKD type I caused by mutations in 
MUC1 gene localized to chromosome 1q21 that encodes mucin1 (Fuchshuber et al, 2001; 
Kirby et al, 2013).  MCKD type II is caused by mutations in UMOD gene located on 
chromosome 16p12 that encodes uromodulin/Tamm-Horsfall mucoprotein (Hateboer et 
al, 2001).  MCKD type I has a later onset of end stage renal failure at a median of age 62, 
whereas MCKD type II has an early onset at a median age 32 (Hildebrandt & Otto, 
2000).  MCKD is characterized by normal or shrunken kidneys and the cysts are 
restricted to renal medulla (Gardner, 1971; Goldman et al, 1966).  Renal histology shows 
tubular basement membrane disruption due to thickening and attenuation, distal tubular 
atrophy, tubulointerstitial infiltration and cyst development (Hildebrandt & Otto, 2000). 
 
Tuberous sclerosis (TS):  TS is an autosomal-dominantly inherited systemic 
malformation syndrome (Bonsib, 2009).  Mutations in tumor-suppressor genes, TSC1 and 
TSC2 mapped to chromosome 9q34 and 16p13 respectively, encode hamartin and tuberin 
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have been linked to this syndrome (van Slegtenhorst et al, 1997; Wienecke et al, 1995).  
TS is characterized by proliferative lesions in multiple organs, including kidneys.  
Approximately 50% of TS patients exhibit renal cysts and neoplasms (Kim et al, 2016).  
In 5% of TS2 patients, cystic kidneys are identical to ADPKD and this is referred to as 
contiguous gene syndrome which is a result of dual mutations of TSC2 and PKD1 genes 
which are in close proximity to each other on chromosome 16.   
 
von Hippel-Lindau (VHL) syndrome:  VHL, inherited as an autosomal dominant 
trait is linked to a mutation in VHL gene located on chromosome 3p25-26 (Latif et al, 
1993; Lonser et al, 2003; Seizinger et al, 1988).  Loss of the VHL gene causes 
uncontrolled cell growth, neoplastic transformation and neoangiogenesis resulting in a 
multisystem preneoplastic disorder.  People with VHL syndrome commonly develop 
cysts in the kidneys, pancreas and genital tract.  Renal cysts are present in approximately 
75% of the VHL patients (Truong et al, 2003).  VHL protein is also localized to the 
primary cilium analogous to other cystoproteins (Esteban et al, 2006; Lutz & Burk, 
2006).  
Recessive forms of inherited polycystic kidney disease 
Autosomal recessive polycystic kidney disease (ARPKD):  ARPKD often causes 
fetal or neonatal death due to bilateral enlargement of kidneys and is linked to PKHD1 
gene mapped to chromosome 6p (Zerres et al, 1994; Zerres et al, 1998). The disease is 
characterized by expansion and elongation of collecting ducts into multiple cysts (Adeva 
et al, 2006).  The PKHD1 gene encodes fibrocystin/polyductin which plays a role in 
terminal differentiation of collecting duct and biliary systems (Onuchic et al, 2002; Ward 
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et al, 2002).  Fibrocystin is a 447-kD membrane-associated receptor-like protein, 
expressed abundantly in fetal-kidney collecting ducts but is absent in the kidneys of 
ARPKD patients.  The protein has putative extracellular-matrix interacting domains and 
intracellular signaling sites (Ward et al, 2002).  Similar to other proteins implicated in 
renal cystic diseases, fibrocystin localizes to the primary cilium of renal epithelial cells 
(Menezes et al, 2004).   
 
Bardet-Biedl syndrome (BBS):  BBS is one of the rare autosomal recessive  
disorders that are characterized by heterogenous clinical manifestations including renal 
abnormalities (Bardet, 1995).  Renal anamolies in BBS patients are comprised of cystic 
tubules resulting in polyuria, polydipsia and anemia. Urine concentration defects are the 
major cause of morbidity and mortality in these patients (Putoux et al, 2012).  This 
disease has been mapped to twenty genes and all of them are involved in primary cilia 
function and disruption in any of the genes leads to cilia impairment (Khan et al, 2016). 
 
Meckel-Gruber syndrome (MKS):  MKS is a lethal autosomal recessive disorder 
that shows extensive heterogeneity. Mutations in 16 genes have been shown to be 
causative of MKS in humans (Barker et al, 2014).  The disease is characterized by 
bilateral renal dysplasia and cyst formation, among others (Chen, 2007).  MKS1 protein 
has been shown to localize to the ciliary transition zone and overlap with protein 
complexes of other ciliary proteins implicated in Joubert syndrome and nephronophthisis 
(Hildebrandt & Zhou, 2007; Sang et al, 2011).  MKS proteins are also found in the ciliary 
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membrane (Barker et al, 2014) and cells from patients with mutations in MKS genes 
exhibit ciliogenenesis defects (Dawe et al, 2009; Valente et al, 2010).   
 
Nephronophthisis (NPHP): NPHP is a group of autosomal recessive kidney 
disorders characterized by chronic tubulointerstitial nephritis that progresses to end stage 
renal disease in the first three decades of life (Fanconi et al, 1951; Hildebrandt & Zhou, 
2007).  The prevalence of NPHP is approximately 5% of all children with end stage renal 
disease (Warady et al, 1997). In NPHP, renal cysts emerge at the corticomedullary 
junctions characterized by tubular basement membrane anomalies, tubular atrophy and 
interstitial fibrosis (Waldherr et al, 1982; Zollinger et al, 1980).  In addition to cystic 
kidneys, some cases present extra-renal symptoms such as, cerebellar ataxia, congenital 
eye disease, polydactyly and skull abnormality.  These symptoms show overlap with 
other ciliopathies such as, Joubert, Senior-Lokun and Meckel-Gruber syndromes and with 
situs inversus in the case of type II nephronophthisis or NPHP2 (Baala et al, 2007).  
Positional cloning and candidate gene approaches together with high throughput 
mutational analysis have led to the identification of 16 causative genes responsible for 
manifestation of NPHP as shown in Table 2 (Halbritter et al, 2013; Salomon et al, 2009).    
Three clinical variants of NPHP have been described depending on the onset of end stage 
renal failure;  infantile, juvenile and adolescent forms (Hildebrandt & Zhou, 2007).  
The current research is focused on NPHP2, the infantile form of NPHP.  
Interestingly, NPHP2 is different from other forms of NPHP wherein the kidneys are 
enlarged and it has overlapping features with ADPKD, the predominant form of renal 
cystic disease (Table 3).  Much of the understanding of cyst growth and expansion come 
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from studies carried out on ADPKD.  In ADPKD patients and in murine models of 
ADPKD, increased cell proliferation, apoptosis, electrolyte secretion and fluid 
accumulation in kidneys have been well documented (Ebihara et al, 1995; Gattone et al, 
2002; Lee et al, 2004; Nakamura et al, 1993). The mechanism for cyst growth and 
expansion in NPHP2 remain unknown.   
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Table 2: Genetic heterogeneity and overlap of NPHP, Senior-Loken, Joubert and Meckel-
Gruber syndrome 
*NPHP, nephronophthisis; JBTS, Joubert syndrome type B; RP, Retinitis Pigmentosa; 
MKS, Meckel-Gruber syndrome; HT, hypertension;  PD, polydactyly;  RD, retinal 
dystrophy;  PCO, polycystic ovaries;  HM, hepatomegaly; VSD, ventricular septal defect; 
LF, liver fibrosis 
 
Gene Chromosome Locus/Protein 
Clinical 
manifestations* 
NPHP1 2q13 NPHP1 (nephrocystin-1) Juvenile NPHP, (mild 
JBTS, mild RP 
INVS 9q31 NPHP2 (inversin) Infantile NPHP, (RP, 
liver fibrosis, HT) 
NPHP3 3q22 NPHP3 (nephrocystin-3) Juvenile NPH (liver 
fibrosis, RP) 
NPHP4 1p36 NPHP4 (nephroretinin) Juvenile NPHP, RP 
IQCB1 3q21 NPHP5/IQ containing B1 Juvenile NPHP + 
severe RP 
CEP290 12q21 NPHP6/centrosomal protein 
290 kDa 
Juvenile NPHP + 
JBTS + severe RP 
GLIS2 16p NPHP7/GLIS family zinc 
finger 2 
Juvenile NPHP 
RGRIP1L 16q NPHP8/RPGRIP1-like Juvenile NPHP + 
JBTS (MKS)  
NEK8 17q11 NPHP9/nima-related kinase 8 Juvenile and infantile 
NPHP 
SDCCAG8 1q43 NPHP10/serologically defined 
colon cancer antigen 8 
Juvenile and 
adolescent NPHP, 
RD, PCO, HM 
TMEM67 8q24 NPHP11/meckelin All forms of NPHP, 
JBTS, MKS, VSD, 
RD 
TTC21B 2q24 NPHP12/tetratricopeptiderepe
at domain 21B 
Juvenile and infantile 
NPHP, HT, LF, 
chondrodysplasia 
WDR19 4p14 NPHP13/WD repeat domain 
19 
Juvenile and infantile 
NPHP, hepatic cysts, 
RD, PD 
ZNF423 16q12 NPHP14/zinc finger protein 14 NPHP and JBTS 
CEP164 11q23 NPHP15/centrosomal protein 
164 
NPHP 
ANKS6 9q22 ANKS6/ankyrin repeat and 
sterile alpha motif domain 
containing 6 
NPHP 
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Table 3: Kidneys in NPHP2 have overlapping features with NPH and ADPKD 
*ADPKD, autosomal dominant polycystic kidney disease; NPHP, nephronophthisis; 
NPHP2, type II NPHP 
  
Features Other forms of 
NPHP* 
NPHP2* ADPKD* 
Inheritance autosomal 
recessive 
autosomal  
recessive 
autosomal dominant 
 
Renal phenotype cystic cystic cystic 
 
Kidney size small enlarged enlarged 
 
Disease 
progression 
rapid-slow  rapid slow 
 
Kidney function 
decline 
renal failure renal failure renal failure 
 
Cyst origin cortico-medullary 
junction 
any tubular 
segment 
any tubular segment 
 
Cyst growth increased 
apoptosis 
apoptosis and/cell 
proliferation ? 
increased cell 
proliferation and 
apoptosis 
 
Cyst expansion  
(fluid 
accumulation) 
mechanism 
unknown 
mechanism 
unknown 
increased Cl
-
 secretion 
and water movement 
into the lumen 
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Type II nephronophthisis (NPHP2) 
Clinical features, mapping and molecular genetics of NPHP2:  Gagnadoux et 
al., in 1989 described the observations made in 7 children who presented with severe 
renal failure and acidosis associated with hypertension in the first months of life. A renal 
biopsy in all the patients showed similar features characterized by diffuse chronic 
tubulointerstitial nephritis and the presence of microcystic dilatation of proximal tubules 
and Bowman’s space. Progression of the renal disease was extremely rapid and all 
patients reached end-stage renal failure before the age of 2 years (Gagnadoux et al, 1989). 
Subsequently, a novel type of infantile nephronophthisis, later to be called 
NPHP2, was identified in an extended Bedouin family from Israel (Haider et al, 1998). 
The pedigree pattern was distinctly that of autosomal recessive inheritance with 
hyperechogenic kidneys, renal insufficiency, hypertension and hyperkalemia.  Affected 
individuals showed rapid deterioration of kidney function, leading to end stage renal 
failure within 3 years.  Histopathology of renal tissues showed variable findings, ranging 
from infantile polycystic kidneys to chronic tubulointerstitial nephritis, fibrosis and 
cortical microcysts. Linkage analysis excluded the familial juvenile nephronophthisis 
locus NPHP1 on 2q13 and the autosomal recessive polycystic kidney disease locus 
PKHD1 on 6p21.1-p12.  A homozygosity mapping strategy was employed to search for 
the locus causing NPHP2 and the disorder was mapped to chromosome 9q22-31 (Haider 
et al, 1998).  
 Inversin (INVS) located on chromosome 9q31 was identified as the gene mutated 
in NPHP2 with and without situs inversus in affected individuals (Otto et al, 2003).  
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Human NPHP2 gene (INVS) and mutations:  The human INVS gene spans over 
150 kb and is organized into 16 exons. There are 7 potential splice variants (Genbank, 
Ensemble).  The full length cDNA is 3.65 kb and encodes a protein containing 1065 
amino acids.  Nine distinct mutations in the INVS gene were detected in these patients, 
seven of which were truncating including four non-sense and three frameshift mutations. 
Two of the mutations were missense mutations resulting in non-conservative exchanges 
of amino acids.  In addition to renal cysts some of the patients had hypertension and 
cardiac ventricular septal defect (Otto et al, 2003).  Recently, additional nonsense 
mutations in the INVS gene have been reported in two severely affected fetuses (Oud et 
al, 2014).  Pathological examination showed enlarged cystic kidneys, liver fibrosis, 
oligohydraminos (deficiency of amniotic fluid) and skeletal abnormalities in the affected 
fetuses. 
Animal models of NPHP2  
Loss of inversin has been shown to recapitulate NPHP2 phenotype in Zebrafish, 
Xenopus, Drosophila and mouse animal models (Feiguin et al, 2001; Lienkamp et al, 
2010; Otto et al, 2003; Yokoyama et al, 1993).  The homozygous inv/inv mouse that 
carries an insertional mutation in inversin (Invs) gene was first discovered for its role 
during mammalian embryonic development.  The homozygous inv/inv mice exhibit a 
complex phenotype including, reversal of left-right polarity (situs inversus) and 
significant kidney pathology with dilated tubules and abnormal glomeruli and usually die 
within a week of birth (Yokoyama et al, 1993).  Subsequently it was shown that the 
mutated Invs gene in inv/inv mice is partially deleted between exons 4-12 (Morgan et al, 
1998).  Transgenic insertion of inversin rescued the mutant inv phenotype, both the situs 
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inversus and kidney pathology demonstrating that Invs is the causal gene in the inv/inv 
mutant mice (Mochizuki et al, 1998).  Consequently, it was shown that the renal cysts of 
inv/inv mice resemble NPHP2 which is caused by mutations in INVS gene in humans 
(Phillips et al, 2004).  An increase in kidney size and weight, expansion of Bowman’s 
capsule, cysts in the collecting ducts, and a diffuse cortical and medullary region with 
cysts are seen in inv/inv mice (Phillips et al, 2004).  In Zebrafish, loss of inversin resulted 
in development of pronephric cysts (Otto et al, 2003).  Inversin knockdown, when 
targeted to pronephros analgen in Xenopus, affects the differentiation of pronephros 
(Lienkamp et al, 2010).   
Mouse inversin 
Gene structure and domain architecture: Mouse Invs is located on chromosome 
4, spans over 150 kb and has 17 exons.  The full length cDNA is 5.5 kb and encodes 1062 
amino acids.  The N-terminal half of the protein contains 16 ankyrin repeat regions of 
approximately 33 amino acids which are involved in protein-protein interactions.  The C-
terminal region contains “infected cell polypeptide 4” (ICP4) domain flanked by two 
calmodulin binding IQ domains, two destruction boxes (D-box 1 and D-box 2) and CtBP 
(C-terminal binding site).  The C-terminus contains a ninein-homology domain required 
for ciliary targeting as shown in Figure 1 (Lienkamp et al, 2012; Shiba et al, 2009).  The 
N-terminal domain of mouse and human inversin are highly conserved whereas the C-
terminal end is poorly conserved.  In the N-terminal region, the amino acids 1-557 are 
96% and amino acids 558-604 are 100% conserved.  In contrast, the C-terminal domain 
corresponding to amino acids 605-1062 is only 62% conserved between mouse and 
human inversin (Morgan et al, 2002b).  
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Figure 1:  Domain architecture of mouse inversin.  N-terminal half of inversin 
contains 16 ankyrin repeat domains, destruction box (D-box1), SKI1 (subtilisin/kexin 
isozyme-1) and C-terminal half contains ICP4 domain (transcriptional regulator, 
immediate early, infected cell polypeptide 4, activator and repressor of transcription), two 
IQ domains (calmodulin-binding), NLS (nuclear localization signal), CtBP (C-terminal 
binding domain site), destruction Box (D-box 2) and ninein (ninein-homology domain 
required for ciliary targeting) (Lienkamp et al, 2012; Shiba et al, 2009).  
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Inversin expression and subcellular localization:  Inversin is detected as early as 
the 2-cell stage mouse embryo (Eley L et al., 2004).  It is expressed in 9+0 cilia of the 
node, renal tubules, pituitary gland, retina, liver, testis, and primary fibroblast cultures 
(Nurnberger et al, 2006). The expected size of mouse inversin is 117 kDa, but in 14.5 dpc 
mouse embryo, a 165 kDa inversin protein has been detected by immunoblot and that 
could be due to post-translational modifications.   Inversin has been shown to localize to 
the primary cilia in confluent cultures of MDCK-II (Madin- Darby Canine Kidney) cells 
(Morgan et al, 2002a).  Additional isoforms, 90, 116, 125 and 140 kDa of inversin have 
been identified; a membrane-associated 125 kDa protein that localizes to the cell-cell 
junctions and complexes with N-cadherin, 90- and 140 kDa proteins that localize to 
nuclear and perinuclear compartments.  The 90 kDa nuclear inversin forms a complex 
with β-catenin (Nurnberger et al, 2002).  The localization of inversin to the lateral cell 
membrane in polarized epithelial cells suggests a role for cell-cell signaling (Nurnberger 
et al, 2002).  
 
Inversin interacting proteins:  Inversin has been shown to interact with several 
proteins with varying function (Eley et al, 2004). The ankyrin repeat region and the lysine 
rich central domain spanning amino acids 558-604 of the inversin protein makes it 
amenable to interact with other proteins (Morgan et al, 2002b).  Inversin has two 
destruction box (D-box) motifs shown to interact with anaphase promoting complex 2 
(Apc2) suggesting its role in cell cycle (Morgan et al, 2002a).  Expression of inversin is 
dynamic throughout the cell cycle; in prophase inversin is expressed in centrosomes, in 
metaphase and anaphase it is expressed in spindle poles and in telophase it is expressed in 
16 
 
midbody, a region where microtubules overlap (Morgan et al, 2002a) and inversin has 
been shown to modulate the cortical actin network during mitosis (Werner et al, 2013).   
Inversin also interacts with Aurora A, a cell cycle kinase that promotes ciliary 
disassembly thereby modulating cell cycle control and proliferation (Mergen et al, 2013). 
Recently, inversin has been shown to interact with Akt and phosphorylation of inversin 
by Akt is required for proper spindle orientation during cell division (Suizu et al, 2016). 
Inversin contains 2 IQ (IQ-1 and IQ-2) domains that interact with calmodulin (Morgan et 
al, 2002b; Yasuhiko et al, 2001).  Studies by Yasuhiko et al, 2001 demonstrated that 
calmodulin binds to IQ2 domain in a calcium-dependent manner and is essential for 
inversin to randomize left-right asymmetry in Xenopus.  In proximal tubular cells, 
inversin is associated with nephrocystin-1 and with components of microtubule 
cytoskeleton (Nurnberger et al, 2004). 
Inversin in development 
Establishment of left-right asymmetry: Inversin is detected as early as the 2-cell 
stage mouse embryo (Eley et al, 2004)  and is a component of node monocilia (Watanabe 
et al, 2003).  Formation of the node occurs by E6.5 and is important for the establishment 
of left-right asymmetry in the mouse (Mercola, 2003).  A normal body axis and left-right 
asymmetry is established by a leftward flow of the extra-embryonic fluid at the ventral 
node (Nonaka et al, 1998). In NPHP2 and in inv/inv mice, inversin deficiency results in 
situs inversus indicating dysfunctional cilia (Otto et al, 2003; Tory et al, 2009).  In inv/inv 
mice the nodal cilia are motile but produce weak, turbulent leftward nodal flow (Okada et 
al, 1999).  The laterality defects in the embryos were corrected by an artificial leftward 
flow of fluid in the node indicating that inversin is essential for the generation of the 
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normal nodal flow (Watanabe et al, 2003).  However, the molecular mechanisms that 
underlie the role of inversin in modulating the nodal flow are unknown.   
 
Planar cell polarity in kidney development:  Planar cell polarity (PCP) is the 
coordinated orientation of tissue cells in a direction that is orthogonal to the apical/basal 
axis (Carroll & Das, 2011). Cell proliferation within the epithelial cell population is 
crucial for lengthening the tubule structures during kidney morphogenesis such that the 
tubules are increased in length and not in diameter.  This is accomplished by cell division 
and that occurs along the mitotic spindle within the plane or parallel to the proximal-
distal axis of the epithelium known as oriented cell division (OCD).  Renal epithelial 
cells have planar polarity i.e., the axis of elongation is vertical to the proximal-distal axis 
of the tubule and this directed cell movement is known as convergent extension (CE).   
One of the signaling pathways in the primary cilium that is required for the proper 
development of the kidneys and cell polarity is the highly conserved Wnt signaling 
pathway.  
Wnt signaling is triggered by the interaction of specific Wnt ligands and frizzled 
receptors.  Activation of canonical Wnt signaling results in β-catenin-dependent 
transcription of target genes. The non-canonical Wnt/planar cell polarity (Wnt/PCP) 
pathway is β-catenin-independent and is stimulated by Ca++ influx in response to the 
bending of cilia.  Wnt/PCP maintains the tissue architecture by controlling cell migration 
and function. Both OCD and CE processes are regulated by Wnt/PCP signaling 
associated with primary cilia (Goggolidou, 2014). During development, the primary cilia 
sense flow upon the start of urine production and fluid flow has been shown to increase 
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the expression and altered localization of inversin protein in ciliated tubular epithelial 
cells which results in the inhibition of canonical Wnt signaling and activation of non-
canonical Wnt signaling (Simons et al, 2005).   
Wnt/PCP signaling is activated by ligands such as Wnt11 and Wnt9b essential for 
normal development of kidney (Majumdar et al, 2003).  Attenuation of Wnt9b signaling 
or loss of Fat4, a PCP protein, results in abnormal polarity of renal epithelia, randomized 
orientation of cell division and abnormal elongation of renal tubules leading to renal cysts 
(Karner et al, 2009; Saburi et al, 2008).  Activation of Wnt signaling via Wnt ligands and 
frizzled receptors results in the recruitment of the cytoplasmic protein, disheveled (Dvl) 
to the membrane.  In Xenopus, loss of inversin prevents the recruitment of Dvl to the 
plasma membrane in response to frizzled 8 (a non-canonical Wnt receptor), indicating 
that inversin is required for this important step in the non-canonical Wnt signaling 
(Lienkamp et al, 2010).   However, the precise mechanism by which inversin recruits Dvl 
to the plasma membrane is not known.  Inversin has been shown to control dorsal to 
ventral but not the posterior to anterior cell migration in Xenopus pronephros (Lienkamp 
et al, 2010).   
Inversin role in cilia of mature renal epithelial cells 
Renal primary cilia are non-motile, microtubule-based sensory organelles 
required for the maintenance of normal kidney architecture.  (Praetorius & Spring, 2001; 
Praetorius & Spring, 2003).  These are hair-like structures that sense fluid flow across the 
renal epithelial surface.  Flow-induced bending of the primary cilia leads to Ca
++
 influx 
via PC-2.  This in turn can activate the Ca
++
-induced Ca
++
 release via ryanodine receptors 
in the endoplasmic reticulum and thereby increasing intracellular Ca
++
 levels (Nauli et al, 
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2003).  Intracellular Ca
++
 homeostasis and signaling is important for regulation of variety 
of cellular functions such as, cell proliferation and differentiation, volume regulation, ion 
and fluid transport. Inversin has been shown to localize to the ‘Inv compartment’, a 
distinctive region in the proximal segment of the ciliary shaft (Shiba et al, 2009).  Other 
NPHP proteins, NPHP3 and Nek8 (product of NPHP9) require inversin for their 
localization to the ‘Inv compartment’ (Shiba et al, 2010).  Primary cell cultures derived 
from normal and inv/inv mice did not show a significant change in the number and length 
of primary cilia (Shiba et al, 2005).  Although studies suggest that inversin is not required 
for ciliogenesis in vivo, a decrease in ciliogenesis was reported in inversin-depleted 
canine kidney MDCK cells in vitro (Mergen et al, 2013).  The localization of these 
proteins to primary cilia of renal epithelial cells supports the unifying theory of renal 
cystogenesis which states that “proteins which are mutated in renal cystic diseases in 
humans, mice or zebrafish are expressed in primary cilia, basal bodies or centrosomes” 
(Hildebrandt & Zhou, 2007).  Two mutant proteins other than inversin, polycystin-2 and 
kinesin family member 3a (Kif3a) that perturb the left-right asymmetry also localize to 
cilia of the renal epithelial cells (Nonaka et al, 1998; Pennekamp et al, 2002).  Thus the 
interaction and co-localization of inversin with NPHP-1 and β-tubulin to cilia and basal 
bodies provides a functional link between the pathogenesis of PKD, ciliary function and 
left-right axis asymmetry.   
Mechanism of cyst growth and expansion   
Renal cystic diseases are caused by mutations in several ciliary genes, including 
polycystin-1, -2, the nephrocystins, inversin, among others.  It is plausible that there 
could be a common mechanism linking the various renal cystic diseases to ciliary 
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function.  Studies done on ADPKD provide much of the understanding of development 
and growth of cysts.  The development and growth of cysts in ADPKD involves the 
proliferation of epithelial cells, changes in the extracellular matrix and fluid accumulation 
within the cyst cavity (Murcia et al, 1999; Sullivan et al, 1998a; Sullivan et al, 1998b).  
Studies have shown that renal cyst expansion in ADPKD is driven by anion secretion 
(Davidow et al, 1996; Grantham et al, 1995; Hanaoka et al, 1996; Mangoo-Karim et al, 
1995; Ye & Grantham, 1993).  Several lines of evidence suggest that the cystic fibrosis 
transmembrane conductance regulator (CFTR) Cl
-
 channel plays a major role in the 
accumulation of fluid and electrolytes within the lumen of ADPKD cysts.  First, 
immunocytochemical studies have demonstrated that CFTR is located in the apical 
membrane of ADPKD cysts (Brill et al, 1996).  Second, Cl
-
 currents with properties and 
regulation identical to those of CFTR have been identified using whole-cell patch clamp 
technique in ADPKD epithelial cells (Hanaoka et al, 1996).  Third, CFTR antisense 
oligonucleotides inhibited cAMP-stimulated fluid secretion by ADPKD epithelia 
(Davidow et al, 1996). Furthermore, inhibitor and electrophysiological studies have 
shown that CFTR is one of the major Cl
-
 channels responsible for fluid accumulation and 
renal cyst growth (Li et al, 2004).   
One of the common occurrences in late stage disease of ADPKD is the increased 
leakage of fluid from the cysts that has the ability to stimulate additional secretory 
activity in remaining renal epithelial cells.  Lysophosphatidic acid has been identified as 
one of the active component in the ADPKD cyst fluid that stimulates Cl
-
 secretion via 
CFTR in mouse principal cortical collecting duct cells (Blazer-Yost et al, 2011).  Taken 
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together, these studies suggest that Cl
-
 transport by CFTR is one of the key mechanisms 
that drive fluid accumulation in ADPKD cysts.   
Other electrolyte transporters may also play roles in the fluid accumulation.  For 
example, a decrease in epithelial sodium channel activity has been demonstrated in the 
principal cells of the collecting duct from the bpk (BALB/c polycystic kidney) autosomal 
recessive PKD (ARPKD) mice (Veizis et al, 2004) as well as in the cystic epithelium of 
PCK rats, an orthologous model of ARPKD with mutations in PKHD1 gene (Pavlov et al, 
2015).  Overall, these studies suggest that ion transport is altered in both ADPKD and 
ARPKD, the dominant and recessive forms of polycystic kidney diseases.   
Research presentation and summary 
Type II nephronophthisis (NPHP2) is a renal cystic disorder that occurs in infants 
and progresses rapidly leading to end stage renal disease by 2-5 years of age. It is caused 
by mutations in the Inversin (INVS) gene that encodes inversin protein.  NPHP2 has 
overlapping features with PKD and other forms of NPH (Table 3).  In human PKD and in 
murine models of PKD the mechanism of cyst growth and expansion is relatively well 
understood compared to NPHP2.  A better understanding of the role of inversin in renal 
function may provide insights into the mechanism of cyst growth and expansion in 
NPHP2.  The goal of this research was to uncover the molecular mechanisms through 
which inversin exerts its effect on kidneys.   The underlying hypothesis for this thesis 
work is that loss of inversin may lead to altered cell proliferation or apoptosis and fluid 
accumulation resulting in development and expansion of renal cysts leading to renal 
failure.  In an effort to address this hypothesis, transcriptome analysis was initially 
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performed to uncover the molecular pathways that are affected in the kidneys of inversin 
knockout mice.   
Chapter 2 describes the transcriptome analysis performed in the kidneys obtained 
from wild-type and inv/inv mice to delineate the mechanisms or pathways that are altered 
in the mutant mice.  Gene array analysis showed that inversin exerts its effect on kidneys, 
at least in part through transcriptional regulation of genes involved in inflammation or 
immune response, cellular metabolism, cell cycle, apoptosis and ion transport. 
Chapter 3 describes the functional consequences of inversin depletion on 
transepithelial ion transport in renal epithelial cells to validate the array findings from 
inv/inv mice kidneys.  Studies from both human and animal models of NPHP2 mutant 
alleles suggest a key role of inversin in early development, especially the renal system.  
The increased kidney size in NPHP2 could be due to fluid accumulation within the cyst 
cavity.  One mechanism by which inversin could exert its effect on renal function is by 
affecting electrolyte transport.  Inversin siRNA and shRNA were used to generate 
inversin knockdown in a mouse renal epithelial cell line with the characteristics of the 
principal cell type of the mouse cortical collecting duct (mCCD) cells.  
Electrophysiological techniques along with stimulators and inhibitors of specific ions (Cl
-
 
and Na
+
) were employed to investigate ion transport in control and inversin knockdown 
cells.  Interestingly, inversin knockdown in mCCD cells decreased Na
+
 transport but did 
not alter Cl
- 
transport as compared to control cells.  These results suggest that inversin 
may play a role in Na
+ 
reabsorption and its loss could lead to fluid accumulation 
contributing to the enlarged kidneys in NPHP2.   
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Chapter 4 describes the in vitro array findings in inversin-depleted versus control 
mCCD cells.  Some of the key molecular and cellular functions that were affected upon 
inversin loss include cell cycle, cellular assembly and organization, DNA replication, 
recombination and repair, cellular development, cell growth and proliferation and ion 
transport.  The control of organ size in multicellular organisms is mediated by the balance 
between cell proliferation, differentiation and apoptosis.  In concordance with the in vivo 
array data from inv/inv mice kidneys, a decrease in the expression of cell cycle and 
apoptotic genes were also seen in the in vitro array data from inversin-depleted mCCD 
cells.   The cyst formation in NPHP2 may involve altered proliferation and or apoptosis 
of epithelial cells.  Cell proliferation was evaluated in inversin-depleted and control cells.  
Loss of inversin decreased cell number as function of time in renal epithelial cells 
indicating a decreased cell proliferation that might affect kidney development.  Also, 
caspase 3/7 activity, a measure of apoptosis was also decreased as a function of time in 
inversin-depleted renal epithelial cells. 
Additionally, the gene array data from inversin-depleted renal epithelial cells in 
vitro was compared with the array data from inv/inv mice cystic kidneys.  The kidney is a 
complex organ comprised of multiple cell types and, in addition, circulating cells also 
infiltrate the renal tissue.  Since inv/inv mice is a global knockout model of inversin loss, 
the gene expression changes observed in inv/inv kidneys alone could be a direct effect of 
inversin on kidney cells per se or an indirect effect of infiltrating cells, or a combination 
of both.  The common gene expression changes observed in vitro in isolated renal cells 
that are recapitulated in vivo may provide insights into the direct effect of inversin loss in 
renal epithelial cells.  Interestingly, genes that were common between in vitro and in vivo 
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data sets represented apoptotic, ion transport, cell cycle, inflammatory pathways 
suggesting that these mechanisms may be a direct effect of inversin loss contributing to 
cyst growth and expansion in inv/inv kidneys. 
In summary, current research helped to further understand the role of inversin in 
renal epithelial cells.  There are several factors that contribute to cyst growth and 
expansion in NPHP2.  Loss of inversin may cause a delay in cell cycle progression and 
decrease apoptosis that can lead to perturbation in renal tubular geometry and may 
contribute to increased kidney size in NPHP2.  In addition, a decrease in Na
+
 
reabsorption together with differential regulation of other transporters can result in 
altered ion transport.  Also, activation of immune or inflammatory pathways may drive 
disease progression contributing to cystogenesis, cyst growth, fluid accumulation and 
cyst expansion in NPHP2.   
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CHAPTER 2: TRANSCRIPTOME ANALYSIS OF inv/inv MICE 
KIDNEYS 
Introduction 
The inv/inv mouse which carries an insertional mutation in inversin (Invs) gene 
was first discovered for its role during mammalian embryonic development (Yokoyama 
et al, 1993).  The mice exhibit a complex phenotype including, reversal of left-right 
polarity (situs inversus) and significant kidney pathology and typically die within a week 
of life (Yokoyama et al, 1993).  An increase in kidney size and weight, expansion of 
Bowman’s capsule, cysts in the collecting ducts, a diffuse cortical and medullary region 
with cysts are seen in inv/inv mice.  The renal cysts of inv/inv mice resemble NPHP2 
which is caused by mutations in INVS gene in humans (Haider et al, 1998; Phillips et al, 
2004).  
Defects in primary cilia cause a broad class of human genetic diseases called 
“ciliopathies” (Okada et al, 1999).  Mutations in ciliary proteins, including polycystin-1, -
2, and nephrocystins cause renal cystic diseases  (Kim et al, 2016). NPHP2 is different 
from other forms of NPH, because the kidney size is enlarged similar to polycystic 
kidney disease (PKD).  In PKD patients and in murine models of PKD, increased cell 
proliferation, apoptosis, electrolyte secretion and fluid accumulation in kidneys have been 
reported (Ebihara et al, 1995; Gattone et al, 2002; Husson et al, 2004; Lee et al, 2004; 
Nakamura et al, 1993).  However, the mechanism of renal cyst growth and expansion in 
NPHP2 is not well understood.   
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To better understand the molecular pathways through which loss of inversin 
affects the kidneys in inv/inv mice, transcriptome analyses was performed to determine 
gene expression changes in wild-type and inv/inv kidneys in one-day old mice. 
Previously, gene expression analysis of mouse embryonic fibroblasts from inv/inv mice 
demonstrated that inversin may play a role in fibroblast polarity and cell migration 
(Veland et al, 2013).  To date global gene expression changes in the inv/inv mice kidneys 
have not been reported. The inversin protein contains various functional domains 
(Lienkamp et al, 2012) that may be involved in several cellular processes (Chapter 1, 
Figure 1).  A study of gene expression changes may help in elucidating the 
mechanisms/pathways involved in enlarged cystic kidneys in inv/inv mice which may 
involve altered cell growth, apoptosis, electrolyte transport and fluid accumulation in the 
cysts.   
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Materials and methods 
Animals:  Lack of pigmentation in albino control mice (+/+) allowed for 
phenotypic distinction between homozygotes (inv/inv) with situs inversus and 
heterozygotes (inv/+) with intact left-right asymmetry (Mochizuki et al, 1998; Morgan et 
al, 1998; Phillips et al, 2004).  The inversin mouse model listed above was backcrossed 
onto the Balb/c background to form a unique animal model where the heterozygotes can 
be determined by their “dirty white” coats.  Newborn homozygous animals are identified 
as having situs inversus where the milk sacs that can be identified in newborns have an 
opposite orientation.  Kidneys from inv/inv and wild-type littermates were harvested from 
newborn mice at postpartum day 1 and flash frozen in liquid nitrogen and stored at -80
o
C 
until further use. At the time of organ harvest, the phenotype of the homozygous (inv/inv) 
animals was confirmed by the notably enlarged size of the kidneys compared to wild-type 
littermates. Rodent use and procedures conformed to the NIH guidelines and all animal 
experiments were approved by the Animal Care Committee of Indiana University-Purdue 
University, Indianapolis (IUPUI).  The Animal Care Division, School of Science, IUPUI, 
is a fully accredited AALAC facility.  
  
Histology:  Kidneys from one-day old wild-ype and inv/inv mice were collected 
and fixed in 10% neutral buffered formalin. Histological analysis was performed using 
hematoxylin-eosin staining of 4µm kidney sections followed by pathogenic evaluation 
under light microscope. 
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Total RNA isolation and real-time PCR:  Total RNA from each sample (kidneys 
from wild-type and inv/inv mice) was isolated using RNeasy mini kit isolation kit from 
Qiagen (Qiagen, Valencia, CA, USA) according to manufacturer’s protocol.   Briefly, the 
samples were homogenized in lysis buffer and the lysate was passed 5 times through a 
blunt 20-guage needle fitted to an RNase-free syringe. One volume of 70% ethanol was 
added to the sample and applied to RNeasy spin column.  The samples were centrifuged 
and the flow-through was discarded.  DNase treatment of the samples was performed 
using the RNase-free DNase reagent from Qiagen (Qiagen, Valencia, CA. USA) and the 
samples were eluted in RNase-free water.  RNA quality and quantity was examined by 
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. Santa Clara, CA, USA) according 
to manufacturer’s instructions.  First strand cDNA was synthesized from 1µg of total 
RNA with random hexamer primers using the SUPERSCRIPT II first strand synthesis kit 
(Invitrogen).  cDNA was used at a dilution of 1:50 and quantitative real-time PCR was 
performed using ABI Prism Sequence Detection System 5700 (Applied Biosystems).  
Fluorogenic primer/probe sets to detect mRNA encoding inversin and 18S RNA were 
obtained from Applied Biosystems as Assays on Demand
TM
 reagents (Table 4).  The 
mRNA levels of inversin (Mm00495002_m1), were normalized to 18S ribosomal RNA 
that served as an internal control.   
 
Microarray experiments: Total RNA was subjected to microarray gene 
expression analysis.  The RNA samples were processed by Asuragen Inc (Asuragen TX, 
USA) using Mouse Gene 230 2.0 arrays according to the company’s procedures.  All 
arrays that met the minimal recommended quality parameters as described in the 
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Affymetrix Data Analysis Fundamentals Guide (P/N 701190) were used for analyses. 
Expression signal was obtained from CEL files using MAS5 algorithm in the Affymetrix 
GCOS software.   
 
Bioinformatics and statistical analysis: Sequential steps were taken to identify 
differentially expressed genes (DEGs). First, the median signal of the entire dataset was 
applied as a threshold to identify genes ‘Present’ in comparing different groups in the 
study. Second, the fold changes of each ‘Present’ gene were computed from estimated 
median of comparing groups obtained in the first step. Genes with absolute fold changes 
equal or larger than 1.45 were kept for testing of statistical significance performed in the 
third step using a t-test implemented in R multtest (Resampling-based multiple 
hypothesis testing) package. False discovery rate (FDR) of each gene was estimated 
using Benjamini & Hochberg method implemented in multtest R package (Pollard et al, 
2005).   
The DEGs were defined as those genes with a p-value < 0.05 and FDR < 0.05. 
Principal component analysis (PCA) was performed using TIBCO Spotfire (TIBCO 
Spotfire, Boston, http://spotfire.tibco.com/).  Enrichment analyses of Gene Ontology 
(GO), KEGG and Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) were performed on the DEGs using the right tailed Fisher’s 
exact test.  
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Table 4: List of primer-probe sets for validation of array findings by real-time 
quantitative PCR 
Gene 
Symbol Gene Name Primer probe set 
Invs Inversin Mm00495002_m1 
Immune/inflammatory  
 Il34 interleukin 34 Mm01243248_m1 
Ccl9 chemokine (C-C motif) ligand 9 Mm00441262_g1 
Tnfrsf12a tumor necrosis factor receptor 
superfamily, member 12a 
Mm01302476_g1 
Il6ra interleukin 6 receptor alpha Mm00439653_m1 
Osmr oncostatin M receptor Mm01307326_m1 
C1qa complement component 1, q 
subcomponent, alpha polypeptide 
Mm00432142_m1 
Arg2 arginase 2 Mm00477592_m1 
Mrc1 mannose receptor, C type 1 Mm01329362_m1 
Sphk1 sphingosine kinase 1 Mm00448841_g1 
Cebpb CCAAT/enhancer binding protein 
(C/EBP), beta 
Mm00843434_S1 
Cebpd CCAAT/enhancer binding protein 
(C/EBP), delta 
Mm00786711_S1 
Nfil3 nuclear factor, interleukin 3 Mm00600292_S1 
Junb Jun-B oncogene Mm04243546_S1 
Cell cycle   
Anapc1 anaphase promoting complex subunit 1 Mm01336123_m1 
Ccnd2 cyclin D2 Mm00438070_m1 
Ccne1 cyclin E1 Mm01266311_m1 
Cdkn1a cyclin-dependent kinase inhibitor 1A 
(P21) 
Mm00432448_m1 
Skp2 S-phase kinase-associated protein 2 (p45) Mm00449925_m1 
Trp53 transformation related protein 53 Mm01731287_m1 
Gadd45b growth arrest and DNA-damage-
inducible 45 beta 
Mm00435123_m1 
Gadd45g growth arrest and DNA-damage-
inducible 45 gamma 
Mm01352550_g1 
Ion transport  
Bdkrb2 bradykinin receptor, beta 2 Mm00437788_S1 
Dbp D site albumin promoter binding protein Mm00439560_m1 
Edn1 endothelin 1 Mm00438656_m1 
Entpd1 ectonucleoside triphosphate 
diphosphohydrolase 1 
Mm00515447_m1 
Igf1 insulin-like growth factor 1 Mm00439560_m1 
31 
 
Statistics:  Data are represented as mean  SD.  Differences between two groups 
were analyzed by an unpaired Student’s t-test.  Differences were considered significant 
when P<0.05.  Line or bar graphs were generated using Microsoft Excel or Sigma Plot 
11.0 software. 
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Results 
Histology and inversin expression levels:  As shown in Figure 2A histological 
assessment showed cystic changes in 1-day old kidneys of inv/inv mice compared to 
wild-type littermates consistent with a previous report (Phillips et al, 2004). The 
expression level of inversin as determined by quantitative PCR was absent in the 
kidneys of inv/inv mice compared to wild type controls in 1-day old mice (Figure 2B). 
The RNA from wild type controls and inv/inv mice kidneys was subjected to 
transcriptome analysis. 
 
Gene expression profiles of wild type and inv/inv mice kidneys:  To gain insights 
into the mechanisms of cyst growth and expansion in inv/inv mice, transcriptome analysis 
was performed on 1-day old kidneys from inv/inv mice and wild-type littermates, 
n=5/group.  Mouse genome 430 2.0 array comprises of 45,101 probe sets corresponding 
to over 39,000 transcripts which in turn represent 20,670 genes. A summary of the gene 
signal data, detection calls and gene annotations for every gene on the chip was generated 
using Affymetrix MAS 5.0 algorithm (GCOS, v1.3).  Of the 20,670 genes present on the 
array, 10,572 (51%) genes were detected in the kidney samples from wild-type and 
inv/inv mouse kidneys. 
 
Identification of differentially expressed genes (DEGs):  For gene classifications 
and functional in silico analyses, the probe sets with low-grade annotations were 
eliminated to enable analysis of data sets with reliable annotations.  The DEGs were 
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identified as significant if the comparisons of wild-type and inv/inv gene expression met 
the criteria of (a) p<0.05, (b) the median signal for all the chips in either group was larger  
 
 
 
A 
 
 
 
 
 
 
 
 
 
B  
 
 
 
 
 
 
 
Figure 2:  Histology and inversin mRNA levels in kidneys from one-day old wild-
type and inv/inv mice.   (A) Hematoxylin and eosin stained 4µM sections of kidneys at 
10x magnification. Cystic tubules are seen in inv/inv mice kidneys (indicated in black 
arrow) (B) Inversin mRNA levels in wild-type and inv/inv mice kidneys.  Total RNA was 
isolated from wild-type and inv/inv mice kidneys and the inversin mRNA levels were 
assessed by quantitative real- time PCR.  The data was normalized to 18S RNA and 
expressed as fold change over wild-type littermates.  Values are mean  SD (n=5). 
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than 250, and (c) an absolute fold change ≥ 1.45.  Of 10,572 genes expressed in kidneys,  
733 genes (6.9%) were differentially expressed in inv/inv mice.  Unannotated genes were 
further removed from 733 DEGs that resulting in overall 646 annotated DEGs in inv/inv 
mice kidneys.   Out of 646 annotated DEGs, 274 genes were upregulated and 372 genes 
were downregulated in inv/inv mice compared to wild-type controls (Appendix, Table 31, 
upregulated genes; Table 32 downregulated genes).  Figure 3 shows the heat map of the 
hierarchial clustering analysis of the DEGs in inv/inv mice compared to wild-type 
controls.   
 
Functional classification of DEGs:  To ascertain common molecular functions, 
DEGs were classified into the categories of the GO (Gene Ontology) terms such as, 
Biological Process (BP), Cellular Component (CC) and Molecular Function (MF) using 
DAVID (the database for annotation, visualization and integrated discovery) 
bioinformatics tool (Huang da et al, 2009a; Huang da et al, 2009b) and Ingenuity 
Pathway Analysis (IPA).  Table 5 shows the significantly enriched GO-BP categories 
of DEGs identified by Fisher’s exact test (P < 0.05).  As shown in Figure 4, the various 
biological processes identified development, macromolecule biosynthetic process, 
metabolic process, sterol/cholesterol transport, catabolism and biosynthetic process 
(carboxylic acid, amino acid, nucleotides, glycoprotein), regulation of cell 
death/apoptosis, cellular metabolism, protein modification (phosphorylation, 
ubiquitination), kinase signaling, immune response, response to wounding, acute 
inflammatory response, cytoskeleton organization, regulation of transcription, cellular 
homeostasis such as ion homeostasis and regulation of blood pressure.  Thus, GO-BP 
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classification suggests that loss of inversin has an effect on various biological processes 
that may be involved in cyst formation, growth and expansion.  Involvement of some of 
these processes such as, cell growth and differentiation, immune response, apoptosis and 
ion homeostasis have also been reported in ADPKD (Song et al, 2009) indicating a 
potential common mechanism in cyst growth and expansion between NPHP2 and PKD. 
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Figure 3: Heat map of hierarchial clustering analysis of 646 differentially 
expressed genes.  Hierarchial clustering was based on genes differentiating the two 
groups wild-type and inv/inv kidneys at a significance levels of p<0.05, an absolute fold 
change ≥ 1.45 and the median signal intensity of 250.  The red color indicates genes that 
are upregulated (274) and the light blue color indicates genes that are downregulated 
(372) in inv/inv mice kidneys compared to controls.  Each column represents an 
individual kidney sample and each row represents a gene.  The heat map is condensed 
and all genes are not represented in the figure.  One branch of the dendrogram contained 
all the wild-type samples (indicated in green) and the other branch contained inv/inv 
kidney samples indicated in dark blue). 
 
 
 
 
 
 
37 
 
Table 5: GO biological process terms considered significantly enriched for the genes 
regulated in inv/inv mice kidneys compared to wild-type
a
 
GO Level Count P-value 
Development 
 
 
in utero embryonic development 23 1.94E-04 
embryonic development ending in birth or egg hatching 28 2.26E-03 
chordate embryonic development 27 3.96E-03 
blood vessel development 18 5.81E-03 
vasculature development 18 7.35E-03 
blood vessel morphogenesis 15 1.03E-02 
embryonic organ development 15 4.60E-02 
placenta development 8 3.34E-02 
embryonic placenta development 7 1.99E-02 
Cellular metabolism 
 
 
carboxylic acid catabolic process 11 5.29E-04 
organic acid catabolic process 11 5.29E-04 
cellular amino acid catabolic process 9 5.54E-04 
phosphagen metabolic process 3 2.31E-02 
glycoprotein metabolic process 11 3.48E-02 
regulation of phosphate metabolic process 18 3.77E-02 
regulation of phosphorus metabolic process 18 3.77E-02 
positive regulation of macromolecule metabolic process 35 9.29E-03 
amine catabolic process 9 1.92E-03 
Inflammatory/immune response   
response to wounding 25 1.28E-03 
acute inflammatory response 9 7.52E-03 
wound healing 10 1.72E-02 
inflammatory response 16 1.35E-02 
acute inflammatory response 9 7.52E-03 
adaptive immune response 9 9.31E-03 
Transport 
  transmembrane transport 26 2.09E-02 
ion transport 35 4.31E-02 
Circulation 
  blood circulation 10 1.63E-02 
circulatory system process 10 1.63E-02 
Blood pressure 
  regulation of blood pressure 7 2.64E-02 
Apoptosis   
negative regulation of apoptosis 18 4.73E-03 
negative regulation of programmed cell death 18 5.81E-03 
negative regulation of cell death 18 6.05E-03 
regulation of apoptosis 31 1.25E-02 
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a
Genes significantly regulated were classified by GO biological process terms (GO level 
FAT) using DAVID 2010 online software.  GO terms with values of P<0.05 (Fisher’s 
exact test) are presented.  Count represents the number of genes involved in each GO 
term. 
Table 5 continued   
regulation of cell death 31 1.58E-02 
Protein modification   
protein modification by small protein conjugation 9 6.48E-03 
protein ubiquitination 8 8.29E-03 
protein polyubiquitination 4 2.04E-02 
protein modification by small protein conjugation or removal 9 3.01E-02 
biopolymer glycosylation 8 4.11E-02 
protein amino acid glycosylation 8 4.11E-02 
Glycosylation 8 4.11E-02 
Biosynthetic process   
phosphagen biosynthetic process 3 3.62E-03 
cellular amino acid biosynthetic process 6 1.85E-02 
carboxylic acid biosynthetic process 11 2.72E-02 
organic acid biosynthetic process 11 2.72E-02 
positive regulation of cellular biosynthetic process 31 1.22E-02 
positive regulation of macromolecule biosynthetic process 29 2.13E-02 
positive regulation of biosynthetic process 32 7.94E-03 
RNA biosynthetic process 10 3.37E-02 
NAD biosynthetic process 3 3.00E-02 
nitrogen compound biosynthetic process 23 1.05E-03 
nucleotide biosynthetic process 12 4.37E-02 
amine biosynthetic process 8 1.41E-02 
Molecular function   
negative regulation of molecular function 15 2.26E-04 
negative regulation of kinase activity 9 3.72E-04 
negative regulation of protein kinase activity 9 3.72E-04 
negative regulation of transferase activity 9 4.87E-04 
negative regulation of catalytic activity 12 8.33E-04 
regulation of phosphorylation 18 2.78E-02 
inactivation of MAPK activity 3 3.00E-02 
regulation of protein kinase activity 13 3.17E-02 
regulation of kinase activity 13 3.90E-02 
regulation of transferase activity 13 4.89E-02 
Cell Organization   
positive regulation of cell-substrate adhesion 5 1.40E-02 
positive regulation of cellular component organization 10 2.82E-02 
Cell growth   
regulation of cell growth 8 4.32E-02 
transcription from RNA polymerase II promoter 7 4.56E-02 
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Figure 4:  Overrepresented GO biological processes altered in inv/inv kidneys.  
Fisher’s exact test was used to identify significant enrichment for pathway annotations. 
Pie chart showing the number of genes representing different categories altered in inv/inv 
mice kidneys compared to wild-type controls.   
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Table 6 shows the DEGs from inv/inv mice kidneys that were subjected to GO 
cellular component (CC) to obtain information about sub-cellular localization.  The 
DEGs classified into the categories of cell-cell junction, plasma membrane, cytoplasm 
and interstitial matrix.  These results suggest that loss of inversin may influence the 
expression of genes localized to various regions of the cell as well as in the interstitial 
matrix and hence may affect cell-cell communication and membrane integrity consistent 
with its localization to the cell-cell junction (Nurnberger et al, 2002) .  
Finally, the DEGs from inv/inv mice kidneys were classified into the categories of 
GO molecular function (MF) (Table 7).  The various categories in molecular functions 
that were significantly altered include, binding (cofactor, coenzyme, vitamin B6, 
nucleotide, nucleoside, ATP, polysachharide, glycosaminoglycan) and activity (MAP 
kinase, protein kinase inhibitor, tyrosine/serine/threonine phosphatase, sodium symporter, 
cyclin-dependent kinase regulator).  These results indicate that loss of inversin may affect 
various molecular functions affecting ion transport, cell cycle progression, cell 
proliferation and apoptosis.  The DEGs were further subjected to molecular and 
functional analysis in IPA.  The key functional categories altered were cellular 
development, cell growth and proliferation, cell death and survival, cell cycle, molecular 
transport and signaling pathways involved in inflammation/immune response consistent 
with GO classification. 
 
 
 
 
 
41 
 
Table 6: GO cellular component terms considered significantly enriched for the genes 
regulated in inv/inv mice kidneys compared to wild-type
a
 
GO level GO Term Count P value 
GO-CC-ALL interstitial matrix 4 1.04E-02 
GO-CC-ALL cytosol 29 1.87E-02 
GO-CC-ALL plasma membrane 117 2.17E-02 
GO-CC-ALL plasma membrane part 70 2.62E-02 
GO-CC-ALL cell junction 25 2.75E-02 
GO-CC-ALL cyclin-dependent protein kinase 
holoenzyme complex 
3 3.46E-02 
GO-CC-ALL cytoplasm 255 5.71E-04 
GO-CC-ALL cytoplasmic part 159 4.47E-02 
GO-CC-ALL cell-cell junction 13 1.39E-02 
a
Genes significantly regulated were classified by GO cellular component (GO level ALL) 
using DAVID 2010 online software.  GO terms with values of P<0.05 (Fisher’s exact 
test) are presented.  Count represents the number of genes involved in each GO term. 
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Table 7: GO molecular function terms considered significantly enriched for the genes 
regulated in inv/inv mice kidneys compared to wild-type
a
 
GO Level GO Term Count P value 
GO-MF-FAT cofactor binding 28 2.88E-08 
GO-MF-FAT coenzyme binding 18 5.03E-05 
GO-MF-FAT FAD binding 10 8.39E-04 
GO-MF-FAT vitamin binding 14 3.40E-04 
GO-MF-FAT vitamin B6 binding 9 5.66E-04 
GO-MF-FAT pyridoxal phosphate binding 9 5.66E-04 
GO-MF-FAT transferase activity,  6 4.91E-03 
GO-MF-FAT protein dimerization activity 24 2.21E-03 
GO-MF-FAT identical protein binding 19 1.46E-02 
GO-MF-FAT protein homodimerization activity 14 1.95E-02 
GO-MF-FAT MAP kinase phosphatase activity 4 7.58E-03 
GO-MF-FAT MAP kinase tyrosine/serine/threonine 
phosphatase activity 
4 7.58E-03 
GO-MF-FAT protein tyrosine phosphatase activity 10 9.33E-03 
GO-MF-FAT tyrosine/serine/threonine phosphatase activity 6 1.03E-02 
GO-MF-FAT phosphoprotein phosphatase activity 11 4.30E-02 
GO-MF-FAT adenyl nucleotide binding 74 4.61E-03 
GO-MF-FAT purine nucleoside binding 74 5.77E-03 
GO-MF-FAT nucleoside binding 74 6.75E-03 
GO-MF-FAT nucleotide binding 96 1.47E-02 
GO-MF-FAT purine nucleotide binding 84 1.48E-02 
GO-MF-FAT ATP binding 64 4.32E-02 
GO-MF-FAT protein serine/threonine kinase inhibitor activity 4 3.13E-03 
GO-MF-FAT cyclin-dependent protein kinase regulator activity 4 1.45E-02 
GO-MF-FAT protein kinase regulator activity 7 1.74E-02 
GO-MF-FAT protein kinase inhibitor activity 4 3.19E-02 
GO-MF-FAT kinase inhibitor activity 4 4.09E-02 
GO-MF-FAT kinase regulator activity 7 4.37E-02 
GO-MF-FAT peptide receptor activity 9 4.07E-02 
GO-MF-FAT peptide receptor activity, G-protein coupled 9 4.07E-02 
GO-MF-FAT carboxylic acid binding 8 3.04E-02 
GO-MF-FAT amine binding 6 6.36E-02 
GO-MF-FAT organic acid:sodium symporter activity 4 4.09E-02 
GO-MF-FAT symporter activity 10 4.41E-02 
GO-MF-FAT polysaccharide binding 10 3.74E-02 
GO-MF-FAT pattern binding 10 3.74E-02 
GO-MF-FAT glycosaminoglycan binding 9 4.86E-02 
a
Genes significantly regulated were classified by GO molecular function terms (GO level 
FAT) using DAVID 2010 online software.  GO terms with values of P<0.05 (Fisher’s 
exact test) are presented.  Count represents the number of genes involved in each GO 
term. 
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Pathway Analysis of DEGs:  To better understand the expression patterns of 
functionally related proteins, the genes altered in inv/inv mice kidneys were subjected to 
Ingenuity Pathway Analysis (IPA).  As shown in Figure 5, the top canonical 
pathways that were affected in inv/inv kidneys included upregulation of Stat3 pathway, 
Il-6 and Il-9 signaling, acute phase response signaling, complement system, pancreatic 
adenocarcinoma signaling, NFB signaling, cell cycle (G1/S checkpoint regulation), cell 
cycle regulation by BTG family of antiproliferative proteins, PTEN signaling and the 
coagulation system.  These results suggest that loss of inversin may increase cytokine 
signaling, acute phase response due to inflammation and also affect cell cycle progression 
in inv/inv mice kidneys.   
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Figure 5:  Canonical pathways altered in inv/inv mice kidneys analyzed using 
IPA.  The numbers to the right of each bar represents the ratio of genes regulated in 
inv/inv mice kidneys to the total number of genes implicated in the pathways indicated.  
The line graph that runs across each bar represents the threshold set for each pathway.  
Red indicates the pathways that are upregulated and blue indicates pathways that are 
downregulated. 
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Activation of immune/inflammatory pathways in inv/inv mice kidneys: Several 
genes implicated in immune/inflammatory responses were upregulated in inv/inv mice 
kidneys compared to wild-type controls (Table 8) and validation of select genes in this 
category is shown in Figure 6.  The upregulation of monocyte/macrophage 
chemoattractants, chemokine C-X-C motif like (Cxcl1) and chemokine C-C motif ligand 
(Ccl9) is consistent with recruitment of monocytes/macrophages to the affected inv/inv 
kidneys. CD163, a transmembrane protein exclusively expressed on macrophages 
(Akahori et al, 2015) was upregulated in inv/inv mice kidneys.  Tumor necrosis factor 
receptor superfamily member, Tnfrsf12a/Tweak receptor that can be activated by TLR4-
mediated innate immune response (Gonzalez-Guerrero et al, 2016) was also upregulated 
in inv/inv kidneys.  Interestingly, among the overexpressed transcripts in inv/inv mice 
kidneys, were a subset of genes implicated in acute phase reactants such as Ambp (alphaI 
macroglobulin), SerpinE1 (serine peptidase inhibitor clade E), oncostatin M receptor 
(Osmr), interleukin receptor (Ilra).  Also, the genes representing the complement system 
(complement component C1q1,-2, -3 and the receptor C5ar1) which links the innate and 
the adaptive immune pathways, and is also known to play a role in the activation of 
monocyte/macrophages, were upregulated in inv/inv mice kidneys.  Additionally, 
transcription factors implicated in immune/inflammatory responses such as Jun-B 
oncogene (JunB), Cebpb (CCAAT/enhancer binding protein, beta), Cebpd 
(CCAAT/enhancer binding protein, delta), nuclear factor interleukin (Nfil3) and forkhead 
box P1 (Foxp1) were also upregulated in inv/inv kidneys.   
Genes associated with JAK-STAT signaling pathway and its downstream targets 
such as Pim1, SOCS 3 and Spred2 were upregulated in the inv/inv mice kidneys (Table 
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8).  Interestingly, Map4k3, an upstream regulator of Nfkb2 and Nfkbiz, induced by T cell 
antigen receptor was also upregulated in inv/inv mice kidneys. Certain upstream 
regulators of Osmr, the matricellular proteins, such as, connective tissue growth factor 
(Ctgf) and tenascin C (Tnc) and downstream signaling molecule Stat3 that can contribute 
to fibrosis were also upregulated in inv/inv kidneys suggesting that loss of inversin can 
result in fibrosis (Sarkozi et al, 2012; Sarkozi et al, 2011) via Ctgf/Osmr/Stat3 signaling. 
Additionally, the voltage-gated potassium channel Kcnc1/Kv1.3 expressed on T 
lymphocytes was also upregulated in inv/inv kidneys. K
+
 channels are expressed on T 
lymphocytes and overexpression of Kcnc1 on lymphocytes can contribute to progression 
of chronic kidney disease by promoting interstitial fibrosis (Kazama, 2015).  Hypoxia-
inducible factor 3a (Hif3a) and its target Serpine1 and cysteine-rich protein 61 (Cyr61), 
an inducer of pro-inflammatory cytokines such as IL-6 were also upregulated in inv/inv 
mice kidneys.  Overall, the observation of increased expression of immune/inflammatory 
genes in inv/inv kidneys is consistent with earlier reports in models of ARPKD  (Mrug et 
al, 2008) and ADPKD (Karihaloo et al, 2011; Swenson-Fields et al, 2013) and could 
represent a common mechanism in cyst growth and expansion or tissue repair in these 
cystic disorders.  
 
 
 
 
 
 
47 
 
Table 8: Immune/inflammatory genes upregulated in inv/inv mice kidneys 
Gene 
ID 
Gene 
Symbol Protein Name  
Fold 
change 
(inv
-/-
/Wild-
type) P-value 
Cytokine-receptor interaction     
76527 Il34 interleukin 34 1.5 7.00E-04 
14825 Cxcl1 chemokine (C-X-C motif) ligand 1 1.7 1.00E-04 
20308 Ccl9 chemokine (C-C motif) ligand 9 2.4 5.10E-03 
16194 Il6ra interleukin 6 receptor, alpha 2.6 0.00E+00 
16177 Il1r1 interleukin 1 receptor, type I 1.7 7.80E-03 
18414 Osmr oncostatin M receptor 3.8 0.00E+00 
252837 Ackr4 chemokine (C-C motif) receptor-like 1 1.6 5.80E-03 
27279 Tnfrsf12a tumor necrosis factor receptor superfamily 
12a 
2.3 9.00E-04 
Complement System      
12259 C1qa complement component 1q, alpha 
polypeptide 
1.7 0.00E+00 
12260 C1qb complement component 1q, beta polypeptide 1.7 0.00E+00 
12262 C1qc complement component 1q, C chain 1.6 0.00E+00 
12273 C5ar1 complement component 5a receptor 1 1.6 2.40E-03 
Macrophage-associated markers/phagocytosis    
11847 Arg2 arginase type II 2.1 2.30E-03 
93671 Cd163 CD163 antigen 2.2 7.00E-04 
11303 Abca1 ATP-binding cassette, sub-family A (ABC1) 1.9 1.60E-03 
13025 Ctla2b cytotoxic T lymphocyte-associated protein 2 
beta 
1.6 4.30E-03 
108664 Atp6v1h ATPase, H+ transporting, lysosomal V1 
subunit H 
1.9 6.00E-04 
14131 Fcgr3 Fc receptor, IgG, low affinity III 1.5 9.10E-03 
17533 Mrc1 mannose receptor, C type 1 1.6 3.90E-03 
20288 Msr1 macrophage scavenger receptor 1 1.6 5.70E-03 
93671 Cd163 CD163 antigen 2.2 7.00E-04 
Fcγr-mediated phagocytosis    
18806 Pld2 phospholipase D2 1.5 0.00E+00 
20698 Sphk1 sphingosine kinase 1 1.9 0.00E+00 
14131 Fcgr3 Fc receptor, IgG, low affinity III 1.5 9.10E-03 
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Table 8 continued   
Acute phase response      
11699 Ambp alpha 1 microglobulin/bikunin 2.4 1.02E-02 
18787 Serpine1 serine (or cysteine) peptidase inhibitor, clade 
E, 1 
5.9 0.00E+00 
Transcription factors in immune/inflammatory response    
16477 Junb Jun-B oncogene 2.1 0.00E+00 
12609 Cebpd CCAAT/enhancer binding protein (C/EBP), 
delta 
2.9 1.30E-03 
12608 Cebpb CCAAT/enhancer binding protein (C/EBP), 
beta 
2.6 0.00E+00 
18030 Nfil3 nuclear factor, interleukin 3 1.6 4.10E-03 
108655 Foxp1 forkhead box P1 1.5 1.70E-03 
Jak/Stat and Nfkb signaling pathways    
13649 Egfr epidermal growth factor receptor 1.7 2.00E-04 
14254 Flt1 FMS-like tyrosine kinase 1 1.5 7.00E-04 
18414 Osmr oncostatin M receptor 3.8 0.00E+00 
16337 Insr insulin receptor 1.5 9.00E-04 
338372 Map3k9 mitogen-activated protein kinase kinase 
kinase 9 
1.6 3.00E-04 
18712 Pim1 proviral integration site 1 2.1 1.00E-04 
12702 Socs3 suppressor of cytokine signaling 3 2.0 0.00E+00 
20848 Stat3 signal transducer and activator of 
transcription 3 
2.0 0.00E+00 
114716 Spred2 sprouty-related, EVH1 domain containing 2 2.0 3.20E-03 
18034 Nfkb2 nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 2, p49/p100 
2.2 4.00E-04 
80859 Nfkbiz nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, zeta 
1.9 0.00E+00 
225028 Map4k3 mitogen-activated protein kinase kinase 
kinase kinase 3 
1.6 8.00E-04 
Fibrosis      
14219 Ctgf connective tissue growth factor 2.8 0.00E+00 
21923 Tnc tenascin C 1.7 2.70E-03 
14268 Fn1 fibronectin 1 1.5 5.00E-04 
20361 Sema7a semaphorin 7A 1.6 6.80E-03 
16502 Kcnc1 potassium voltage gated channel, Shaw-
related subfamily, member 1 
2.2 4.50E-03 
13653 Egr1 early growth response 1 2.0 0.00E+00 
16007 Cyr61 cysteine rich protein 61 2.3 0.00E+00 
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Figure 6:  Validation of select immune/inflammatory genes from in vivo array 
analysis. Select genes from in vivo array analysis involved in inflammation/immune 
response were validated in one-day old wild-type and inv/inv mice kidneys.  Total RNA 
was isolated and mRNA levels were assessed by quantitative real-time PCR.  The data 
was normalized to 18S RNA and expressed as fold change over wild-type littermates.  
Values are mean  SEM (n=5); *p<0.05 vs wild-type. 
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Decreased expression of cell cycle genes in inv/inv mice kidneys:  Some of the 
key cell cycle genes that were altered in inv/inv mice kidneys compared to the wild-type 
controls are shown in Table 9.   Select genes implicated in cell cycle validated by real-
time PCR are shown in Figure 7.   Genes involved in interphase, and different stages of 
cell cycle (G0/G1, G1/S and G2/M phase) progression such as, anaphase promoting 
complex 1 (Anapc1), cyclin D2 (Ccnd2), cyclin E (Ccne1), S-phase kinase protein (Skp2) 
and transformation related protein (Trp53), cell cycle and neuronal differentiation 
(Cend1) were downregulated.  Conversely, the negative regulators of cell cycle such as 
cyclin-dependent kinase inhibitor (Cdkn1a), growth arrest and DNA damage-inducible 
(Gadd45b) and Gadd45g were upregulated in inv/inv mice kidneys (Figure 7).  
In addition, tubulin polyglutamylase complex subunit (Tpgs2) an enzyme 
involved in polyglutamylation of tubulin; gamma glutamylcyclotransferase (Ggct), in cell 
cycle arrest at G0/G1 phase (Lin et al, 2015); Bzw1 (Basic leucine zipper and 2 
domains2), a conserved regulatory factor for transcription control of histone H4 gene at 
G1/S transition (Yu et al, 2006) were downregulated in inv/inv mice kidneys (Table 9).  
Zinc is an indispensable element vital for the functioning of several cellular processes 
like cell replication and growth (Pal et al, 2014).  The decrease in Slc39a10, a zinc 
transporter (Zip-10) in inv/inv mice kidneys is in concordance with the decrease in 
various genes involved in cell cycle progression.  Overall, these results suggest that loss 
of inversin affects several genes that can cause delay or arrest in cell cycle progression 
consistent with its expression during various stages of cell cycle in normal epithelial cells 
(Morgan et al, 2002a) and in turn can have an effect on cell proliferation.   
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Decreased cell proliferation in inv/inv mice kidneys:  Interestingly, several genes 
known to decrease cell proliferation were also altered in inv/inv mice kidneys. For 
example, the expression of B-cell translocation gene (Btg1), an anti-proliferative gene 
was upregulated in inv/inv mice kidneys.  On the other hand, CDK-associated, cullin 
domain-1 (Calcul1) which inhibits cell proliferation by G1 cell cycle arrest (Zheng et al, 
2013) was downregulated in inv/inv mice kidneys (Table 9).  Acylglycerol kinase (Agk), 
a lipid kinase that phosphorylates substrates such as, diacylglycerol and ceramide 
(Waggoner et al, 2004) and also promotes cell proliferation (Wang et al, 2014b)  was 
downregulated in inv/inv mice kidneys.  Agk activity is inhibited by sphingosine and 
sphk (sphingosine kinase) that phosphorylates sphingosine was upregulated and may 
contribute to decreased proliferation in inv/inv mice kidneys.  Csrnp1 (Axud1), a tumor 
suppressor gene induced by axin (a regulator of β-catenin) was upregulated in inv/inv 
mice kidneys.  Together, these data suggest a decrease in the expression of cell cycle 
genes upon loss of inversin could affect or delay cell cycle progression that may result in 
decreased cell proliferation in inv/inv mice kidneys (Table 9).   
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Table 9: Regulation of genes affecting cell cycle progression and proliferation in inv/inv 
mice kidney 
Gene 
ID 
Gene 
Symbol Protein Name  
F
Fold 
change 
(inv
-/-
/wild-
type) P-value 
Cell 
cycle 
phase 
Delay in cell cycle progression 
   235320 Zbtb16 zinc finger and BTB domain 
containing 16 
7.7 2.30E-03 G1-S 
23882 Gadd45g growth arrest and DNA-damage-
inducible 45 gamma 
2
2.3 
0.00E+00 S 
17873 Gadd45b growth arrest and DNA-damage-
inducible 45 beta 
1
1.9 
3.00E-04 S 
12575 Cdkn1a cyclin-dependent kinase inhibitor 1A 
(P21) 
1
1.6 
7.90E-03 G1 
14852 Gspt1 G1 to S phase transition 1 1.6 1.40E-03 G1-S 
17222 Anapc anaphase promoting complex subunit 1 -
1.7 
0.00E+00 M 
27401 Skp2 S-phase kinase-associated protein 2 
(p45) 
-
1.9 
7.00E-04 G1 
12444 Ccnd2 cyclin D2 -
1.5 
1.10E-03 G1 
12447 Ccne1 cyclin E1 -
1.5 
8.50E-03 G1 
22059 Trp53 transformation related protein 53 -
1.5 
1.40E-03 S 
209456 Trp53bp2 transformation related protein 53 
binding protein 2 
-
1.6 
1.40E-03 S 
110175 Ggct gamma-glutamyl cyclotransferase -
1.6 
0.00E+00 G0-
G1 
66882 Bzw1 basic leucine zipper and W2 domains 1 -
1.5 
3.10E-03 G1-S 
227059 Slc39a10 solute carrier family 39 (Zinc 
transporter), 10 
-
1.7 
2.00E-03  
12567 Cdk4 cyclin-dependent kinase 4 -
1.5 
4.30E-03 G1 
66648 Tpgs2 tubulin polyglutamylase complex 
subunit 2 
-
1.6 
5.30E-03  
Decreased Cell proliferation    
215418 Csrnp1 cysteine-serine-rich nuclear protein 1 3.1 0.00E+00  
78832 Cacul1 CDK2 associated, cullin domain 1 -1.9 1.00E-04  
69923 Agk acylglycerol kinase -2.1 7.00E-04  
12226 Btg1 B-cell translocation gene 1, anti-
proliferative 
1.6 5.80E-03  
12227 Btg2 B-cell translocation gene 2, anti-
proliferative 
1.5 0.00E+00  
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Figure 7:  Validation of select cell cycle genes from in vivo array analysis. Select 
genes from in vivo array analysis involved in cell cycle progression were validated in 
one-day old wild-type and inv/inv mice kidneys.  Total RNA was isolated and mRNA 
levels were assessed by quantitative real-time PCR.  The data was normalized to 18S 
RNA and expressed as fold change over wild-type littermates.  Values are mean  SEM 
(n=5); *p<0.05 vs wild-type. 
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Decrease in apoptosis and increase in cell survival gene expression in inv/inv 
mice kidneys: Control of organ size is mediated by the balance of cell proliferation, 
differentiation and apoptosis in multicellular organisms (Yang & Xu, 2011).  Certain 
activators of apoptosis such as caspase (Casp3) were downregulated whereas the 
inhibitors of apoptosis such as baculoviral IAP-containing (Birc6), B-translocation gene 
(Btg-1), nicotinamide N-methyltransferase (Nnmt), serine incorporator (Serinc3), 
Fam129a/Niban were upegulated in inv/inv mice kidneys (Table 10).  Kruppel-like (Klf) 
family of transcription factors such as, Klf-3, Klf-6 and Klf-9 implicated in cell 
survival/inhibition of apoptosis (Lebrun et al, 2013; Mallipattu et al, 2017) were 
upregulated in inv/inv mice (Table 10).  Overall, these data suggest that loss of inversin 
may decrease apoptosis and increase cell survival in inv/inv kidneys. 
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Table 10:  Regulation of genes representing a decrease in apoptosis and increase in cell 
survival in inv/inv mice kidneys 
Gene 
ID 
Gene 
Symbol Protein Name  
Fold change 
(inv
-/-
/wild-
type) P-value 
Decrease in apoptosis 
  2367 Casp3 caspase 3 1.6 4.90E-03 
52864 Dusp15 dual specificity phosphatase-like 
15 
1.5 3.00E-04 
2059 Trp53 transformation related protein 53 1.5 1.40E-03 
8035 Nfkbia nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, alpha 
1.6 0.00E+00 
2259 C1qa complement component 1, q 
subcomponent, alpha polypeptide 
1.7 0.00E+00 
84783 Irs2 insulin receptor substrate 2 2.8 1.00E-04 
2211 Birc6 baculoviral IAP repeat-containing 
6 
1.8 1.00E-04 
2226 Btg1 B-cell translocation gene-1, anti-
proliferative 
1.6 5.80E-03 
63913 Fam129
a 
family with sequence similarity 
129, member A 
3.0 2.60E-03 
80890 Trim2 tripartite motif-containing 2 2.8 1.00E-04 
8113 Nnmt nicotinamide N-methyltransferase 2.2 3.80E-03 
6943 Serinc3 serine incorporator 3 2.2 2.50E-03 
4579 Gem GTP binding protein (gene 
overexpressed in skeletal muscle) 
2.3 8.50E-03 
6305 Pitpnb phosphatidylinositol transfer 
protein, beta 
-1.5 2.80E-03 
1789 Tfpi2 tissue factor pathway inhibitor 2 -1.6 1.40E-03 
24454 Zdhhc14 zinc finger, DHHC domain 
containing 14 
-1.7 1.70E-03 
Increase in cell survival   
3849 Klf6 Kruppel-like factor 6 2.2 2.00E-04 
6601 Klf9 Kruppel-like factor 9 2.1 6.80E-03 
0794 Klf13 Kruppel-like factor 13 1.6 0.00E+00 
6599 Klf3 Kruppel-like factor 3  1.5 3.00E-03 
2865 Cox7a1 cytochrome c oxidase,VIIa 1 -1.8 0.00E+00 
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Development:  Genes involved in early development including certain 
transcription factors, ligands, regulators of chromatin and proteoglycans were 
differentially regulated in inv/inv mice kidneys (Table 11).  Loss of inversin decreased 
the expression of Wnt 11 and impairment in Wnt11 function may lead to kidney tubular 
abnormalities in inv/inv kidneys (Nagy et al, 2016).  Certain transcription factors such as 
Prdm16, a member of the PR domain-containing protein known to be a regulator of cell 
differentiation is expressed in kidneys at E14.5 (Horn et al, 2011) and was upregulated in 
inv/inv mice kidneys.  General transcription factor 2i (Gtf2i) known to activate 
developmental genes during differentiation of mESCs (Chimge et al, 2012) was 
downregulated in inv/inv kidneys.  Micro RNAs (miRNA) are known to play a key role in 
development and Dgcr8, a miRNA processing enzyme was downregulated in inv/inv 
mice kidneys.  Nepn (Nephrocan), a small leucine-rich repeat proteoglycan which is 
expressed during early stages of embryogenesis (Mochida et al, 2006) was downregulated 
in inv/inv kidneys suggesting its role during kidney development.  Proline 4-hydroxylase, 
alpha 1 polypeptide (P4ha1), a catalytic subunit of collagen prolyl 4-hydroxylase in 
collagen synthesis was downregulated in inv/inv kidneys and may contribute to basement 
membrane malformation.  Swi/snf related, matrix-associated actin-dependent regulator of 
chromatin (Smarcad1/Etl1), an early developmental gene (Schoor et al, 1999) was 
downregulated in inv/inv kidneys.  Zfpm2/Fog2, a cofactor for GATA3, a transcription 
factor involved in vertebrate embryonic development was also downregulated in inv/inv 
kidneys.  
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Table 11: Genes associated with development altered in inv/inv mice kidneys 
Gene 
ID 
Gene 
Symbol Protein Name  
Fold change 
(inv
-/-
/wild-
type) P-value 
22411 Wnt11 wingless-related MMTV 
integration site 11 
-1.8 3.60E-03 
70673 Prdm16 PR domain containing 16 7.9 2.00E-04 
14886 Gtf2i general transcription factor II I -1.5 6.90E-03 
94223 Dgcr8 DiGeorge syndrome critical 
region gene 8 
-2.6 1.00E-04 
66650 Nepn Nephrocan -1.6 0.00E+00 
18451 P4ha1 proline 4-hydroxylase, alpha 1 
polypeptide 
-2.0 9.30E-03 
13990 Smarcad1 SWI/SNF-related, matrix-
associated actin-dependent 
regulator of chromatin, 
subfamily a, containing DEAD/H 
box 1 
-1.5 3.00E-04 
22762 Zfpm2 zinc finger protein, multitype 2 -1.5 3.20E-03 
14048 Eya1 eyes absent 1 homolog 
(Drosophila) 
-2.4 6.00E-04 
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Regulation of cell migration and trafficking in inv/inv mice kidneys:   Genes 
associated with cell migration and trafficking were downregulated in inv/inv mice 
kidneys (Table 12).  Extracellular matrix genes such as collagen14a1 and hyaluronan and 
proteoglycan link protein (Hapln1) were also downregulated in inv/inv mice kidneys.  In 
polarized renal epithelial cells, membrane trafficking events are facilitated by 
microtubules and actin microfilaments (Brown & Stow, 1996; Hamm-Alvarez & Sheetz, 
1998).  Interestingly, genes involved in axon guidance that included semaphorin-3a 
(Sema 3a), ephrin A3 (Efna3) and its receptor Epha3 were downregulated in the kidneys 
of inv/inv mice.  In addition, microtubule-associate protein, Tau (Mapt) and PDZ 
containing 1 (Pdzk1) that guides specific motors for trafficking of certain transporters 
like organic anion transporter 1a1 (Oatp1a1) (Wang et al, 2014a) and sodium-dependent 
inorganic phosphate (Na/P(i) (Giral et al, 2011) were also downregulated in inv/inv 
kidneys.    Kinesin light chain 1 (Klc1), a motor protein and Gephyrin (Gphn), a tubulin-
binding protein involved in trafficking of glycine receptors (Hanus et al, 2004) to the cell 
surface were downregulated.   Angiomotin 1 (Amot1), involved in endothelial cell 
migration (Troyanovsky et al, 2001) was also downregulated in inv/inv kidneys.  These 
results suggest that loss of inversin may affect the genes involved in cytoskeletal changes, 
trafficking and migration and is consistent with the previous observation on the role of 
inversin in cell migration (Veland et al, 2013).  Overall, these data suggest that loss of 
inversin may result in impaired transcriptional regulation of genes involved in early 
development, differentiation and migration thus affecting the normal renal tubular 
geometry.   
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Table 12: Downregulation of genes that affect migration and trafficking in inv/inv mice 
kidneys 
Gene 
ID 
Gene 
Symbol Protein Name  
Fold change 
(inv
-/-
/wild-
type) P-value 
12818 Col14a1 Collagen, type XIV, alpha 1 -1.6 8.00E-03 
12950 Hapln1 hyaluronan and proteoglycan link 
protein 1 
-2.0 
0.00E+00 
13638 Efna3 ephrin A3 -1.6 5.30E-03 
13837 Epha3 Eph receptor A3 -2.8 0.00E+00 
241226 Itga8 integrin alpha 8 -1.7 4.80E-03 
20346 Sema3a semaphorin 3A -1.8 3.70E-03 
17762 Mapt microtubule-associated protein 
tau 
-1.8 
3.00E-03 
16593 Klc1 kinesin light chain 1; similar to 
kinesin light chain 1 
-1.6 8.40E-03 
268566 Gphn Gephyrin -1.5 6.00E-04 
66648 Tpgs2 tubulin polyglutamylase complex 
subunit 2 
-1.6 5.30E-03 
108100 Baiap2 brain-specific angiogenesis 
inhibitor 1-associated protein 2 
-1.6 1.80E-03 
59020 Pdzk1 PDZ domain containing 1 -1.8 1.60E-03 
27494 Amot Angiomotin -1.5 7.70E-03 
50490 Nox4 NADPH oxidase 4 -2.2 6.90E-03 
109246 Tspan9 tetraspanin 9 -2.8 2.40E-03 
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Decreased expression of sodium reabsorption and sodium-dependent co-
transporter genes in inv/inv mice kidneys: The major effect of arginine vasopressin 
(AVP) is water reabsorption; however AVP, to a lesser extent can also stimulate Na
+
 
absorption in the principal cells of collecting duct (Hasler et al, 2009; Hawk et al, 1996).  
The stimulatory effect of AVP is due to increased intracellular cAMP via arginine 
vasopressin receptor 2 (Avpr2).  Interestingly, several mediators that negatively modulate 
the AVP action by altering the intracellular levels of cAMP either at the level of 
production or degradation, such as, α2 adrenergic agonists, endothelin (Edn1) or 
bradykinin (Feraille & Doucet, 2001) were altered in inv/inv mice kidneys. While Avpr2 
expression levels was not changed in the current array data, there was an increase in the 
expression levels of Edn1, bradykinin receptor (Bdkrb2), adrenergic receptor alpha 2a 
(Adra2a) in inv/inv mice kidneys.  In addition, expression levels of phosphodiesterase 4d 
(Pde4d), a cAMP degrading enzyme was upregulated in inv/inv kidneys.  AVP can also 
stimulate the kallikrein-kinin system that can be counteracted by bradykinin (Fejes-Toth 
et al, 1980).  Interestingly, kallikrein was also downregulated in inv/inv mice kidneys 
(Table 13).  Angiotensin II type receptor 1b (Agtr1b) and its associated protein (Agtrap) 
which affects sodium handling and blood pressure (Wakui et al, 2015) were 
downregulated.  Taken together, these data suggest that Na
+
 transport was affected in 
inv/inv kidneys resulting in overall decreased Na
+
 reabsorption.  Select genes implicated 
in Na
+
 reabsorption (Bdkrb2, Dbp, Edn1, Entpd1, Igf1) were validated by real-time PCR 
(Figure 8).  
Several Na
+
-dependent co-transporters were also downregulated in inv/inv mice 
kidneys (Table 13).  For example, Slc6A20b, a Na
+
-dependent amino acid transporter, 
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Slc10a1, a sodium/taurocholate co-transporting polypeptide (Ntcp), Slc8a1, a Na
+
-
dependent Ca
++
 exchanger (Ncx1), Slc17a3, a Na
+
-dependent phosphate transporter 
(Npt4) and Slc34a1, also a Na
+
-dependent phosphate co-transporter (Npt2a), and Slc5a8, 
a Na
+
- coupled transporter for short chain fatty acids (Takebe et al, 2005), were 
downregulated in inv/inv mice kidneys.  Additionally, genes known to decrease Na
+
 
wasting, such as neurotensin (Nts), a peptide hormone  (Bloom et al, 1983) were 
downregulated in inv/inv kidneys.  Taken together, these results suggest that loss of 
inversin not only contributes to decreased Na
+ 
reabsorption, it also affects the Na
+
-
dependent transporters resulting in overall increase Na
+
 wasting/natriuresis.  A decrease 
in Na
+
 reabsorption can contribute to a decrease in blood pressure.  Interestingly, some of 
the genes implicated in regulation of blood pressure, such as, zinc finger protein 260 
(Zfp260), a regulator of alpha 1 adrenergic signaling, succinate receptor (Sucnr1)/Gpr91, 
kidney androgen-regulated protein (Kap), Slc22a8, a organic anion transporter (Oat3) 
(Debrus et al, 2005; Sadagopan et al, 2007; Tornavaca et al, 2009; Vallon et al, 2008)  
were downregulated in inv/inv mice kidneys  indicating that loss of inversin may decrease 
blood pressure in inv/inv mice (Table 13).  Interestingly, Slc23a1, a Na
+
-dependent 
vitamin C/ascorbate transporter (Svct1) that plays a key role in perinatal survival (Corpe 
et al, 2010) was downregulated in inv/inv mice kidneys.  Overall, these data suggest that 
loss of inversin may decrease Na
+
 reabsorption that in turn can alter some of the Na
+
-
dependent transporters affecting, amino acid, fatty acid, calcium and phosphate transport, 
blood pressure as well as perinatal survival in inv/inv mice.   
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Table 13: Regulation of genes affecting Na
+
 reabsorption and Na
+
-dependent transporters 
in inv/inv mice kidneys 
Gene 
ID 
Gene 
Symbol Protein Name  
Fold 
change   
(inv
-/-    
/wild-
type) P-value 
Decreased Na
+ 
reabsorption      
12062 Bdkrb2 bradykinin receptor, beta 2 4.0 0.00E+00 
13614 Edn1 endothelin 1 2.2 0.00E+00 
11551 Adra2a adrenergic receptor, alpha 2a 1.8 3.20E-03 
12495 Entpd1 ectonucleoside triphosphate diphosphohydrolase 1 1.7 3.00E-04 
16612 Klk1 kallikrein 1 -4.3 1.40E-03 
13170 Dbp D site albumin promoter binding protein -1.5 5.00E-04 
16000 Igf1 insulin-like growth factor 1 -1.6 7.30E-03 
11610 Agtrap angiotensin II, type I receptor-associated protein -1.5 3.40E-03 
67405 Nts Neurotensin -1.5 2.70E-03 
238871 Pde4d phosphodiesterase 4d, cAMP specific 2.0 0.00E+00 
11608 Agtr1b angiotensin II receptor, type 1b -1.6 4.70E-03 
83814 Nedd4l neural precursor cell expressed, developmentally 
down-regulated gene 4-like 
1.7 0.00E+00 
Blood pressure     
64652 Nisch Nischarin 1.5 7.60E-03 
268782 Agxt2 alanine-glyoxylate aminotransferase 2 -2.9 0.00E+00 
84112 Sucnr1 succinate receptor 1 -2.4 5.60E-03 
26466 Zfp260 zinc finger protein 260 -1.5 9.10E-03 
54140 Avpr1a arginine vasopressin receptor 1A -1.6 7.30E-03 
60596 Gucy1a3 guanylate cyclase 1, soluble, alpha 3 -1.6 6.20E-03 
11441 Chrna7 cholinergic receptor, nicotinic, alpha polypeptide 
7 
-1.5 3.90E-03 
19879 Slc22a8 solute carrier family 22, member 8 -3.4 3.60E-03 
16483 Kap kidney androgen regulated protein -2.8 3.90E-03 
Na
+
 dependent cotransporters and exchangers     
22599 Slc6a20
b 
solute carrier family 6 (neurotransmitter 
transporter), member 20B 
-2.5 8.20E-03 
20493 Slc10a1 solute carrier family 10, bile acid cotransporter,1 -2.4 1.60E-03 
75750 Slc10a6 solute carrier family 10, bile acid cotransporter,6  2.2 5.30E-03 
105355 Slc17a3 solute carrier family 17, phosphate cotransporter,3 -2.6 2.60E-03 
20505 Slc34a1 solute carrier family 34, phosphate cotransporter,1 -2.8 9.30E-03 
109342 Slc5a10 solute carrier family 5,  glucose cotransporter,10 -2.6 2.30E-03 
20541 Slc8a1 solute carrier family 8 ,calcium exchanger,1 -1.6 1.40E-03 
75750 Slc10a6 solute carrier family 10, member 6 2.2 5.30E-03 
20522 Slc23a1 solute carrier family 23 (nucleobase 
transporters),1 
-2.3 5.90E-03 
216225 Slc5a8 solute carrier family 5, member 8 -3.0 6.50E-03 
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Decreased expression levels of organic anion, cations and small molecule 
transporters in inv/inv mice kidneys:  The members of the solute carrier 22 (Slc22) 
family represent organic anion or cationic transporters (Table 14).  Slc22a22, Slc22a12, 
Slc22a13 were downregulated in inv/inv mice kidneys.  Slc22a22, a kidney-specific 
organic anion transporter that transports prostaglandins (PG) and is localized on the 
basolateral membrane of the proximal tubule was downregulated 12-fold.  Slc22a22 is 
proposed to be involved in the local PGE2 clearance and metabolism for the inactivation 
of PG signals in the kidney cortex (Shiraya et al, 2010).   Slc22a12, an anion urate 
transporter (Urat1), (Hosoyamada et al, 2010) was downregulated in this study indicating 
attenuated urate reabsorption in inv/inv kidneys.  Slc22a6, an organic anion transporter 
(Oat1) involved in the clearance of endogenous toxins (Wikoff et al, 2011) was 
downregulated in inv/inv mice kidneys.  These results suggest that loss of inversin alters 
the expression levels of genes associated with renal failure and uremia.  Slc22a7, an 
organic anion transporter (Oat2) is involved in the transport of short chain fatty acid 
propionate (Islam et al, 2008), a potent glucogenic compound, was decreased by 2.5-fold 
in this study.  Downregulation of Slc22a7 in inv/inv mice kidneys suggests that inversin 
may play a role in the regulation of cellular metabolism through transport of metabolites 
via Slc22a7.  Slc7a13/Agt1, a cystine, aspartate and glutamate transporter (Nagamori et 
al, 2016) expressed in the S3 segment of the proximal tubule was also downregulated in 
inv/inv kidneys.   
 
Acid-base balance: Glutaryl-CoA dehydrogenase (Gcdh) deficiency results in 
accumulation of glutaric acid and 3-hydroxyglutaric acid (3OH-GA) (Stellmer et al, 
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2007).  Slc13a3 (NaDC3), expressed in the proximal tubules, is a Na
+
-dependent 
dicarboxylate transporter that translocates 3-hydroxyglutaric acid to the membrane 
(Stellmer et al, 2007). Interestingly, Gcdh and Slc13a3 were downregulated in inv/inv 
mice kidneys (Table 14).  Gcdh deficiency can also result in downregulation of 
Slc22a2/Oct2, an ion transporter involved in renal secretion of organic cations and toxic 
waste.  Car12 (Carbonic anhydrase-12), expressed in basolateral plasma membrane of S1 
and S2 proximal tubule segments as well as in both cortical and medullary collecting 
ducts has a crucial role in renal bicarbonate absorption (Kyllonen et al, 2003).  Car12 was 
downregulated in inv/inv mice kidneys and may have effects on bicarbonate absorption.  
Bicarbonate is the biological buffer that maintains acid-base balance in cells (Allen et al, 
1993).   Overall, these data suggest that loss of inversin may affect acid-base balance in 
inv/inv mice kidneys. 
 
Genes involved in cellular metabolism were affected in inv/inv mice kidneys:  
Severely affected kidneys underexpress genes associated with major metabolic pathways 
involved in the generation of precursor metabolites and energy compared to the normal 
kidneys (Zhang et al, 2004).  The majority of the genes involved in purine, pyramidine, 
pyruvate, peroxisome, glycine, serine, threonine, arginine, proline, glutathione, and 
sphingolipid metabolism were downregulated in inv/inv mice kidneys (Table 15). 
Downregulation of these various metabolic genes are consistent with the reduction of 
functional parenchyma in inv/inv mice kidneys (Phillips et al, 2004). 
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Table 14: Regulation of genes affecting organic anion and cation transporters and acid-
base balance in inv/inv mice kidneys 
Gene 
ID 
Gene 
Symbol Protein Name  
Fold 
change 
(inv
-/-
/wild-
type) P-value 
Organic cation transporters 
 
 
102570 Slc22a13 solute carrier family 22, member 13 -2.9 5.00E-04 
74087 Slc7a13 solute carrier family 7, amino acid transporter 13 -2.5 1.60E-03 
11987 Slc7a1 solute carrier family 7, member 1 1.5 0.00E+00 
Organic anion transporters   
18399 Slc22a6 solute carrier family 22, member 6 -2.6 1.20E-03 
108114 Slc22a7 solute carrier family 22, member 7 -2.5 4.10E-03 
101488 Slco2b1 solute carrier, member 2b1 1.6 0.00E+00 
319800 Slc22a30 solute carrier family 22, member 30 -2.2 1.30E-03 
28254 Slco1a6 solute carrier, member 1a6 -3.3 4.10E-03 
210463 Slc22a22 solute carrier family 22, member 22 -12.6 0.00E+00 
20521 Slc22a12 solute carrier family 22 (urate transporter),12 -2.9 1.00E-04 
Acid-base balance 
 
 
 114644 Slc13a3 solute carrier family 13, dicarboxylate 
cotransporter,3 
-3.3 5.80E-03 
20518 Slc22a2 solute carrier family 22, member 2 -3.0 1.30E-03 
270076 Gcdh glutaryl-Coenzyme A dehydrogenase -1.7 7.00E-04 
76459 Car12 carbonic anyhydrase 12 -1.9 1.60E-03 
Monocarboxylic acid transporters   
69309 Slc16a13 solute carrier family 16 , member 13 -1.6 1.90E-03 
229699 Slc16a4 solute carrier family 16, member 4 -2.8 1.00E-03 
Increased K
+
 secretion   
16502 Kcnc1 potassium voltage gated channel, member 1 2.2 4.50E-03 
Glucose transport   
 20525 Slc2a1 solute carrier family 2 (facilitated glucose 
transporter),1 
1.8 5.00E-04 
Others 
 
  
 58176 Rhbg Rhesus blood group-associated B glycoprotein 
(ammonia excretion) 
-2.5 1.10E-03 
11416 Slc33a1 solute carrier family 33 (acetyl-CoA transporter),1 -1.5 3.40E-03 
227059 Slc39a10 solute carrier family 39 (zinc transporter),10 -1.7 2.00E-03 
19212 Pter phosphotriesterase related (organphosphate 
transporter) 
-2.4 7.70E-03 
246696 Slc25a28 solute carrier family 25, member 28 1.5 8.80E-03 
21366 Slc6a6 solute carrier family 6, taurine transporter,6 1.9 2.50E-03 
 
 
66 
 
 
Figure 8:  Validation of select Na+ reabsorption genes from in vivo array analysis. 
Select genes from in vivo array analysis implicated in Na+ reabsorption were validated in 
one day old wild-type and inv/inv mice kidneys.  Total RNA from one-day old wild-type 
and inv/inv mice kidneys was isolated and mRNA levels were assessed by quantitative 
real-time PCR.  The data was normalized to 18S RNA and expressed as fold change over 
wild-type littermates.  Values are mean  SEM (n=5); *p<0.05 vs wild-type. 
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Table 15: Genes associated with metabolic pathways altered in inv/inv mice kidneys 
Gene 
ID 
Gene 
Symbol Protein Name  
Fold 
change 
(inv
-/-
/wild-
type) P-value 
Purine and pyramidine metabolism 
110639 Prps2 phosphoribosyl pyrophosphate synthetase 2 -1.6 4.70E-03 
234889 Gucy1a2 guanylate cyclase 1, soluble, alpha 2 -1.7 4.60E-03 
60596 Gucy1a3 guanylate cyclase 1, soluble, alpha 3 -1.6 6.20E-03 
67005 Polr3k polymerase (RNA) III (DNA directed) 
polypeptide K 
-1.5 5.00E-04 
19076 Prim2 DNA primase, p58 subunit -1.5 2.50E-03 
13178 Dck deoxycytidine kinase -1.5 4.20E-03 
11639 Ak4 adenylate kinase 4 -2.3 3.00E-04 
22247 Umps uridine monophosphate synthetase -1.7 4.30E-03 
80914 Uck2 uridine-cytidine kinase 2 -1.5 6.80E-03 
50493 Txnrd1 thioredoxin reductase 1 -1.5 7.00E-04 
22436 Xdh xanthine dehydrogenase 40.2 1.30E-03 
238871 Pde4d phosphodiesterase 4D, cAMP specific 2.0 0.00E+00 
242202 Pde5a Phosphodiesterase 5A 2.0 1.03E-02 
12495 Entpd1 ectonucleoside triphosphate 
diphosphohydrolase 1 
1.7 3.00E-04 
18583 Pde7a phosphodiesterase 7A 1.5 1.20E-03 
Pyuruvate metabolism 
66204 Acyp1 acylphosphatase 1 -1.5 0.00E+00 
621603 Aldh3b2 aldehyde dehydrogenase 3 family -1.5 9.90E-03 
76238 Grhpr glyoxylate reductase/hydroxypyruvate 
reductase 
-1.6 0.00E+00 
75572 Acyp2 acylphosphatase 2, muscle type -1.6 6.30E-03 
18563 Pcx pyruvate carboxylase -2.4 3.80E-03 
60525 Acss2 acyl-CoA synthetase short-chain family, 2 -1.8 4.30E-03 
Amino acid metabolism 
67092 Gatm glycine amidinotransferase -3.9 2.00E-04 
74129 Dmgdh dimethylglycine dehydrogenase precursor -3.5 4.50E-03 
14431 Gamt guanidinoacetate methyltransferase -1.7 0.00E+00 
27364 Srr serine racemase -1.5 7.00E-04 
268782 Agxt2 alanine-glyoxylate aminotransferase 2 -2.9 0.00E+00 
12715 Ckm creatine kinase, muscle -1.5 2.00E-04 
18451 P4ha1 proline 4-hydroxylase, alpha 1 polypeptide -2.0 9.30E-03 
621603 Aldh3b2 aldehyde dehydrogenase 3 family -1.5 9.90E-03 
58865 Tdh L-threonine dehydrogenase 1.8 4.60E-03 
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Table 15 continued   
Glutathione metabolism 
110175 Ggct gamma-glutamyl cyclotransferase -1.6 0.00E+00 
14782 Gsr  glutathione reductase -1.8 0.00E+00 
Fatty acid oxidation 
111175 Pecr peroxisomal trans-2-enoyl-CoA 
reductase 
-1.5 1.00E-04 
235674 Acaa1b acetyl-Coenzyme A acyltransferase 1A -2.0 3.90E-03 
17117 Amacr alpha-methylacyl-CoA racemase -1.8 2.00E-03 
56794 Hacl1 2-hydroxyacyl-CoA lyase 1 -1.9 1.00E-04 
Sphingolipid metabolism 
22239 Ugt8a UDP galactosyltransferase 8A -2.3 9.60E-03 
20773 Sptlc2 serine palmitoyltransferase, long chain 
base subunit 2 
4.5 0.00E+00 
11847 Arg2 arginase type II 2.1 2.30E-03 
20698 Sphk1 sphingosine kinase 1 1.9 0.00E+00 
56386 B4galt6 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 6 
1.7 0.00E+00 
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Discussion 
Mutations in inversin gene cause renal cysts in NPHP2 patients as well as in 
inv/inv mice (Morgan et al, 1998; Otto et al, 2003). The molecular basis of cyst growth 
and expansion in NPHP2 is not well understood. To elucidate the molecular pathways 
that modulate renal cysts in inv/inv mice transcriptome analysis was performed on the 
kidneys of mutant and the wild-type littermates. This study provides for the first time a 
comprehensive map of the key pathways that are associated with cystic kidneys of inv/inv 
mice. The main transcriptional profiles that were altered include activation of 
immune/inflammatory cascades, cell proliferation (decrease in cell cycle progression), 
extracellular matrix deposition, fibrosis, apoptosis and electrolyte or ion transport. 
Hypoxia or inflammation associated with disease or injury can induce the 
expression of certain members of the classic complement pathway such as, C1qa, C1qb 
and C1qc involved with innate immune system that were upregulated in the kidneys of 
inv/inv mice.  These findings are consistent with the previous reports on the activation of 
the C1qa and C1qb in cpk mouse, a model of ARPKD (Mrug, 2008).  Additionally, 
activation of C1qa, C1qb and C1qc been shown to mediate renal injury in models of 
diabetic nephropathy (Kelly et al, 2015).  Macrophages play an important role in 
promoting inflammation (M1 macrophages) and its resolution (M2 macrophages) in 
response to injury (Gordon, 2003; Lambert et al, 2008).  Interestingly, CD163, a receptor 
expressed on M2 macrophages (Kristiansen et al, 2001) that promotes tissue remodeling 
was upregulated in inv/inv mice kidneys. Activation of Tnfrsf12a/TweakR/Fn14 shown to 
have pro-inflammatory effects on podocytes (Sanchez-Nino et al, 2013) was also 
upregulated in inv/inv mice kidneys.  Endothelial adhesion molecule Icam known to play 
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a role in the neutrophil migration (Sligh et al, 1993) was upregulated in inv/inv kidneys.  
Upregulation of hypoxia inducible factor (Hif3α) following ischemic injury has been 
suggested to play a role protective role in kidney (Heidbreder et al, 2003) and was also 
increased in our array analysis of inv/inv kidneys.  Together, it is possible that 
inflammatory responses associated with both tissue damage and repair may co-exist in 
inv/inv kidneys. 
Cytokines or growth factors that are released in response to inflammation can 
activate Janus kinase/signal transduction and activator of transcription (Jak/Stat) 
signaling (Leonard & O'Shea, 1998) which was one of the pathways altered in inv/inv 
mice kidneys. Certain cytokines, chemokines (IL34, Cxcl1 and Ccl9) and receptors 
(Il1ra, Il6ra, and Tnfrsf12a) among others showed increased expression in inv/inv mice 
kidneys that can result in the activation of Jak/Stat signaling cascade and its downstream 
effectors. Stat3, a component of Jak/Stat that mediates the expression of a variety of 
genes involved in cell processes such as cell growth, apoptosis and differentiation (Yang 
et al, 2007; Yuan et al, 2004).  Activation of Jak/Stat pathway has been shown to 
upregulate p21/Cdkn1a, an inhibitor of cyclin D2 activity thereby inducing cell cycle 
arrest in G0/G1 phase in canine kidney cells (Bhunia et al, 2002).  An increase in the 
expression of Stat3 in this study accompanied by an increase in p21/Cdkn1a indicates a 
possible delay in cell cycle progression in inv/inv mice kidneys.  Furthermore, additional 
cell cycle genes altered in inv/inv mice kidneys is consistent with the role of inversin 
during different stages of cell cycle in renal epithelial cells (Morgan et al, 2002a).  
Overall, a possible delay in cycle progression or cell cycle arrest may affect cell 
proliferation for proper renal tubule formation in inv/inv kidneys.  Interestingly, genes 
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implicated in cell proliferation such as gammaglutamytransferase (Ggct), and Cdk2-
associated cullin domain-1 (Calcul) were downregulated in inv/inv mice kidneys.  
Knockdown of Ggct in lung cancer cell lines have been shown to decrease cell 
proliferation (Lin et al, 2015). Silencing of Cacul1 in gastric cell line resulted in 
decreased cell growth by cell cycle arrest (Zheng et al, 2013). Additionally, acylglycerol 
kinase (Agk), a kinase that phosphorylates a-acylglycerol has been shown to promote cell 
proliferation in breast cancer lines (Wang et al, 2014b) was also downregulated in inv/inv 
mice kidneys.  Overall, a decrease in the expression of cell cycle and proliferation genes 
were seen in one-day old inv/inv mice kidneys. 
Extracellular matrix proteins such as connective tissue growth factor (Ctgf) and 
tenascin C (Tnc) have been shown to play a crucial role in many fibrotic conditions 
including renal fibrosis (Fu et al, 2016; Phanish et al, 2010; Toba et al, 2016).  Ctgf is 
expressed in glomerular podocytes, mesangial cells and proximal tubular epithelial cells 
and acts synergistically with TGF-β1 to promote tissue fibrosis (Mori et al, 1999).  In 
proximal tubular cells, TGF-β1has been shown to induce Ctgf and tenascin C mRNA 
levels (Sarkozi et al, 2011).   The increase in TGF-β1-induced Ctgf expression can be 
inhibited by Oncostatin M (Osm) via Osm receptor (Osmr)-activated Stat3 (Sarkozi et al, 
2012; Sarkozi et al, 2011).  The upregulation of both Ctgf and Tnc, Osmr as well as Stat3 
in this study suggest that signaling via Ctgf/Osmr/Stat3 axis may promote fibrosis in 
inv/inv kidneys consistent with interstitial fibrosis reported in NPHP2 patients 
(Gagnadoux et al, 1989; Haider et al, 1998).   
Apoptosis or programmed cell death is a fundamental and complex biologic 
process that enables an organism to remove unwanted cells during development, normal 
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homeostasis and disease (Jacobson et al, 1997; Thompson, 1995).  Caspases are crucial 
mediators of apoptosis (Porter & Janicke, 1999)  Caspase-3, a frequently activated death 
protease was downregulated in inv/inv mice kidneys; whereas certain inhibitors of 
apoptosis (Nnmt, Btg-1, Serinc3) were upregulated.  Overexpression of Nnmt 
(nicotinamide N-methyl transferase), has been shown to inhibit lipotoxicity-induced 
oxidative stress and cell death in kidney proximal tubule cells (Tanaka et al, 2015).   
Oxidative stress upregulates B-cell translocation gene (Btg-1) mRNA and Btg1 activation 
represses NF-kb activity, an inducer of apoptosis in macrophages (Cho et al, 2005).  
Serinc (serine incorporator3/TDE1), a carrier protein that incorporates serine residue into 
cell membranes has been shown to inhibit apoptosis and stimulate tumorigenesis in Rat-1 
fibroblasts (Bossolasco et al, 2006) was upregulated in inv/inv kidneys.  Since loss of 
Niban/Fam129A, an endoplasmic reticulum stress-inducible protein was shown to 
increase apoptosis in He La cells (Sun et al, 2007), an increased expression of Niban in 
this study may hinder apoptosis in inv/inv kidneys.  Members of the Kruppel-like 
transcription factors implicated in cell survival and inhibition of apoptosis were 
upregulated in inv/inv mice kidneys. Overexpression of Klf6, an essential regulator of 
mitochondrial function prevented podocyte apoptosis (Mallipattu et al, 2015).  
Overexpression of Klf9 has been shown to increase the Purkinje cell survival (Lebrun et 
al, 2013).  Overall, an increase in the expression of cell survival genes and a decrease in 
the expression of apoptotic genes may contribute to enlarged cystic kidneys in inv/inv 
mice.   
Inversin plays a role in non-canonical Wnt/planar cell polarity pathway 
(Lienkamp et al, 2010).  Wnt 11, a ligand for non-canonical signaling that has been 
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shown to control early steps in ureteric bud branching was downregulated in inv/inv mice 
kidneys.  Interestingly, impairment of Wnt11 function in Wnt11
-/-
 mice leads to kidney 
tubular abnormalities and glomerular cysts (Nagy et al, 2016).  Prdm16, a transcription 
regulator of cell differentiation has been shown to be expressed in kidneys at E14.5 (Horn 
et al, 2011).  Upregulation of Prdm16 in this study may have differentiation effects 
during early stages of developing inv/inv kidneys.  Gtf2i encoding TFII-I family of 
transcription and known to activate developmental genes during differentiation of mESCs 
(Chimge et al, 2012) was downregulated in inv/inv kidneys suggesting a possible role of 
Gtf2i in differentiation.   
Micro RNAs (miRNA) are known to play a key role in tissue development 
(Ambros, 2004).   Dgrc8, a miRNA processing enzyme was downregulated in inv/inv 
mice kidneys indicating its role in renal development. Conditional deletion of Dgcr8 in 
the developing renal tubule results in hydronephrosis, renal cysts, progressive renal 
failure and premature death within first two months consistent with inv/inv mice and 
NPHP2 phenotype (Bartram et al, 2015).  Nepn (nephrocan), a small leucine-rich repeat 
proteoglycan which is expressed during early stages of embryogenesis was 
downregulated in inv/inv kidneys suggesting its role during kidney development 
(Mochida et al, 2006).  P4ha1 (proline 4-hydroxylase, alpha 1 polypeptide), a catalytic 
subunit of collagen prolyl 4-hydroxylase involved in collagen synthesis was 
downregulated in inv/inv kidneys that may have effects on basement membrane integrity 
(Pietila et al, 2016). Smarcad1/Etl1 (Swi/snf related, matrix-associated actin-dependent 
regulator of chromatin), is expressed at 2-cell stage during development and loss of this 
gene has been implicated in skeletal dysplasia, growth retardation and reduced postnatal 
74 
 
survival in mice (Schoor et al, 1999). Downregulation of Smarcad1 in this study is 
consistent with short life-span and growth retardation observed with inv/inv mice and 
short life-span and skeletal dysplasia in NPHP2 phenotype (Oud et al, 2014).  Overall, 
changes in several early developmental genes observed in this study may affect kidney 
development in inv/inv mice.  
Fluid accumulation is a hallmark of renal cystic diseases and defective ion 
transport has been shown to play a role in this process (Terryn et al, 2011).  One of the 
significantly altered categories in the array analysis of inv/inv mice kidneys was 
molecular transport. Genes involved in Na
+
 transport, Na
+
-dependent co-transporters and 
exchangers, acid-base balance, organic anion and cation transporters were downregulated 
inv/inv mice kidneys.  The antidiuretic hormone (ADH) or AVP (arginine vasopressin) 
can stimulate Na
+
 absorption in distal nephron epithelium (Reif et al, 1986; Tomita et al, 
1985).  The stimulatory effect of AVP on Na
+
 transport is due to increased intracellular 
cAMP via AVP receptor 2 (Marunaka & Eaton, 1991).  Expression levels of several 
mediators (endothelin, bradykinin receptor, adrenergic receptor alpha 2a) that negatively 
modulate cAMP (Feraille & Doucet, 2001) were increased in inv/inv mice kidneys.  The 
increased expression of the negative modulators of cAMP may contribute to decreased 
Na
+
 reabsorption in inv/inv mice kidneys.  A decrease in Na
+
 reabsorption in the AVP-
sensitive segments of the kidneys could have an effect on blood pressure.   
Blood pressure associated genes such as, Zinc finger protein (Zfp260), kidney 
androgen-regulated protein (Kap), Slc22a8, an organic anion transporter and succinate 
receptor (Sucnr1/Gpr91) were downregulated in inv/inv mice kidneys.  Knockdown of 
Zfp260, a nuclear effector of alpha-1-adrenergic signaling in cardiac cells, decreases the 
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atrial natriuretic factor (Anf) (Debrus et al, 2005) and decreases blood pressure.  Kap 
transgenic mice have been shown to exhibit hypertension (Tornavaca et al, 2009).  Mice 
lacking Slc22a8 exhibit lower blood pressure compared to wild-type controls (Vallon et 
al, 2008).   In addition, succinate receptor (Sucnr1/Gpr91) activation has been shown to 
induce hypertension in mice (Sadagopan et al, 2007).  Overall, the regulation of genes 
involved in Na
+
 reabsorption and hypertension indicates that loss of inversin may have an 
effect on blood pressure in inv/inv mice. 
Several sodium-dependent transporters were also downregulated in inv/inv mice 
kidneys.   Slc34a1/Npt2, a Na
+
-dependent phosphate transporter expressed in the brush 
border membrane of proximal tubular cells was downregulated in inv/inv kidneys.  Npt2
-/-
 
mice show decreased Na
+
/Pi cotransport (Hoag et al, 1999).  The decreased expression of 
Npt2 in inv/inv mice kidneys suggest a possible decrease in Na
+
/Pi cotransport.   
Glutaryl-CoA dehydrogenase (Gcdh) was downregulated in inv/inv mice kidneys.  
Gcdh deficiency results in accumulation of glutaric acid and 3-hydroxyglutaric acid 
(3OH-GA).  Slc13a3/NaDC3, a Na
+
-dependent dicarboxylate transporter that mediates 
the translocation of 3OH-GA through membranes was also downregulated inv/inv mice 
kidneys (Stellmer et al, 2007).  The decrease in the expression levels of Gcdh and 
Slc13a3 may result in accumulation of organic acids in inv/inv mice kidneys. Carbonic 
anhydrase (Car12), a bicarbonate transporter was downregulated in inv/inv mice kidneys.  
Car12 expressed in basolateral membrane of S1 and S2 segment of proximal tubule, 
cortical and medullary collecting ducts is important for bicarbonate absorption and acid-
base balance (Kyllonen et al, 2003).  Together, the downregulation of Gcdh, Slc13a3, and 
Car12 may affect acid-base balance in inv/inv mice kidneys.   
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Slc23a1, an ascorbate transporter was downregulated in inv/inv mice mice 
kidneys.  Slc23a1
-/- 
mice exhibited increased ascorbate excretion and increased perinatal 
mortality (Corpe et al, 2010).  The decrease in Slc23a1 in inv/inv mice kidneys may 
contribute to short life span observed in these mice (Yokoyama et al, 1993).   
Slc22a6/Oat1, an organic anion transporter expressed in the proximal renal tubule 
was downregulated in inv/inv mice kidneys.  Slc22a6
-/-
 mice showed accumulation of 
endogenous toxins such as urate, and certain metabolites (indoxyl sulfate, xanthurenic 
acid) in the plasma associated with renal failure and uremia (Eraly et al, 2006; Wikoff et 
al, 2011).  The decreased expression of Slc22a6 suggests that clearance of endogenous 
toxins might be affected in inv/inv
 
mice kidneys.  Slc22a12/Urat1, a urate transporter was 
downregulated in inv/inv mice kidneys.  Slc22a12
-/-
 mice show higher urinary 
urate/creatinine ratio indicating decreased urate reabsorption (Hosoyamada et al, 2010).  
The decrease in Slc22a12 in this study suggests urate reabsorption may be affected in the 
kidneys of inv/inv mice. Overall, several gene implicated in ion transport were regulated 
inv/inv mice.  In particular, genes involved in Na
+
 transport, Na
+
-dependent co-
transporters and exchangers, acid-base balance, organic anion and cation transporters 
may contribute to enlarged kidneys in inv/inv mice. 
In summary, this study generated a comprehensive gene expression profile of one-
day old wild-type and inv/inv mice kidneys.  The genes identified categorized into 
functional pathways that were altered included cell proliferation, apoptosis, inflammation 
and ion transport.  It appears that decreased cell proliferation and apoptosis accompanied 
by changes in Na
+
 reabsorption and other genes associated with ion transport may 
contribute to cyst growth and expansion in inv/inv mice kidneys.  The inv/inv mouse is a 
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global knockout model of inversin loss and the gene expression changes observed in 
kidneys could be a direct or an indirect effect of inversin.  The changes in gene 
expression observed in this study is a snap shot in time, and will not capture all the gene 
changes that may occur during development.  In addition, some of the gene regulation 
that occurs by protein-protein interactions may not be captured in the transcriptome 
analysis.  The array findings on ion transport and cell proliferation were validated in an in 
vitro model of inversin loss in renal epithelial cells and are separately dealt in subsequent 
chapters.    
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CHAPTER 3: LOSS OF INVERSIN DECREASES 
TRANSEPITHELIAL SODIUM TRANSPORT IN MURINE RENAL 
CELLS OF THE CORTICAL COLLECTING DUCT 
Introduction 
Gene array analysis of inv/inv mice kidneys showed that inversin can have effects 
on ion transport through transcriptional regulation of genes.  The array findings regarding 
ion transport were further validated in an in vitro model of inversin loss in a mouse renal 
epithelial cell line. Studies from both human and animal models containing NPHP2 
mutant alleles suggest a key role of inversin in early development and in renal cyst 
formation.  The increased kidney size in NPHP2 could be due to increased electrolyte 
secretion or decreased absorption resulting in fluid accumulation within the cyst cavity.  
One mechanism by which inversin could exert its effect on renal function is by directly 
affecting electrolyte transport.  In a Xenopus model, loss of inversin has been shown to 
result in edema (Lienkamp et al, 2010).  Although these data support the premise of fluid 
accumulation it does not address specific regulation of electrolytes and ion transport in 
renal epithelial cells.  The intentional depletion of inversin in a well characterized 
epithelial cell line will help determine the function of inversin in transepithelial ion 
transport processes.   
The cystic enlargement of kidneys is one of the features observed in the more 
common forms of polycystic kidney disease (PKD) arising from mutations in polycystin 
1 or 2 or fibrocystin (Bergmann et al, 2003; Mochizuki et al, 1996; Ravine et al, 1992).  
In autosomal dominant PKD patients and animal models, increased Cl
-
 secretion across 
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the cyst-lining epithelial cells has been implicated as a mechanism for fluid accumulation 
in kidneys (Mangoo-Karim et al, 1995; Wallace et al, 1996).  The cystic fibrosis 
transmembrane conductance regulator (CFTR) is the major Cl
-
 channel responsible for 
secretion into renal cysts (Davidow et al, 1996; Hanaoka et al, 1996).  However, the 
mechanism of fluid accumulation and cyst expansion in kidneys of NPHP2 is not well 
understood.  A better understanding of the role of inversin in normal renal function may 
provide additional insights into the mechanism of cyst growth and expansion in NPHP2.   
Homeostasis of body fluids is maintained by the reabsorptive and secretory 
processes in the kidney tubules (Summa et al, 2001).  The tubular reabsorption of filtered 
sodium (Na
+
) in the kidney is tightly controlled to maintain whole body fluid volume 
homeostasis which together with stored Na
+
 in the skin and the skeletal muscle is central 
for long-term regulation of blood pressure (Titze, 2015).  Over 99% of the filtered Na
+
 
reabsorbed in the kidneys by the epithelia of the renal tubules occurs via ion transport 
processes (Marunaka, 1997).  The majority of the Na
+
 reabsorption in the proximal 
nephron occurs by a constitutively active Na
+
 co-transport system but the amount of Na
+
 
reabsorbed in the distal nephron is under hormonal control (Alvarez de la Rosa et al, 
2002; Blazer-Yost et al, 1998; Loffing & Korbmacher, 2009).  The principal cells of the 
distal nephron and cortical collecting duct (CCD) are the site of hormonally controlled 
Na
+
 and water reabsorption and are influenced by the action of aldosterone, insulin and 
arginine vasopressin (AVP) (Blazer-Yost et al, 1998; Loffing et al, 2006; Loffing & 
Korbmacher, 2009).    Stimulation of Na
+
 reabsorption by AVP occurs by coordinated 
activation of epithelial sodium channel (ENaC) and Na
+
, K
+
 ATPase (Feraille & Doucet, 
2001; Hasler et al, 2009; Hawk et al, 1996).  Luminal Na
+ 
crosses the apical plasma 
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membrane along its electrochemical gradient through ENaC.  The ENaC-derived 
intracellular sodium is then actively extruded into the interstitial space by the Na
+
, K
+
-
ATPase located on the basolateral membrane (Feraille & Doucet, 2001).   
  The extrinsic factors that regulate ENaC activity include hormonal, mechanical, 
cytoskeletal activity and proteolytic cleavage (Bhalla & Hallows, 2008).  Intrinsic factors 
comprise ENaC trafficking and its phosphorylation, Na
+
 self- and feedback inhibition, as 
well as neural precursor cell-expressed developmentally downregulated-like 
(Nedd4l/Nedd4-2) mediated ubiquitination of ENaC (Bhalla & Hallows, 2008; Staub et 
al, 1996).  Nedd4-2 ubiquitinates ENaC leading to its endocytosis and degradation (Zhou 
et al, 2007).  Serum/glucocorticoid kinase 1 (Sgk1), an aldosterone-regulated gene, 
stimulates ENaC-mediated Na
+
 transport in part by phosphorylating Nedd4l (Snyder et al, 
2002).  Phosphorylation of Nedd4l prevents the interaction of Nedd4l with ENaC, 
resulting in increased number of active ENaC subunits at the apical surface 
(Debonneville et al, 2001).  Sgk1 is, in turn, regulated by creb-regulated transcription 
coactivator (Crtc2), a kinase that phosphorylates Sgk1 (Lu et al, 2010).  Overall, the 
Crtc2, Sgk1 and Nedd4l appear to play a role in Na
+
 transport in epithelial cells.   
The goal of this study was to provide functional validation of array findings from 
inv/inv mice kidney to determine whether inversin plays a role in transepithelial ion 
transport in renal cells.  The underlying hypothesis is that loss of inversin leads to 
abnormal fluid accumulation resulting in growth and expansion of renal cysts leading to 
kidney failure.  This study utilized two different methods of inversin knockdown to 
deplete inversin in a mouse cortical collecting duct (mCCD) cell line and used 
electrophysiological techniques to measure transepithelial ion transport.   
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Materials and methods 
Accell SMART pool INVS siRNA (E-061511) was obtained from GE 
Dharmacon, Inc. (Lafayette, CO),  INVS MISSION

 shRNA lentiviral transduction 
particles in pLKO-puro vector, TRCN0000086438 (construct 438), TRCN0000086440 
(construct 440), TRCN0000086441 (construct 441), TRCN0000086442 (construct 442), 
TRCN0000331571 (construct 571), arginine vasopressin (AVP) and amiloride were 
obtained from Sigma-Aldrich (St. Louis, MO).  CFTR inhibitor (GlyH 101, 5485) was 
purchased from Tocris, Minnaepolis, MN.  Fluorogenic primer/probe set to detect mRNA 
encoding inversin (Mm00495002_m1), sodium channel non-neuronal (Scnn1α, 
Mm00803386_m1), (Scnn1β, Mm00441215_m1), (Scnn1γ Mm00441228_m1), ATP1a1 
(Na
+
/K
+ 
transporting, alpha1 polypeptide Mm00523255_m1), Nedd4l 
(Mm00459584_m1), Sgk1 (Mm00441380_m1), Crtc2 (Mm01219960_m1) and 18S RNA 
(Mm03928990_g1) were obtained from Applied Biosystems as Assays on Demand
TM
 
reagents.  Rabbit anti-Nedd4l, (ab131167) was purchased from Abcam (Cambridge, 
MA).  Rabbit anti-Sgk1 (PA5-21147) and rabbit anti-Crtc2 (PA5-34547) were procured 
from Thermo Fisher (Rockford, IL).  Rabbit anti-Phospho Nedd4l (S342; 12146S), rabbit 
anti-GAPDH, secondary antibodies for Western blotting analysis (anti-rabbit IgG 
conjugated to horse-radish peroxidase; #7074S) and biotinylated protein ladder (#7727) 
were from Cell Signaling Technology, Beverly, MA.  
 
Cell culture:  The mouse cortical collecting duct (mCCD) cell line expressing the 
characteristics of the principal cell type in the collecting duct of the kidneys was obtained 
from Edith Hummler, University of Lausanne (Gaeggeler et al, 2005). The mCCD cells 
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are high resistance, Na
+
 reabsorbing epithelial cells that respond to various hormones 
(vasopressin, aldosterone, insulin) with an increase in transepithelial movement of 
electrolytes (Gaeggeler et al, 2005).   The mCCD cells were cultured in 75 cm
2
 flask and 
grown in a humidified chamber at 37
ο
C, 5% CO2.  Cell culture medium comprised of 
DMEM/F12 (1:1) supplemented with 2% FBS, 80U/ml penicillin, 80µg/ml streptomycin, 
epidermal growth factor (10ng/ml), 5ml per liter of insulin-transferrin-selenium (100x) to 
a final concentration of 0.172 mM insulin, 6µM transferrin, 3.87µM sodium selenite, 
dexamethasone (5x10
-8
M), 10
-9 M 3,3̍,5-triiodo-L-thyronine.  The medium was replaced 
three times per week and the cells were passaged weekly.  
 
Establishment of inversin knockdown in mCCD cells by Accell inversin 
siRNA: Long term inversin knockdown in mCCD cells was done using Accell 
technology according to the manufacturer’s instructions.  Briefly, confluent mCCD cells 
in a 6-well plate were transfected with Accell siRNA targeting inversin at a 
concentration of 1µM.  The sequences of siRNAs targeting the inversin mRNA is shown 
in Table 16.  The cells received 1-5 treatments (ranging between 1-5 µM siRNA) during 
the course of 2 weeks.  The medium was replaced three times per week.  At the end of 2 
weeks, the cells were collected and the inversin mRNA level was assessed by quantitative 
real-time PCR and the transepithelial ion transport was measured by electrophysiology. 
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Table 16: Sequences of siRNA targeting mouse Invs 
siRNA Target sequence INVS gene Inversin protein 
sequence 
1 5'CCGTGAAGTTATTATTGGA-3' Exon 8 VKLLLD 
2 5'-CCTTGATTATGCATTGCTT-3' Exon 11 PLDYQLL 
3 5'-GCTGAAGCAGTAATGTAA-3' 3'-UTR
a
  
4 5'-GTATGTACCCTTAGGAGTA-3' 3'-UTR   
a
UTR, untranslated region 
 
Establishment of transgenic cell lines:  The use of lentiviral plasmid vector for 
stable transfection conformed to the Biosafety level 2 (BL2) protocol 1170 approved by 
the Biosafety committee at Indiana University-Purdue University, Indianapolis.  The 
mCCD cells were stably transduced with a lentiviral plasmid vector (pLKO-puro) 
encoding a shRNA mediating inversin knockdown and carrying a puromycin resistance 
gene for selection of transduced clones.  A total of 5 shRNAs targeting different regions 
of the inversin mRNA were transfected separately into mCCD cells to determine 
efficiency of knockdown.  The sequences of shRNAs targeting the inversin gene are 
shown in Table 17.  Following initial transduction with 2, 10 and 20 MOI (multiplicity of 
infection) of the lentiviral particles for 48 h, stable pools were generated by placing the 
cells in media containing 2µg/ml of puromycin for selection of transduced cells 
containing inversin shRNA.  The puromycin concentration was optimized in the mCCD 
cells.  For clonal selection of the transduced cells, single cells from the stable pools from 
20 MOI were sorted by BDFACS Aria II flow cytometer according to manufacturer’s 
protocol and plated in a 96-well plate.  The cells were allowed to grow in the puromycin-
containing selection media.  The clones were expanded, aliquoted and stored in liquid 
nitrogen for further use.  MISSION

 TRC2-pLKO-puro control vector containing an 
insert that does not target mouse or human sequence was used as non-targeting control 
84 
 
(NTC). The levels of inversin knockdown in stable pools and individual clones were 
determined by quantitative real-time PCR using inversin primers. 
 
 
Table 17: Sequences of shRNA constructs targeting mouse Invs 
Construct  Target sequence 
INVS 
gene 
441 5'CGGAGGGTACATCAACTGTAT-3'  Exon 9 
440 5'-CCTAATCAGATGGAGAACAAT-3' Exon 10 
442 5'-GCAGTCTATACATCTTGACAAC-3' Exon 16 
432 5'-CGCTTTACTATTTGCACCTAA-3' 3'-UTR
a
 
571 5'-GCGCTTTACTATTTGCACCTAACT-3' 3'-UTR 
a
UTR, untranslated region 
 
Total RNA isolation and real-time PCR:  Total RNA from each sample was 
isolated using RNeasy mini kit isolation kit (Qiagen, Valencia, CA) according to 
manufacturer’s protocol.   Briefly, the samples were homogenized in lysis buffer and the 
lysate was passed five times through a blunt 20-guage needle fitted to an RNase-free 
syringe. One volume of 70% ethanol was added to the sample which was then applied to 
RNeasy spin column.  The samples were centrifuged and the flow through was discarded.  
DNase treatment of the samples was performed using the RNase-free DNase set from 
Qiagen (Valencia, CA) and the samples were eluted in RNase-free water.  RNA quality 
and quantity were determined by Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. 
Santa Clara, CA, USA) according to manufacturer’s instructions.  First strand cDNA was 
synthesized from 1.5µg of total RNA with random hexamer primers using the 
SUPERSCRIPT II first strand synthesis kit (Invitrogen).  The mRNA levels were 
determined by quantitative real-time PCR using ABI Prism Sequence Detection System 
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5700 (Applied Biosystems).  The mRNA levels were normalized to 18S ribosomal RNA 
that served as an internal control.   
 
Immunodetection: Cells were lysed in lysis buffer (M-PER mammalian protein 
extraction reagent, Thermo Fisher Scientific Inc. Waltham, MA) supplemented with 
complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) and HALT 
phosphatase inhibitor cocktail (Thermo Fisher Scientific Inc, Waltham, MA).  The 
protein concentrations were measured using Pierce Protein assay kit.  Equal amounts of 
protein were separated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) on 4-20% Tris-glycine gels (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA).  The proteins were transferred to nitrocellulose membranes using iBlot
 
gel transfer system. The membranes were blocked in 5% non-fat dry milk in TBS-T 
(Tris-buffered saline containing 0.05% Tween-20) for 1 h at room temperature.  The 
blocking reagent was removed and appropriate primary antibodies at a dilution of 1:1000 
were added to the membranes and incubated for 2 h at room temperature.  The 
membranes were washed with TBS-T for 15 min at room temperature by agitation.  The 
wash step was repeated three times to reduce the background.  The membranes were 
incubated with secondary antibodies (anti-rabbit IgG-HRP) at a dilution of 1:2000 in 1% 
milk-TBS-T for 1 h at room temperature with gentle agitation.  The membranes were 
washed three times with TBS-T for 15 min at room temperature by agitation.  The 
proteins were visualized using SuperSignal
 
West Pico Chemiluminescent substrate 
(Thermo Fisher Scientific, Waltham, MA).  GAPDH was used as internal control.   
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Electrophysiological analyses:  siRNA or stably transfected mCCD cells with 
shRNA-mediated inversin knockdown (as determined by quantitative RT-PCR) or non-
targeting control were used for measuring transepithelial ion transport.  
Electrophysiological techniques were employed to monitor changes in ion flux across the 
cellular monolayers as described previously (Shane et al, 2006).  Briefly, transwell 
permeable membranes containing the confluent monolayers (14-16 days post-seeding) of 
mCCD cells were mounted onto Ussing chambers and connected to a DVC-1000 
voltage/current clamp (World Precision Instruments) with voltage and current electrodes 
on either side of the membrane.  The cells were bathed in serum-free medium maintained 
at 37
ο
C via water-jacketed buffer chambers on either side of the filter.  Media were 
circulated and kept at constant pH using a 5% CO2/95% O2 gas lift.  The spontaneous 
transepithelial potential difference was clamped to zero, and the resultant short circuit 
current (SCC) was monitored continuously.  Under these conditions, SCC is a measure of 
net transepithelial ion flux.  Basal SCC was measured for 30 min prior to the addition of 
arginine vasopressin (AVP), a stimulator of Cl
-
 and Na
+
 transport at time=0.  AVP (100 
mU/ml) was added to the serosal (basolateral side) bathing medium and the SCC were 
monitored for 30 min.  Amiloride (1x10
-5 
M), a specific inhibitor of ENaC was added to 
the apical bathing medium 30 min following the addition of AVP to determine if the 
changes observed in SCC were due to Na
+
 transport via ENaC.   
 
Statistics:  Data are represented as means  standard deviation or standard error 
of mean.  Differences between two groups were analyzed by an unpaired Student’s t-test.  
Differences were considered significant when P<0.05.   
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Results 
The mCCD cell line exhibits the characteristics of the distal tubule cortical 
collecting duct principal cell type including high transepithelial resistance 
(≥1,000Ω.cm2), expression of ion transporters and responsiveness to hormones such as 
AVP and aldosterone (Gaeggeler et al, 2005; Gaeggeler et al, 2011).    These features 
together with endogenous expression of inversin make the mCCD cell line an ideal model 
to examine the role of inversin in ion transport.  For ion transport measurements the cells 
were grown in culture for two weeks to develop a fully polarized high resistant 
phenotype.  Long-term gene silencing of endogenous inversin was performed using two 
approaches in mCCD cells, (1) Accell technology that utilizes a passive delivery of 
siRNA (2) stable knockdown of inversin by lentiviral delivery of inversin shRNA.  The 
inversin-depleted mCCD cells from both approaches were used to measure transepithelial 
ion transport by electrophysiology. 
 
Inversin knockdown in mCCD cell line by Accell siRNA technology:  Initially, 
inversin siRNA was used to test the feasibility of inversin knockdown in mCCD cells.  
As shown in Figure 9, treatment with different concentrations (1-4µM) of siRNA resulted 
in 12-43% decrease in inversin mRNA levels following 2 weeks in culture.  Surprisingly, 
the least concentration of siRNA (1µM-1 treatment) resulted in the highest knockdown 
(43%) in this experiment.  The increase in siRNA concentration did not correlate with the 
reduction in inversin expression.  This effect could be the result of inefficient siRNA 
uptake due to cell growth as the cells were in culture for 2 weeks.  Nevertheless, the 
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siRNA treatments did result in different levels of inversin knockdown in mCCD cells that 
were useful in preliminary experiments on ion transport. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9:  Long-term gene silencing in mCCD cells using inversin Accell 
siRNA.  Following initial plating in the growth medium the cells were treated with 1µM 
of inversin siRNA resuspended in Accell delivery media.  After 24 h of siRNA treatment 
the Accell delivery media was replaced with the growth medium.  The treatment with 
siRNA was repeated for a total of 1-4 times for 2 weeks.  At the end of the treatment 
mRNA levels were assessed by quantitative real-time PCR.  The data were normalized to 
18S RNA and expressed as fold-change over untreated control. Value above each bar 
represents the % inversin knockdown with siRNA treatment. 
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Inversin modulates transepithelial ion transport in inversin-depleted mCCD 
cells obtained using Accell siRNA technology:  Initially, the functional effect of 
inversin loss was measured as changes in net transepithelial ion transport across high 
resistance epithelia formed by the mCCD cell line.  Confluent cell layers grown on 
permeable supports were mounted onto Ussing chambers and short circuit current (SCC) 
was used to measure electrogenic ion flux.  By convention, a change in SCC in epithelial 
cells could be due to an anion moving from basolateral to apical media (secretory) or a 
cation moving from apical to basolateral media (absorptive).  Following the equilibration 
of basal SCC for 30 min, AVP (100 mU/ml) was added at time=0 to the serosal 
(basolateral side) bathing medium and the SCC was monitored for additional 30 min.  As 
shown in Figure 10A, AVP stimulation showed a biphasic response in these cells, a rapid 
transient anion secretory response peak possibly via CFTR (Cl
- 
secretion) followed by a 
delayed cation absorptive response via ENaC (Na
+
 absorption).  Interestingly, inversin 
knockdown did not alter the AVP-induced anion secretory peak but decreased the cation 
absorptive peak compared to control cells.  Addition of amiloride, a specific blocker of 
epithelial sodium channel (ENaC) to the apical side decreased the net ion transport to 
zero in both inversin knockdown and control cells, indicating ENaC involvement (Figure 
10A).   
The majority of the basal SCC in principal cells is due to the flux of Na
+
 in an 
absorptive direction (Shane et al, 2006).  As shown in Figure 10A, loss of inversin had a 
profound negative effect on the basal SCC in inversin knockdown cells as compared to 
control.  As indicated in Figure 10B, the magnitude of basal SCC correlates with inversin 
mRNA levels in control and inversin knockdown mCCD cells.  
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The changes in basal SCC associated with net transepithelial ion transport in 
inversin knockdown compared to control cells appear to be due to an amiloride-sensitive 
absorptive Na
+
 flux. However, multiple ion channels may be activated in response to 
stimulation with hormones that are known to be active in renal principal cells.  The 
predominate channels previously shown to be present in canine collecting duct cells 
(Lahr et al, 2000) indicate that the transport changes could be due to an anion (Cl
-
 or 
HCO3
-
) secretion and/or cation (Na
+
, K
+
) reabsorption.   Arginine vasopressin (AVP), an 
anti-diuretic hormone regulates the activities of water channels and ion channels in the 
collecting duct.  The two ion channels that are positively regulated by AVP are cystic 
fibrosis transmembrane regulator (CFTR), a Cl
-
 channel and ENaC (Nofziger et al, 2009).   
Although Accell siRNA technology provided inversin knockdown for proof of 
concept studies on ion transport, siRNA technique had limitations for long term gene 
silencing in mCCD cells.  Since ion transport studies require cells to be grown in culture 
for 2 weeks, the addition of siRNA with every media change may interfere with 
consistency between experiments.  Additionally, there was no positive correlation with 
dose of siRNA and the inversin knockdown levels in this study.  Alternatively, further 
experiments on ion transport were conducted in mCCD cells carrying a shRNA-mediated 
stable inversin knockdown.  shRNAs can be stably integrated through virus-mediated 
integration into the nucleus that provide prolonged stable gene silencing.  
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Figure 10:  Transepithelial ion transport in inversin knockdown mCCD cells 
obtained from Accell siRNA technology.  The cells with inversin knockdown and the 
control were grown to confluence on permeable Transwell supports for two weeks and 
the net ion transport was measured as short circuit current (SCC) using Ussing-chamber 
electrophysiological techniques.  Basal SCC was measured for approximately 30 min. 
(A) Electrophysiological tracings show changes in basal SCC with 12, 14, 34 and 43 % 
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respectively in inversin knockdown compared to control cells as indicated by the arrow.  
Following the measurement of basal SCC for 30 minutes, the cells were stimulated with 
arginine vasopressin (AVP) at a concentration of 100mU/ml at time=0 and the SCC were 
recorded for 30 minutes.  Electrophysiologic traces show no change in the initial chloride 
secretory peak but a decrease in the delayed sodium absorptive peak in an inversin-level 
dependent manner.   (B)  Basal SCC correlates with inversin mRNA levels. Value above 
each bar represents the % change in basal SCC.   
 
 
Stable inversin knockdown using shRNA in mCCD cells: Since gene silencing 
with Accell technology had limitations for long term knockdown of inversin in mCCD 
cells as shown above, it was crucial to generate a cell line with stable inversin 
knockdown. To induce inversin depletion, mCCD cells were stably transduced with a 
lentivirus encoding inversin shRNA.  A total of 5 different shRNAs sequences (Table 17) 
targeting different regions of the inversin mRNA were used to determine efficiency of 
inversin knockdown as determined by quantitative RT-PCR.  Multiplicity of infection 
(MOI) corresponding to 2 and 10 transducing lentiviral particles/mCCD cell were tested 
with each construct to determine the optimal transduction efficiency.  As shown in Table 
18, out of five inversin shRNA constructs tested, two constructs (440 and 441) showed 
the highest levels of inversin knockdown.  The levels of inversin knockdown with 
construct 440 were 17, and 45% and construct 441 were 7, and 31% respectively, with 2, 
and 10 MOI.  For the remaining three constructs (438, 442 and 571) the inversin 
knockdown levels ranged between 0 to 21% knockdown with 2 and 10 MOI compared to 
NTC. The higher levels of inversin knockdown in shRNA constructs 440 and 441 
compared to the other 3 constructs could be due to the targeting of exon 9 and 10 versus 
the rest of the constructs that targeted exon 16 and 3’UTR (Table 17).  Constructs 440 
and 441 were further tested at 20 MOI to determine if increased levels of transduction 
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particles would result in even higher levels of inversin knockdown. Construct 440 at 20 
MOI showed a 62% reduction in inversin levels compared to 45% at 10 MOI.  Construct 
441 at 20 MOI showed a 32% reduction in inversin levels compared to 31% at 10 MOI.  
Therefore, construct 440 was selected for further experimentation based on the dose-
dependent increase (17, 45 and 62%) in inversin knockdown levels observed with 2, 10 
and 20 MOI.   
 
 
Table 18: Percent levels of inversin knockdown with different doses of inversin shRNA 
lentiviral particles in mCCD cells compared to NTC
 a 
 
 
 
 
 
 
 
 
 
 
a
mCCD cells were treated with different doses of lentiviral particles carrying inversin 
shRNA.  Total RNA was isolated following 48 hours infection and levels of inversin 
were assessed by quantitative RT-PCR.  The levels of inversin were normalized to 18S 
ribosomal RNA and the data are expressed as fold change over NTC. Each dilution of 
lentiviral particles was plated in triplicate and the samples were pooled for gene 
expression analysis.  NTC when compared to untransfected control cells showed a 10%, 
4% and 0% change in inversin expression level at 2, 10 and 20 MOI.  NTC, non-targeting 
control; 
b
ND, not determined  
 
 
  
Construct 
ID  Multiplicity of infection 
  2 10 20 
440 17 45 62 
441 7 31 32 
442 5 13 ND
b
 
438 0 17 ND 
571 6 -1 ND 
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Following clonal selection, 11 stable clones were obtained from shRNA construct 
440.  As shown in Table 19, the levels of inversin knockdown ranged between 18-81% 
compared to NTC in clones obtained from construct 440 and this could be due to 
differences in the sites of integration of the construct in the genome. Clones with 81% 
(clone 440-2) and 18% (clone 440-9) inversin knockdown was used for 
electrophysiological experiments.  Since electrophysiology requires the cells be grown in 
culture for 2 weeks for formation of tight junctions, inversin mRNA levels were 
measured in cells from clones 440-2 and 440-9 following 2 weeks in culture. As shown in 
Figure 11, clone 440-2 showed 75% inversin knockdown, whereas in clone 440-9 the 
inversin knockdown levels increased from 18 to 38% compared to NTC.  This increased 
inversin knockdown in (clone 440-9) cells with prolonged culture (2 weeks) perhaps 
could be attributed to an increased transcription of shRNA over time in culture. 
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Table 19: Percent inversin knockdown in stable clones and non-targeting control
a
 
Clone # 
Percent inversin knockdown versus NTC-
11 
NTC-11 0 
 440-2
b
 81
440-3 53 
440-4 62 
 440-9
b
 18 
 440-10 79 
 440-12 61 
 440-13 52 
 440-15 71 
 440-19 56 
 440-20 63 
 440-22 59 
a
Stable clones carrying inversin shRNA from construct ID 440 were selected in 
puromycin containing selection media.  Total RNA was isolated from the clones and 
levels of inversin were assessed by quantitative RT-PCR.  The levels of inversin were 
normalized to 18S ribosomal RNA and the data are expressed as fold change over NTC.  
NTC when compared to untransfected control cells showed 6% knockdown.  NTC, non-
targeting control; 
b
clones used for subsequent experiments  
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Figure 11:  Expression levels of inversin in stable inversin knockdown using 
shRNA and untransfected mCCD cells.  Cells were transduced with shRNA (construct 
440) or non-targeting control (NTC).  NTC is the control vector containing an insert that 
does not target the mouse or human sequence.  Inversin mRNA levels in the confluent 
cells were assessed by quantitative real-time PCR.  The data were normalized to 18S 
RNA and expressed as fold change over NTC.  Inversin mRNA levels in cells from 
untransfected control, NTC, clone 440-9 and 440-2 following 3 days in culture. Values 
are mean  SD; n=5.  
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Loss of inversin decreases basal and AVP-stimulated Na
+
 transport in mCCD 
cells:  Confluent 440-9 and 440-2 cell layers grown on permeable supports were mounted 
onto Ussing chambers and short circuit current (SCC) was used to measure electrogenic 
ion flux.    Following the equilibration of basal SCC for 30 min, arginine vasopressin 
(AVP) was added to the basolateral side of the cell monolayer.  Addition of AVP resulted 
in a rapid, transient (0-4 min) anion Cl
-
 secretory response and delayed (4-30 min) cation 
Na
+
 absorptive response in control and inversin knockdown cells (Figure 12A).  A 
significant decrease in basal SCC was observed in both 440-9 and 440-2 clones 
indicating an altered ion flux with inversin loss. Interestingly, the basal SCC paralleled 
the inversin mRNA levels as shown in Figure 12B.   
AVP stimulation did not show a significant change in the Cl
- 
secretory response 
but decreased cation (Na
+
) flux in both 440-9 and 440-2 inversin-depleted clones 
compared to the control cells.  Furthermore, addition of amiloride, a specific inhibitor of 
ENaC decreased the net ion transport to zero indicating ENaC involvement (Figure 12A).  
The magnitude of Na
+
 absorptive response of the control and inversin knockdown clones 
was calculated as a mean change in SCC from baseline to the maximal response at 30 
min following addition of AVP.  The Na
+
 flux was significantly decreased in both 
inversin-depleted (440-2 and 440-9) clones compared to the control cells (Figure 12C).  
The magnitude of Cl
 - 
secretion was calculated as the mean change in SCC from baseline 
to maximal response on the Cl
- 
peak from all the replicates.  As shown in Figure 12D the 
magnitude of Cl
-
 secretion was not statistically significant between control and inversin 
knockdown cells.  Furthermore, the transepithelial resistances of cells measured were not 
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statistically different between NTC and inversin knockdown clones.  These results 
suggest that inversin plays a role in Na
+
 transport via ENaC.  
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Figure 12:  Transepithelial ion transport in stably transduced inversin knockdown 
in mCCD cells. 
 
100 
 
C 
 
 
 
 
 
 
 
 
 
 
 
D 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 continued 
 
Figure 12:  Transepithelial ion transport in stably transduced inversin knockdown 
in mCCD cells.  The inversin knockdown (clones 440-9 and 440-2) and control (NTC) 
cells were grown to confluence on permeable Transwell supports for two weeks and the 
basal ion transport was measured as short circuit current (SCC) using Ussing-chamber 
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electrophysiological techniques.  Basal SCC was measured for approximately 30 min 
(shown 10 min) and the cells were stimulated with arginine vasopressin (AVP) at a 
concentration of 100mU/ml at time=0 and SCC was recorded for additional 30 min.  
Amiloride (a specific inhibitor of ENaC; 1x10
-5
M) added at the end of 30 min. (A) 
Electrophysiological tracings of control and inversin knockdown clones (440-9 and 440-
2). (B) Quantitation of basal SCC in control and inversin knockdown cells correlates with 
inversin mRNA levels as shown.  Values are mean  SEM; n=19 for NTC; n=17 for 
clones 440-9 and 440-2 inversin knockdown samples; *p<0.05 vs NTC, # vs 440-9 clone.  
(C)  SCC representing the amiloride-sensitive response showing a decreased Na
+
 
transport in inversin knockdown clones compared to control.  (D) Magnitude of Cl
-
 
secretory peak showing no significant change in inversin-depleted cells compared to 
control. Values are mean  SEM; n=9 for NTC; n=6 for clone 440-9; n=8 for 440-2.  
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To further confirm that the effect of inversin knockdown on the AVP-induced 
delayed cation flux response was due to Na
+
, the cells were pre-treated with amiloride. 
As shown in Figure 13A, addition of amiloride caused an immediate decrease in the basal 
SCC in both control and inversin knockdown cells from clones 440-2 and 440-9 
demonstrating that the basal ion flux is primarily due to Na
+
 transport consistent with an 
earlier report in a collecting duct cell line (Shane et al, 2006).   Subsequent stimulation of 
the cells with AVP showed a rapid transient anion secretory response but, as expected, 
not the delayed Na
+
 flux in either control or inversin knockdown cells (clones 440-2 and 
440-9).  As in the previous experiment, the changes in Cl
- 
secretion (Figure 13B) were 
not statistically different between control and inversin-depleted cells from clones 440-2 
and 440-9. These data suggest that loss of inversin decreases Na
+
 transport from apical to 
basolateral side (reflecting decreased Na
+
 reabsorption in vivo) in mCCD cells via ENaC. 
To validate if the arginine vasopressin-stimulated Cl
-
 secretory response is via 
CFTR, the control cells were stimulated with 100µM GlyH-101, a CFTR inhibitor prior 
to addition of vasopressin.  As shown in Figure 13C, addition of CFTR inhibitor 
significantly inhibited the Cl
- 
secretory response stimulated by vasopressin indicating that 
Cl
-
 secretion is occurring via CFTR. 
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Figure 13: Loss of inversin decreases transepitihelial sodium transport. 
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Figure 13 continued 
 
Figure 13:  Loss of inversin decreases transepithelial sodium transport.  To 
confirm the delayed Na
+
 absorptive response is via ENaC, following stabilization of 
SCC, the cells were pre-treated with amiloride (a specific inhibitor of ENaC; 1x10
-5 
M) 
and the SCC was recorded for 10 min. The cells were then treated with arginine 
vasopressin (AVP) at a concentration of 100mU/ml and the SCC was recorded for 
additional 30 min.  (A) Amiloride treatment decreased the basal ion transport to zero and 
stimulation with AVP showed a rapid anion secretory (Cl
-
 peak) but not the delayed Na
+
 
absorptive response in inversin knockdown compared to control cells.  (B) Magnitude of 
Cl
-
 secretion showing no significant change in inversin-depleted cells compared to 
controls. Values are mean  SEM; n=5.  (C) Addition of CFTR inhibitor GlyH-101 
significantly decreased the vasopressin-stimulated Cl
-
 secretory peak.  Values are mean  
SEM; n=4 for control group and n=5 for GlyH-101group   
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Loss of Inversin modulates the expression of ENaC and its upstream 
regulators:  Mechanisms for regulation of ion transport include transcriptional and post-
translational modifications such as, phosphorylation, ubiquitinylation and enzymatic 
cleavage (Bhalla & Hallows, 2008).  These processes together determine the abundance 
and activity of ion transporters at the plasma membrane.  ENaC is a heteromeric protein 
made up of three homologous subunits; Scnn1 (sodium channel non neuronal1) alpha (α), 
Scnn1 beta (β) and Scnn1 gamma (γ) that form the channel (Canessa et al, 1994).   To 
elucidate the mechanism of inversin knockdown on ENaC-mediated Na
+
 transport, 
transcript levels encoding the Scnn1α, Scnn1β, Scnn1γ subunits of ENaC were measured.   
As shown in Figure 14 there was a significant increase in Scnn1α (1.4-fold) in clone 440-
2 but not in clone 440-9 compared to control cells; Scnn1β expression was significantly 
decreased in both clones (440-9 and 440-2) in inversin-depleted cells compared to 
controls.  In addition, a decrease in Scnn1γ mRNA (2-fold) was observed in clone 440-9 
compared to the control cells.  To examine potential regulatory components, expression 
levels of Nedd4l, an ubiquitin ligase that has been to shown to target ENaC for 
degradation and two of the upstream regulators of Nedd4l, Sgk1 and Crtc2 were also 
evaluated in inversin-depleted renal epithelial cells.  As shown in Figure 16, an increase 
in the expression levels of the Nedd4l and a decrease in Sgk1 and Crtc2 would be 
expected to accompany a reduced ENaC activity.  However, as shown in Figure 14, the 
transcript levels of Nedd4l was not significantly altered upon loss of inversin but a 
significant increase in the mRNA levels of Sgk1 (~ 6-fold) were accompanied by a 
significant decrease in Crtc2 (1.3-fold) in both inversin-depleted clones (440-9 and 440-
2) compared to the control cells.  Since stimulation of Na
+
 absorption occurs by 
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coordinated activation of epithelial sodium channel (ENaC) and Na
+
, K
+
 ATPase, the 
expression level of Atp1a1, a subunit of Na
+
, K
+
 ATPase was evaluated in inversin-
depleted renal epithelial cells.  Interestingly, there was a significant increase in Atp1a1 
subunit in clone 440-2 (1.5-fold).   These results suggest that inversin modulates the 
transcription of ENaC subunits and its upstream regulators involved in Na
+
 transport in 
mCCD cells either directly or via a complex interplay of factor involved in ENaC 
synthesis and membrane targeting.   
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Figure 14:  Expression levels of epithelial sodium channel (ENaC) subunits and 
genes that regulate ENaC in inversin knockdown mCCD cells.  Total RNA was isolated 
from control (NTC) and inversin knockdown cells (clones 440-9 and 440-2) and gene 
expression changes were determined by quantitative real-time PCR.   The mRNA levels 
were normalized to 18S ribosomal RNA that served as an internal control.  The changes 
in gene expression of (Scnn) 1α (sodium channel non neuronal 1α), Scnn1β (sodium 
channel non neuronal 1β) Scnn1γ (sodium channel non neuronal 1γ), Nedd4l (neural 
precursor cell expressed, developmentally downregulated 4 like), Atp1a1 (Na
+
/K
+
 
ATPase transporting subunit alpha 1), Sgk1 (serum glucocorticoid-inducible kinase1) and 
Crtc2 (creb-regulated transcription coactivator) are expressed as fold change over NTC 
(non-targeting control).  Values are mean  SEM. (n=5), *p<0.05 vs NTC 
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Loss of Inversin decreases the phosphorylated form of Nedd4l: Since 
phosphorylation regulates the activity of Nedd4l, both phosphorylated and total forms of 
this enzyme was measured.  As shown in Figure 15A, Nedd4l is phosphorylated by Sgk1 
which in turn is activated by phosphorylation by Crtc2 kinase within the C-terminal 
hydrophobic motif (Ser422).  The phosphorylated form of Nedd4l which renders Nedd4l 
inactive was decreased in inversin-depleted cells compared to the control cells (Figure 
15B) with no change in the total Nedd4l levels (Figure 15C) consistent with RNA levels.  
The decrease in phosphorylated form of Nedd4l would result in a relative increase in the 
active Nedd4l. Since Nedd4l is a negative regulator of ENaC (Snyder et al, 2002) 
(Wilson, 2004)an increase in its active form would be expected to result in decreased 
ENaC activity.  Unfortunately, validated reagents are not available to measure 
phosphorylated Sgk1 but levels of total Sgk1 were slightly increased at the protein level 
(Figure 15D) although the transcript levels were significantly increased as compared to 
control.  However, Crtc2 protein levels were decreased in clone 440-2 (highest 
knockdown) but not in 440-9 inversin-depleted mCCD clones (Figure 15E). These results 
suggest that reduced ENaC activity upon inversin loss is mediated in part via the post-
translational regulation of Crtc2/Sgk1/Nedd4l axis in addition to transcriptional effects. 
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Figure 15:  Regulation of Crtc2, Sgk1 and Nedd4l protein expression in inversin 
knockdown mCCD cells.  (A) Diagram depicting the regulation of epithelial sodium 
channel activity via Crtc2/Sgk1/Nedd4l.   (B-E)  Western blot analysis of Crtc2 (creb-
regulated transcription coactivator 2), Sgk1 (serum and glucocorticoid-inducible kinase1) 
and Nedd4l (neural precursor cell expressed, developmentally downregulated 4 like) in 
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control and inversin knockdown mCCD cells. Whole cell lysates were prepared as 
described in Materials and Methods. The proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes.  The blots were immunostained using antibodies 
directed against (B) Total Nedd4l (C) phosphorylated Nedd4l (D) total Sgk1, (E): Crct2 
at 1:1000 dilution.  Anti-GAPDH was used as internal control. NTC, (non-targeting 
control) 
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Discussion 
NPHP2 is an infantile form of autosomal recessive disease caused by mutations in 
the Invs (inversin) gene that causes microcystic dilatations within tubules, as well as in 
the Bowman’s space, glomerulus and collecting ducts at the corticomedullary junctions 
of the kidney (Gagnadoux et al, 1989).  This study validates the gene array findings of 
inv/inv mice kidneys on ion transport mechanism to understand inversin function in renal 
cyst growth and expansion associated with NPHP2.  Using stable clones of inversin 
knockdown in mouse cortical collecting duct (mCCD) cells, together with arginine 
vasopressin (AVP), a stimulator of cation reabsorption and anion secretion, this study 
demonstrates that depletion of inversin results in a dose-responsive reduction in Na
+
 
transport.  There have been some previous findings that support a role of inversin in ion 
transport.  For example, in a Xenopus model, loss of inversin has been shown to result in 
edema (Lienkamp, 2010).  Also, in mouse embryonic fibroblasts obtained from inv
-/-
 
mice aberrant expression and targeting of the Na
+
/H
+
 exchanger NHE, an antiporter 
involved in volume and pH regulation have been reported (Veland et al, 2013).  Although 
these data support the premise of fluid accumulation and abnormal ion transport upon 
inversin loss, they do not address the regulation of specific ion transport in the kidney.    
In this study, the reduced AVP-induced cation response seen in inversin-depleted 
cells was amiloride-sensitive demonstrating reduced ENaC activity and hence suggesting 
that Na
+
 transport contributes to the reduced cation transport seen in inversin-depleted 
mCCD cells.    Decreased ENaC activity has also been demonstrated in the principal cells 
of the collecting duct from the bpk (BALB/c polycystic kidney) autosomal recessive PKD 
(ARPKD) mice (Veizis et al, 2004) as well as in the cystic epithelium of PCK rats, an 
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orthologous model of autosomal recessive PKD (ARPKD) with mutations in PKHD1 
gene (Pavlov et al, 2015; Ward et al, 2002).  This form of ARPKD also causes fetal or 
neonatal death but is characterized by the expansion and elongation of collecting ducts 
into multiple small cysts (Adeva et al, 2006). A decrease in Na
+
 reabsorption via ENaC 
upon loss of inversin in renal epithelial cells may be a common mechanism in autosomal 
recessive kidney disorders.  Since fine tuning of Na
+
 reabsorption occurs in the collecting 
ducts and ENaC activity is a rate-limiting step, a minor decrease in ENaC activity could 
have an impact on Na
+
 transport and over time contribute to fluid accumulation in renal 
cysts.   
AVP can also stimulate Cl
-
 secretion via CFTR, a chloride channel expressed in 
renal epithelial cells.  This activity was not altered in inversin knockdown cells. The 
observation on the lack of effect of inversin knockdown on Cl
-
 secretion is in contrast to 
that observed in autosomal dominant polycystic kidney disease (ADPKD).  In ADPKD, 
fluid accumulation in renal cysts is primarily driven by increased Cl
-
 secretion together 
with increased channel-mediated water permeability via aquaporins (Terryn et al, 2011).  
The results of this study lead to the conclusion that despite overall phenotypic similarities 
in terms of enlarged cystic kidneys with both recessive and dominant forms of PKD, 
different mechanisms of ion transport control cyst growth and expansion.  This may 
relate in part to the different mechanisms of cyst formation in these two disease states.  In 
contrast to tubular dilatations in NPHP2 or ARPKD, in ADPKD the renal cysts bud off 
from the nephron and no longer communicate with the tubule from which they originate 
(Wilson, 2004).  
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ENaC plays an important role in the regulation of Na
+
 homeostasis (Bhalla & 
Hallows, 2008; Rossier et al, 2002).  To understand how loss of inversin may lead to 
reduced ENaC activity in mCCD cells, the expression levels of ENaC subunits and its 
upstream regulator Nedd4l were examined on inversin knockdown in renal epithelial 
cells.  Direct evidence of the importance of ENaC in salt homeostasis has come from the 
molecular analysis of genetic diseases disturbing salt reabsorption leading to hypo- or 
hypertensive phenotypes (Warnock, 1998).  Liddle syndrome is an autosomal form of 
salt-sensitive hypertension due to abnormal sodium reabsorption by the renal tubule 
(Warnock, 1998).  Patients with Liddle syndrome carry mutations in β or γ subunit of 
ENaC that results in increased ENaC numbers and activity resulting in increased Na
+
 
reabsorption (Schild et al, 1995; Shimkets et al, 1994).  This is in part due to the inability 
of Nedd4l binding to ENaC (Kamynina et al, 2001; Staub et al, 1996).  Nedd4l, an 
ubiquitin protein ligase, modulates ENaC surface expression (Kabra et al, 2008).  
Unphosphorylated Nedd4l represses epithelial Na
+
 flux by ubiquitination, endocytosis 
and degradation of ENaC (Snyder et al, 2002).  Interestingly, mice deficient in β subunit 
of ENaC exhibit increased natriuresis and die within 2 days after birth (McDonald et al, 
1999).  The observed decrease in phosphorylated Nedd4l (which renders Nedd4l inactive) 
together with a decrease in the RNA levels of Scnn1β upon loss of inversin may explain 
the reduced ENaC activity observed in this study. 
Sgk1 has been established as a convergence point for multiple regulators of Na
+
 
transport and dysfunctions of Sgk1 in the kidneys has been linked to altered renal Na
+
 
transport (Faletti et al, 2002; Loffing et al, 2006).  Sgk1
-/-
 mice display significant loss in 
renal NaCl and body weight under dietary Na
+
 restriction (Wulff et al, 2002).  In 
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addition, ex vivo experiments on collecting ducts showed a decreased transepithelial 
amiloride-sensitive potential that is consistent with reduced Na
+
 transport in the cortical 
collecting duct (Wulff et al, 2002).  The mineralocorticoid aldosterone, a principal 
regulator of Na
+
 homeostasis is central to the control of extracellular fluid volume and 
blood pressure (Pearce, 2003).  Sgk1 expression is induced by aldosterone and its 
catalytic activation is stimulated by phosphorylation (Pearce, 2003).  In this study, loss of 
inversin increased the transcript levels of Sgk1 but did not alter total Sgk1 protein.  
Although the phosphorylated form of Sgk1could not be assayed in this study  (due to lack 
of reagents), the levels of Crtc2, a kinase that is essential for Sgk1 activity and required 
for ENaC-dependent Na
+
 reabsorption were decreased (Lu et al, 2010).  Interestingly, 
Crtc2 has previously been shown to regulate renal tubule Na
+
 homeostasis through Sgk1-
dependent modulation of ENaC activity (Gleason et al, 2015).  A possible model of the 
effects of inversin loss on ENaC via the Crtc2/Sgk1/Nedd4l axis is shown in Figure 16.  
Further studies will be needed to determine if inversin has a direct or indirect effect on 
this axis.  It is also possible that the effects of inversin loss on Na
+
 transport via ENaC 
could be due to changes in cytoskeletal activity (Veland et al, 2013).  In addition, this 
study does not exclude the contribution of other transporters such as K
+
 secretion to fluid 
accumulation in NPHP2.    
In summary, the data demonstrate for the first time that inversin plays a role in 
transepithelial ion transport in renal epithelial cells.  The findings suggest that loss of 
inversin leads to decreased Na
+
 reabsorption via ENaC and this effect is in part mediated 
by transcriptional and post-translational regulation of the Crtc2/Sgk1/Nedd4l axis. A 
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defective Na
+
 absorption in renal epithelial cells as observed in this study may contribute 
to fluid accumulation in NPHP2. 
 
 
 
 
 
 
 
 
 
Figure 16:  Proposed model for epithelial sodium channel (ENaC) regulation upon 
inversin loss in renal epithelial cells.  Loss of inversin may reduce Crtc2 (creb-regulated 
transcription coactivator 2) levels that may result in decreased phosphorylation of Sgk1 
(serum and glucocorticoid-inducible kinase) which in turn can cause decreased 
phosphorylation of Nedd4l (neural precursor cell expressed, developmentally 
downregulated 4 like) leading to increased degradation of ENaC by Nedd4l.   Thus 
reduced ENaC activity can result in decreased Na
+
 transport in inversin-depleted mCCD 
cells. 
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CHAPTER 4: TRANSCRIPTOME ANALYSIS OF INVERSIN-
DEPLETED RENAL EPITHELIAL CELLS: COMPARSION OF IN 
VITRO WITH IN VIVO ARRAY DATA 
Introduction 
Gene array data on inv/inv mice cystic kidneys showed that inversin effects on 
kidneys are attributed, at least, in part through transcriptional regulation of genes 
implicated in inflammation, immune response, cellular metabolism, cell cycle and ion 
transport.  The kidney is a complex organ comprising of multiple cell types and in 
addition, circulating immune cells also infiltrate the renal tissue (Mattson, 2014).  Since 
inv/inv mice is a global knockout model of inversin loss, the gene expression changes 
observed in inv/inv kidneys alone could be a direct effect of inversin on kidney cells per 
se or an indirect effect of infiltrating cells, or a combination of both.   
Renal histology of inv/inv mice kidneys shows cysts in the collecting ducts in 
addition to other nephron segments (Phillips et al, 2004).  Transcriptome analysis in 
inversin-depleted mouse cortical collecting (mCCD) cell line expressing the 
characteristics of the principal cell type of the collecting duct may provide additional 
insights into inversin function in this isolated cell type.  For example, a decrease in Na
+
 
transport in collecting duct cells can have an effect on cell proliferation and apoptosis 
(Hu et al, 2012; O'Donnell et al, 1983).  To decipher additional similarities in the 
molecular and functional pathways affected in mouse cystic kidneys due to inversin loss, 
the transcriptome data from inv/inv mice cystic kidneys was compared to the gene array 
data from inversin-depleted renal epithelial cells, specifically a cell line with the 
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characteristics of the principal cells of the distal nephron and cortical collecting duct.  
The common gene expression changes observed in vitro in isolated renal cells that are 
recapitulated in vivo may provide insights into the direct effect of inversin loss in renal 
epithelial cells. 
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Materials and Methods 
Cell culture:  Inversin-depleted clone 440-2 with 80% knockdown (Table 19) and 
control mCCD cells transfected with NTC (non-targeting control) were used in this 
experiment.  The cells were cultured in 6-well plates and grown in a humidified chamber 
at 37
ο
C, 5% CO2.  Cell culture medium comprised of DMEM/F12 (1:1) supplemented 
with 2% FBS, 80U/ml penicillin, 80µg/ml streptomycin, epidermal growth factor 
(10ng/ml), 5ml per liter of insulin-transferrin-selenium (100x) to a final concentration of 
0.172 mM insulin, 6µM transferrin, 3.87µM sodium selenite, dexamethasone (5x10
-8
M), 
10
-9 M 3,3̍,5-triiodo-L-thyronine.  The medium was replaced three times per week and the 
cells were passaged weekly.   Confluent cultures grown for two weeks were collected for 
gene expression analysis. 
 
Total RNA isolation and real-time PCR:  Total RNA from each sample was 
isolated using RNeasy mini isolation kit (Qiagen, Valencia, CA) according to 
manufacturer’s protocol.   Briefly, the samples were homogenized in lysis buffer and the 
lysate was passed five times through a blunt 20-guage needle fitted to an RNase-free 
syringe. One volume of 70% ethanol was added to the sample which was then applied to 
RNeasy spin column.  The samples were centrifuged and the flow through was discarded.  
DNase treatment of the samples was performed using the RNase-free DNase set from 
Qiagen (Valencia, CA) and the samples were eluted in RNase-free water.  RNA quality 
and quantity were determined by Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. 
Santa Clara, CA, USA) according to manufacturer’s instructions.  First strand cDNA was 
synthesized from 1.5µg of total RNA with random hexamer primers using the 
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SUPERSCRIPT II first strand synthesis kit (Invitrogen).  The mRNA levels were 
determined by quantitative real-time PCR using ABI Prism Sequence Detection System 
5700 (Applied Biosystems).  The mRNA levels were normalized to 18S ribosomal RNA 
that served as an internal control.  
  
Microarray experiments: Total RNA was subjected to microarray gene 
expression analysis.  The RNA samples were processed by Asuragen Inc (Asuragen TX, 
USA) using Mouse Gene 230 2.0 arrays according to the company’s procedures.  All 
arrays that met the minimal recommended quality parameters as described in the 
Affymetrix Data Analysis Fundamentals Guide (P/N 701190) were used for analyses. 
Expression signal was obtained from CEL files using MAS5 algorithm in the Affymetrix 
GCOS software.  The criteria and the potential outcome as described in Table 20 were 
employed to obtain genes that were differentially regulated upon inversin knockdown in 
renal epithelial cells in confluent cultures grown for 2 weeks.    A stringent criterion was 
used to further remove potential NTC effects.  The genes that were common to 
comparisons 1 and 2 and altered in the same direction of change were considered as 
genes altered by inversin knockdown.  These genes were subjected to bioinformatics and 
pathway analysis. 
 
Bioinformatics and statistical analysis: Sequential steps were taken to identify 
differentially expressed genes (DEGs). First, the median signal of the entire dataset was 
applied as a threshold to identify genes ‘Present’ in comparing different groups in the 
study. Second, the fold changes of each ‘Present’ gene were computed from estimated 
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median of comparing groups obtained in the first step. Genes with absolute fold changes 
larger or equal to 1.45 were kept for testing of statistical significance performed in the 
third step using a t-test implemented in R multtest (Resampling-based multiple 
hypothesis testing) package (Dudoit and Ge, 2005). False discovery rate (FDR) of each 
gene was estimated using Benjamini & Hochberg method implemented in multtest R 
package (Pollard et al, 2005).   
The DEGs were defined as those genes with a p-value < 0.05 and FDR < 0.05. 
Principal component analysis (PCA) was performed using TIBCO Spotfire (TIBCO 
Spotfire, Boston, http://spotfire.tibco.com/).  Enrichment analyses of Gene Ontology 
(GO), KEGG and Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) were performed on the DEGs using the right tailed Fisher’s 
exact test.  
 
Table 20: Criteria for gene array analysis and potential outcome in inversin-depleted 
renal epithelial cells in vitro 
Comparisons Groups Potential Outcome 
1 
Untransfected control  
vs Inv-KD
a
 
Genes alteres by Inv-KD but 
may include non-targeting 
effects 
2 NTC
b
 vs Inv-KD 
Genes altered by Inv-KD, 
controlled for NTC effects 
3 
Genes altered in the 
same direction from 
comparison 1 and 2 
Genes altered by Inv-KD 
a
Inv-KD, inversin knockdown; 
b
NTC, non-targeting control 
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Cell proliferation:  Cells with 80% inversin knockdown (clone 440-2) and the 
non-targeting control were plated in a 96-well plate at a density of 3x10
3 
cells per well.  
Cells were collected at different time points 2, 6, 20, 30, 45, and 48h after plating and 
fixed in PREFER fixative (Anatech Ltd, Battle Creek, MI).  The cells were stained with 
Hoechst (2mg/ml) at a dilution of 1:5000.  To each well 50 µl of diluted Hoechst reagent 
was added and incubated at room temperature for one hour.  Cells were washed with PBS 
and the cell counts were determined using the CellInsight NXT High Content 
Imager.  Scan limits were set at maximum of 15 fields or 1000 total cells per well.  Data 
were normalized within the analysis software by dividing the total number of cells by the 
number of fields counted. 
 
Comparison of in vitro and in vivo gene array data of inversin-depleted renal 
epithelial cells and inv/inv mice kidneys: The in vitro array data from confluent cultures 
of inversin-depleted mCCD cells were compared with the array data from inv/inv mice 
cystic kidneys.  Pathway analysis was performed on the common genes derived from 
these two data sets in IPA.   
 
Measurement of caspase 3/7 activity: Cells with 80% inversin knockdown (clone 
440-2) and the non-targeting control were plated in a 96-well plate at a density of 2x10
4 
cells per well.  Caspase 3/7 activity was measured at 6, 18, 24, 48 and 72h after plating 
using Caspase-Glo

3/7 assay kit (Promega) according to manufacturer’s instructions.   
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Statistics:  Data are represented as mean  SD.  Differences between two groups 
were analyzed by an unpaired Student’s t-test.  Differences were considered significant if 
P<0.05.  Line or bar graphs were generated using Microsoft Excel or Sigma Plot 11.0 
software. 
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Results 
Gene expression profiles of inversin-depleted renal epithelial cells:  To gain 
insights into inversin function, transcriptome analysis was performed on inversin-
depleted mouse renal epithelial cells.  Untransfected mCCD control cells, cells 
transfected with non-targeting control (NTC) and inversin-depleted clone 440-2 with 
80% knockdown were grown in culture for 2 weeks.  Replicates of 5 per group were used 
for this experiment.  Mouse genome 430 2.0 array comprises of 45,101 probe sets 
corresponding to over 39,000 transcripts which in turn correspond to 20,670 genes. A 
summary of the gene signal data, detection calls and gene annotations for every gene on 
the chip was generated using Affymetrix MAS 5.0 algorithm (GCOS, v1.3).  Of the 
20,670 genes on the chip, 11,275 (54.5%) genes were detected in the untransfected 
control mCCD cells, 11,414 (55.2%) genes in cells transfected with NTC and 11, 616 
(56.2%) in inversin-depleted cells.  Genes altered by the stringent criteria set to remove 
non-targeting control effects are shown in Table 21.  Number of genes altered in inversin-
depleted cells when compared with the untransfected control (comparison 1) was higher 
compared to the number of genes altered when compared to NTC (comparison 2), 
potentially indicating the effects of NTC.  A total of 992 genes that were altered in the 
same direction of change from comparison 1 and 2 were considered as genes altered by 
inversin knockdown and were used for further analysis. 
 
Identification of differentially expressed genes (DEGs) in inversin-depleted 
renal epithelial cells:  For gene classifications and functional in silico analyses, the probe 
sets with low-grade annotations were eliminated to enable analysis of data sets with 
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reliable annotations.  The DEGs were identified as significant if the comparisons of 
control and inversin-depleted cells gene expression met the criteria of (a) p<0.05, (b) the 
median signal for all the chips in either group was larger than 250 (c) an absolute fold 
change ≥ 1.45.  Of 11,616 genes expressed in inversin-depleted cells, 738 genes (6.4%) 
were differentially expressed in inversin-depleted renal epithelial cells compared to 
control cells.  Out of 738 annotated DEGs, 400 genes were upregulated and 338 genes 
were downregulated in inversin-depleted renal epithelial cells compared to controls 
controls (Appendix, upregulated genes, Table 33; downregulated genes, Table 34).  
 
Table 21: Number of genes altered in control and inversin-depleted renal epithelial cells 
in vitro 
Comparisons Groups 
Number of 
genes altered 
in Inv-KD
a
 
clone Potential Outcome 
1 Untransfected 
control vs Inv-KD 
4219 Genes altered by Inv-KD but 
may include non-targeting 
effects 
2 NTC
b
 vs Inv-KD 3542 Genes altered by Inv-KD, 
controlled for NTC effects 
3 Genes altered in 
the same direction 
from comparison 
1 and 2 
992 Genes altered by Inv-KD 
with stringent criterion 
a
Inv-KD, inversin-knockdown; 
b
NTC, non-targeting control 
 
Functional classification of DEGs in inversin-depleted renal epithelial cells:  
To find common molecular functions of DEGs derived from inversin-depleted renal 
epithelial cells, the DEGs were classified into the categories of the GO (Gene Ontology) 
terms such as, Biological Process (BP), Cellular Component (CC) and Molecular 
Function (MF) using DAVID (the database for annotation, visualization and integrated 
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discovery) bioinformatics tool (Huang da et al, 2009a; Huang da et al, 2009b) and 
Ingenuity Pathway Analysis (IPA).  Table 22 shows the significantly enriched GO-BP 
categories of DEGs identified by Fisher’s exact test (P < 0.05) and an enrichment score 
of 1.45 and above.  As shown in Figure 17, the various biological processes altered in 
inversin-depleted renal epithelial cells compared to control, included regulation of 
transcription, cell migration, chromatid separation and cell cycle, biosynthetic processes, 
morphogenesis, metabolic processes, apoptosis and ion transport.  The majority of these 
genes classified under biological processes that represented increased transcription and 
regulation of RNA biosynthetic process suggesting that loss of inversin may overall 
impact the transcription machinery (Table 22). Another enriched category that was 
altered in inversin knockdown cells was regulation of apoptosis. Overall, the findings on 
regulation of transcription, apoptosis, cell cycle and ion transport are consistent with the 
gene expression changes observed in inv/inv mice cystic kidneys as described in Chapter 
2. Interestingly, the genes associated with negative regulation of sodium transport 
category are also consistent with the decreased sodium ion transport observed in inversin-
depleted cells by electrophysiology.   Thus, GO-BP classification suggests that loss of 
inversin in vitro in isolated renal cells impact various biological processes that may be 
involved in cyst formation, growth and expansion observed in NPHP2.  Involvement of 
some of these processes such as, cell growth and differentiation, immune response, 
apoptosis and ion homeostasis have also been reported in ADPKD (Song et al, 2009), 
ARPKD (Mrug et al, 2008) and in mouse embryonic fibroblasts derived from inv/inv 
mice (Veland et al, 2013) indicating a potential common mechanism in cyst growth and 
expansion in renal diseases between NPHP2, ADPKD and ARPKD. 
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Table 22: GO biological process terms considered significantly enriched for the genes 
regulated in inversin-depleted renal epithelial cells
a
 
Category Term Count P-Value 
Regulation of transcription 
  GO-BP-FAT positive regulation of transcription, DNA-templated 84 2.29E-04 
GO-BP-FAT positive regulation of nucleic acid-templated transcription 84 2.29E-04 
GO-BP-FAT positive regulation of RNA biosynthetic process 84 2.52E-04 
GO-BP-FAT regulation of nucleic acid-templated transcription 171 1.24E-02 
GO-BP-FAT regulation of transcription, DNA-templated 171 1.22E-02 
Cell migration 
  GO-BP-FAT epithelial cell migration 22 9.82E-04 
GO-BP-FAT epithelium migration 22 1.15E-03 
GO-BP-FAT substrate-dependent cerebral cortex tangential migration 4 1.35E-03 
GO-BP-FAT cerebral cortex tangential migration 4 7.14E-03 
GO-BP-FAT tissue migration 22 1.58E-03 
Chromatid separation and cell cycle 
  GO-BP-FAT regulation of mitotic sister chromatid separation 9 1.06E-03 
GO-BP-FAT metaphase/anaphase transition of cell cycle 9 1.22E-03 
GO-BP-FAT mitotic sister chromatid separation 9 1.38E-03 
GO-BP-FAT regulation of mitotic sister chromatid segregation 9 2.26E-03 
GO-BP-FAT negative regulation of mitotic metaphase/anaphase 
transition 
6 1.32E-02 
GO-BP-FAT negative regulation of mitotic sister chromatid separation 6 1.32E-02 
GO-BP-FAT mitotic spindle checkpoint 6 1.32E-02 
GO-BP-FAT 
negative regulation of mitotic sister chromatid 
segregation 6 1.67E-02 
GO-BP-FAT 
negative regulation of metaphase/anaphase transition of 
cell cycle 6 1.67E-02 
GO-BP-FAT negative regulation of sister chromatid segregation 6 2.07E-02 
GO-BP-FAT negative regulation of chromosome segregation 6 2.79E-02 
Biosynthetic process 
  GO-BP-FAT nucleobase-containing compound biosynthetic process 200 2.30E-03 
GO-BP-FAT regulation of RNA biosynthetic process 172 1.04E-02 
GO-BP-FAT aromatic compound biosynthetic process 201 4.24E-03 
GO-BP-FAT heterocycle biosynthetic process 200 4.62E-03 
Transport of nucleic acids 
  GO-BP-FAT nucleic acid transport 15 1.56E-03 
GO-BP-FAT RNA transport 15 1.56E-03 
GO-BP-FAT establishment of RNA localization 15 1.92E-03 
GO-BP-FAT RNA localization 15 1.11E-02 
Ion transport 
  GO-BP-FAT negative regulation of sodium ion transmembrane 
transporter activity 
4 9.51E-03 
GO-BP-FAT negative regulation of sodium ion transmembrane 
transport 
4 1.23E-02 
GO-BP-FAT negative regulation of sodium ion transport 4 2.32E-02 
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Table 22: continued   
Morphogenesis 
  GO-BP-FAT negative regulation of angiogenesis 10 9.39E-03 
GO-BP-FAT negative regulation of blood vessel morphogenesis 10 1.17E-02 
GO-BP-FAT negative regulation of vasculature development 10 1.63E-02 
Peptidase activity   
GO-BP-FAT positive regulation of cysteine-type endopeptidase 
activity 
12 1.17E-02 
GO-BP-FAT positive regulation of endopeptidase activity 12 1.65E-02 
GO-BP-FAT positive regulation of peptidase activity 12 2.03E-02 
Axon guidance   
GO-BP-FAT branchiomotor neuron axon guidance 4 9.51E-03 
GO-BP-FAT semaphorin-plexin signaling pathway involved in axon 
guidance 
4 1.55E-02 
GO-BP-FAT semaphorin-plexin signaling pathway involved in neuron 
projection guidance 
4 1.55E-02 
Catabolic process   
GO-BP-FAT ubiquitin-dependent protein catabolic process 32 2.83E-02 
GO-BP-FAT modification-dependent protein catabolic process 32 3.51E-02 
GO-BP-FAT modification-dependent macromolecule catabolic process 32 4.15E-02 
Apoptosis    
GO-BP-FAT positive regulation of cysteine-type endopeptidase 
activity involved in apoptotic process 
12 6.20E-03 
GO-BP-FAT apoptotic process 116 4.61E-06 
GO-BP-FAT regulation of apoptotic process 98 1.70E-05 
GO-BP-FAT regulation of programmed cell death 98 2.72E-05 
GO-BP-FAT programmed cell death 116 4.29E-05 
GO-BP-FAT regulation of cell death 102 7.82E-05 
GO-BP-FAT cell death 121 9.14E-05 
GO-BP-FAT negative regulation of apoptotic process 66 8.78E-05 
GO-BP-FAT negative regulation of programmed cell death 66 1.36E-04 
GO-BP-FAT negative regulation of cell death 68 6.12E-04 
Hypoxia    
GO-BP-FAT response to hypoxia 23 8.14E-03 
GO-BP-FAT response to decreased oxygen levels 23 1.13E-02 
a
Genes significantly regulated were classified by GO biological process terms (GO level 
FAT) using DAVID 2010 online software.  GO terms with values of P<0.05 (Fisher’s 
exact test) are presented.  Count represents the number of genes involved in each GO 
term. 
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Figure 17:  Overrepresented GO biological processes altered in inversin-depleted 
renal epithelial cells.  Fisher’s exact test was used to identify significant enrichment for 
pathway annotations. Pie chart showing the percent of genes representing different 
categories altered in inversin-depleted renal epithelial cells compared to controls.   
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Table 23 shows the DEGs from inversin-depleted renal epithelial cells that were 
subjected to GO cellular component (CC) analyses to obtain information about sub-
cellular localization.  The DEGs classified into the categories of CC include 
chromosome, mitotic spindle, microtubule cytoskeleton and condensed chromosome 
(Table 23).  These results suggest that loss of inversin may influence the expression of 
genes localized to various regions during different stages of cell cycle consistent with its 
localization during cell cycle (Morgan et al, 2002a; Werner et al, 2013). Additionally, 
genes also classified into organelle outer membrane category, that include nuclear outer 
membrane consistent with the localization of 140 kDa inversin isoform to perinuclear 
compartment (Nurnberger et al, 2002). 
Finally, the DEGs from inversin-depleted renal epithelial cells were classified into 
the categories of GO molecular function (MF) (Table 24).  The various categories in MF 
that were significantly altered due to inversin loss in renal epithelial cells include, binding 
(nucleotide, nucleoside, GTPase, ATP, lipoprotein, L-ascorbic acid, cell adhesion 
molecule), cytoskeletal protein binding (tubulin), ion binding, and activity (protein 
dimerization, phosphatase, kinase, helicase, ligase) and microtubule motor activity.  
These results indicate that loss of inversin may affect various molecular functions in this 
isolated renal epithelial cell type associated with ion transport, trafficking, cell cycle 
progression, cell proliferation and apoptosis.  The DEGs from inversin-depleted renal 
epithelial cells were further subjected to molecular and functional analysis in IPA.  The 
key functional categories altered were cell cycle, cellular assembly and organization, 
DNA replication, recombination and repair, cellular growth and proliferation and cell 
death and survival consistent with GO classification. 
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Table 23: GO cellular component terms considered significantly enriched for the genes 
regulated in inversin-depleted renal epithelial cells compared to controls
a
 
Category Term Count P-value 
GO-CC-FAT Chromosome 104 1.47E-14 
GO-CC-FAT mitotic spindle or spindle pole 43 3.86E-10 
GO-CC-FAT microtubule cytoskeleton 101 4.36E-10 
GO-CC-FAT condensed nuclear chromosome, 
centromeric region 
9 1.42E-05 
GO-CC-FAT cell cortex 26 7.59E-04 
GO-CC-FAT organelle outer membrane 17 0.0199 
GO-CC-FAT secretory granule membrane 12 0.00265 
a
Genes significantly regulated were classified by GO Cellular Component (GO level- 
FAT) using DAVID 2010 online software.  GO terms with values of P<0.05 (Fisher’s 
exact test) are presented.  Count represents the number of genes involved in each GO 
term 
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Table 24: GO molecular function terms considered significantly enriched for the genes 
regulated in inversin-depleted renal epithelial cells compared to controls
a
 
Category Term Count P-Value 
Binding       
GO-MF-FAT nucleotide binding 159 6.58E-09 
GO-MF-FAT nucleoside phosphate binding 159 6.58E-09 
GO-MF-FAT ATP binding 109 1.87E-08 
GO-MF-FAT carbohydrate derivative binding 147 5.75E-08 
GO-MF-FAT GTPase binding 23 0.01418 
GO-MF-FAT lipoprotein particle binding 5 0.01675 
GO-MF-FAT L-ascorbic acid binding 4 0.04934 
GO-MF-FAT cell adhesion molecule binding 29 0.02297 
Cytoskeletal protein binding    
GO-MF-FAT tubulin binding 35 3.46E-08 
GO-MF-FAT microtubule binding 29 4.11E-08 
GO-MF-FAT cytoskeletal protein binding 70 6.90E-08 
Ion binding      
GO-MF-FAT metal ion binding 221 9.90E-06 
GO-MF-FAT ion binding 230 1.49E-05 
Protein dimerization     
GO-MF-FAT protein homodimerization activity 62 4.28E-06 
GO-MF-FAT protein dimerization activity 82 2.88E-05 
Protein activity    
GO-MF-FAT pyrophosphatase activity 58 4.29E-05 
GO-MF-FAT hydrolase activity, acting on acid 
anhydrides, in phosphorus-containing 
anhydrides 
58 
4.73E-05 
GO-MF-FAT nucleoside-triphosphatase activity 55 5.79E-05 
GO-MF-FAT ATPase activity 34 5.69E-04 
GO-MF-FAT kinase activity 59 1.90E-04 
GO-MF-FAT protein serine/threonine kinase activity 36 5.67E-04 
GO-MF-FAT protein kinase activity 45 8.43E-04 
GO-MF-FAT helicase activity 15 0.00337 
GO-MF-FAT vascular endothelial growth factor-activated 
receptor activity 
3 
0.03211 
GO-MF-FAT ligase activity 35 5.00E-05 
Motor activity    
GO-MF-FAT microtubule motor activity 9 0.01417 
GO-MF-FAT ATP-dependent microtubule motor activity, 
plus-end-directed 
4 
0.01537 
GO-MF-FAT motor activity 12 0.03693 
a
Genes significantly regulated were classified by GO Molecular Function terms (GO 
level FAT) using DAVID 2010 online software.  GO terms with values of P<0.05 
(Fisher’s exact test) are presented.  Count represents the number of genes involved in 
each GO term. 
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Pathway analysis of DEGs: To understand the expression patterns of functionally 
related proteins, the genes altered in inversin-depleted renal epithelial cells were 
subjected to Ingenuity Pathway Analysis (IPA).  As shown in Figure 18, the top 
canonical pathways that were affected in inversin-depleted renal epithelial cells included 
the upregulation of thrombin, phosphoinositide 3-kinase (PI3K), epidermal growth factor 
(EGF), protein kinase A, gonadotropin-releasing hormone (GnRH), AMP-activated 
protein kinase (AMPK), corticotropin releasing hormone and renin-angiotensin signaling.  
On the other hand, the pathways involving polo-like kinase in mitosis, cyclins and cell 
cycle regulation were downregulated in inversin-depleted cells compared to controls.  
These results suggest that loss of inversin may affect cell growth and differentiation, 
inflammation, lipid homeostasis and cell cycle progression in renal epithelial cells. 
Key molecular and cellular functions that were identified by IPA analysis in 
inversin-depleted renal epithelial cells included cell cycle, cellular assembly and 
organization, DNA replication, recombination and repair, cell death and survival and 
cellular development. Transcription factors such as cyclin D1 (Ccnd1) and E2f 
transcription factor 1 (E2f1) involved in cell proliferation, cell cycle progression and 
apoptosis were downregulated in inversin-depleted renal epithelial cells (Table 25).  In 
addition, key disease categories in IPA analysis that were altered in inversin-depleted 
cells included glomerulosclerosis and fibrosis of kidney.   
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 18:  Canonical pathways altered in inversin-depleted renal epithelial cells analyzed using IPA.  The numbers to the 
right of each bar represents the ratio of genes regulated in inv/inv mice kidneys to the total number of genes implicated in the 
pathways indicated.  The line graph that runs across each bar represents the threshold set for each pathway.  Orange indicates the 
pathways that are upregulated and blue indicates pathways that are downregulated.  The orange points connected by thin line represent 
the ratio and is calculated as number of genes in a given pathway that meets the cut-off criteria set divided by the total number of 
genes in the reference data set. 
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       Decreased expression of upstream transcription regulators in inversin-depleted 
renal epithelial cells:  Upstream regulator analysis in IPA

 was used to gain insights into 
certain observed gene expression changes in inversin-depleted renal epithelial cells.  As 
shown in Table 25,    certain transcription regulators such as, cyclin D1 (Ccnd1) and E2f 
transcription factor 1 (E2f1) involved in cell proliferation, cell cycle progression and 
apoptosis were downregulated, in inversin-depleted renal epithelial cells. Forty genes 
downstream of Ccnd1 and 55 genes downstream of E2f1 were altered in inversin-
depleted renal epithelial cells.  Together these data suggest that loss of inversin affects 
the expression of certain transcription factors and regulators that target downstream genes 
involved in cell cycle progression, apoptosis and inflammation.   
 
Decrease in the expression levels of cell cycle genes in inversin-depleted renal 
epithelial cells:  Genes in the key canonical pathways representing cell cycle progression 
such as, cyclin A2 (Ccna2), cyclin D1 (Ccnd1), cyclin E2 (Ccne2), cell division cycle A 
(Cdc25a) and E2f1 were downregulated in inversin-depleted renal epithelial cells (Figure 
19).  As shown in Figure 20,  Polo-like kinase (Plk1), a serine/threonine protein kinase 
highly expressed in mitosis, and genes downstream of Plk-1 such as Kif11 (kinesin 
family member11/Eg5) and Chek2 (checkpoint kinase 2/Chk2) were downregulated 
which may affect mitotic entry and exit, centrosome separation and maturation, and 
cytokinesis in inversin-depleted renal epithelial cells. Genes representing DNA synthesis, 
S-phase entry, alignment of chromosomes and chromosomal aberration were altered in 
inversin-depleted renal epithelial cells and may affect cell cycle progression (Table 26).
Table 25: Transcription regulators and the downstream targets affected in inversin-depleted renal epithelial cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2000-2017 QIAGEN. All rights reserved. 
a
Genes indicated in red are upregulated and in blue are downregulated in inversin-depleted renal epithelial cells.                                               
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                        
Transcription 
regulator 
Expression 
fold change 
in clone 440-
2 
Predicted 
activation 
state 
Activation z-
score 
P-value of 
overlap 
Target genes in the dataset
a
 Number 
of genes 
CCND1 -1.46 Inhibited -4.661 1.75E-12 ATAD2,AURKA,BIRC5,BRCA1,CCNA2,CCND1,CCNE2,
CDC6,CDCA2,CDCA8,CENPF,CENPH,CENPK,CEP55,D
EPDC1,DNMT1,DTL,E2F1,ELOVL7,FGFR1,GAS2L3,ITG
B6,KIF11,KIF20B,KIF2C,MBD5,MCM4,MELK,NCAPH,P
LK1,PSRC1,RAD51,RRM2,SPC25,SPP1,STARD4,TPX2,T
SC2,UHRF1,USE1 
40 
E2F1 -1.54 Inhibited -4.172 1.96E-12 ABCG2,ATAD2,AURKA,AURKB,BIRC5,BRCA1,CASP3,
CCNA2,CCNB2,CCND1,CCNE2,CDC20,CDC25A,CDC6,
CDK1,CFLAR,CHEK1,CHEK2,DHFR,DNMT1,E2F1,FEN
1,FGFR1,GINS1,GMNN,GTF2H4,HELLS,HES1,HSPD1,L
TA4H,MAD2L1,MAPK14,MCM3,MCM4,MCM5,MDC1,
MSH2,NRP1,NUSAP1,PKNOX1,PPP1R26,RAD51,RRM1,
RRM2,SP1,TERT,THBS1,TK1,TOP2A,UCK2,UNG 
51 
1
3
5
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Figure 19:  Network of genes represented in the estrogen-mediated S-phase entry 
of cell cycle identified by pathway analysis in IPA

 with a Z-score of -2.5 and P-value 
1.1E-03 in inversin-depleted renal epithelial cells.  Genes shaded in green in the pathway 
are detected and downregulated (indicated by blue arrow) in inversin-depleted renal 
epithelial cells compared to controls affecting G1-S progression. 
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Figure 20:  Network of genes represented in the mitotic roles of polo-like kinase 
identified by pathway analysis in IPA

 with a Z-score of -2.6 and P-value 2.44E-04 in 
inversin-depleted renal epithelial cells.  Genes shaded in green in the pathway are 
detected and downregulated (indicated by blue arrow) in inversin-depleted renal 
epithelial cells compared to controls affecting (A) centrosome separation and maturation 
(B) mitotic entry (C) septum-inducing network and cytokinesis (D) metaphase to 
anaphase transition and mitotic exit 
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Table 26: Genes affecting cell cycle progression are altered in inversin-depleted renal 
epithelial cells 
Gene ID 
Gene 
Symbol Protein Name  
 
Fold 
change/ 
NTC 
  
P-value 
DNA synthesis        
16598 Klf2 Kruppel-like factor 2 (lung) 2.13 0 
18803 Plcg1 phospholipase C, gamma 1 1.95 0 
26416 Mapk14 mitogen-activated protein kinase 14 1.53 0 
15382 Hnrnpa1 heterogeneous nuclear 
ribonucleoprotein A1 
1.49 5.00E-04 
18854 Pml promyelocytic leukemia 1.6 0.0013 
22084 Tsc2 tuberous sclerosis 2 1.84 0 
14083 Ptk2 PTK2 protein tyrosine kinase 2 1.48 0 
18973 Pole polymerase (DNA directed), epsilon -11.57 0 
16007 Cyr61 cysteine rich protein 61 -6.39 0 
20750 Spp1 secreted phosphoprotein 1 -2.95 0 
14677 Gnai1 guanine nucleotide binding protein (G 
protein), alpha inhibiting 1 
-2.63 0 
11799 Birc5 baculoviral IAP repeat-containing 5 -2.46 0.0124 
21814 Tgfbr3 transforming growth factor, beta 
receptor III 
-2.44 0 
67177 Cdt1 chromatin licensing and DNA 
replication factor 1 
-2.22 0 
15901 Id1 inhibitor of DNA binding 1 -2.12 0 
18817 Plk1 polo-like kinase 1 -2.19 0.006 
12428 Ccna2 cyclin A2 -2.7 0 
12450 Ccng1 cyclin G1 -2.06 0 
18140 Uhrf1 ubiquitin-like, containing PHD and 
RING finger domains, 1 
-1.88 0.004 
15945 Cxcl10 chemokine (C-X-C motif) ligand 10 -1.87 0.0111 
58186 Rad18 RAD18 homolog (S. cerevisiae) -1.76 2.00E-04 
17387 Mmp14 matrix metallopeptidase 14 
(membrane-inserted) 
-1.67 0 
14156 Fen1 flap structure specific endonuclease 1 -1.66 0 
12530 Cdc25a cell division cycle 25A -1.63 5.00E-04 
12448 Ccne2 cyclin E2 -1.61 0.0011 
13433 Dnmt1 DNA methyltransferase (cytosine-5) 
1 
-1.61 0.0013 
21752 Tert telomerase reverse transcriptase -1.59 0.0113 
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Table 26 continued 
13555 E2f1 E2F transcription factor 1 -1.54 0.0378 
12443 Ccnd1 cyclin D1 -1.46 0 
26909 Exo1 exonuclease 1 -1.43 0.0186 
S-phase entry     
12236 Bub1b budding uninhibited by 
benzimidazoles 1 homolog, beta (S. 
cerevisiae) 
-3.13 0.0037 
12235 Bub1 budding uninhibited by 
benzimidazoles 1 homolog (S. 
cerevisiae) 
-3.93 0.005 
107995 Cdc20 cell division cycle 20 -2.97 0.0018 
56150 Mad2l1 MAD2 mitotic arrest deficient-like 1 -2.49 3.00E-04 
Alignment of chromosomes     
110033 Kif22 kinesin family member 22 -3.18 0.0013 
12428 Ccna2 cyclin A2 -2.7 0 
11799 Birc5 baculoviral IAP repeat-containing 5 -2.46 0.0124 
72415 Sgol1 shugoshin-like 1 (S. pombe) -2.45 0.0057 
73804 Kif2c kinesin family member 2C -2.31 0.0024 
20878 Aurka aurora kinase A -1.87 0.0071 
2E+05 Cenpe centromere protein E -1.77 0.0049 
Chromosomal aberration   
12236 Bub1b budding uninhibited by 
benzimidazoles 1 homolog, beta (S. 
cerevisiae) 
-3.13 0.0037 
11799 Birc5 baculoviral IAP repeat-containing 5 -2.46 0.0124 
12443 Ccnd1 cyclin D1 -1.46 0 
26909 Exo1 exonuclease 1 -1.43 0.0186 
15205 Hes1 hairy and enhancer of split 1 
(Drosophila) 
-1.55 0 
16881 Lig1 ligase I, DNA, ATP-dependent -1.65 0 
56150 Mad2l1 MAD2 mitotic arrest deficient-like 1 -2.49 3.00E-04 
17762 Mapt microtubule-associated protein tau 1.62 0 
18771 Pknox1 Pbx/knotted 1 homeobox 1.47 4.00E-04 
19712 Rest RE1-silencing transcription factor -1.52 0 
21752 Tert telomerase reverse transcriptase -1.59 0.0113 
80914 Uck2 uridine-cytidine kinase 2 -1.61 0 
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To determine if the changes in the expression of cell cycle genes has an effect on 
cell number, cell proliferation was evaluated in an in vitro model of inversin loss in renal 
epithelial cells.  As shown in Figure 21, loss of inversin decreased cell number as a 
function of time in inversin-depleted renal epithelial (mCCD) cells compared to controls.  
These data suggest that loss of inversin results in decreased cell proliferation in inv/inv 
mice kidneys that may affect the development of kidneys. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21:  Assessment of cell proliferation in inversin-depleted renal epithelial 
(mCCD) cells.  Cells with inversin knockdown (clone 440-2) and the control were plated 
at a density of 3x10
3   
cells/ well.  Cell number was evaluated at different time points by 
Hoechst staining of nuclei and imaging using ArrayScan.  Values are mean  SD; NTC 
n=4, Clone 440-2, n=6; 
*
P < 0.05 vs NTC; mCCD, mouse cortical collecting duct 
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Upregulated pathways in inversin-depleted renal epithelial cells:  Key 
upregulated signaling pathways in inversin-depleted renal epithelial cells included 
thrombin, phosphoinositide 3-kinase (PI3K), epidermal growth factor (EGF), protein 
kinase A (PKA), gonadotropin-releasing hormone (GnRH), AMP-activated protein 
kinase (AMPK), corticotropin releasing hormone (CRH) and renin-angiotensin signaling. 
Genes representing these pathways are shown in Table 27.  Certain common downstream 
targets of the Egf signaling via Egfr, angiotensin signaling via angiotensin II receptor 
(Agtr1) and GnRH signaling via GnRH-1 and II receptors include, inositol 1-4-5, 
trisphosphate receptor 2 (Itpr2), mitogen-activated protein kinase (Mapk12), Mapk14, 
phospholipase C-gamma 1 (Plcg1), and Sos Ras/Rac guanine nucleotide exchange factor 
(Sos1) were also upregulated in inversin-depleted renal epithelial cells.  GnRH signaling 
via GnRH-1 and II receptors has been shown to have anti-proliferative effects on ovarian 
cells suggesting possible involvement of GnRH in some of extra-pituitary functions (Kim 
et al, 2006).  The results suggest that upregulation of these pathways can contribute to 
cell proliferation, cytoskeletal changes and cell migration.   
AMPK is a master metabolic regulator which inhibits enzymes of ATP 
consuming pathways and is activated in response to injury, inflammation, hypoxia or 
ischemia (Long & Zierath, 2006).  Certain downstream genes of AMPK activation such 
as 3-hydroxy-3-methylglutaryl CoA reductase (Hmgcr), Mapk12 and Mapk14, ribosomal 
protein S6 kinase 1 (Rps6kb1), sirtuin1 (Sirt1) and tuberous sclerosis complex (Tsc2) 
were upregulated in inversin-depleted renal epithelial cells.  CRH signaling via CRH 
receptor, a mediator of stress response was upregulated in inversin-depleted renal 
epithelial cells.  CRH functions through activation of several signaling pathways 
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including adenylate cyclase/PKA, phospholipase C/protein kinase and MAPK pathways 
(Subbannayya et al, 2013).  Genes associated with CRH signaling such as, adenylate 
cyclase 6 (Adcy6), Plcg1, Mapk12 and 14 were also upregulated in inversin-depleted 
renal epithelial cells.   
PI3 kinase signaling has been implicated in wide range of cellular processes and 
B-cell differentiation (Baracho et al, 2011).  Downstream genes of PI3K signaling such 
as calcium/calmodulin dependent protein kinase 2a (Camk2a) and Camk2d, activating 
transcription factor 6 beta (Atf6b) and Atf, Itpr2 and malt1 paracaspase (Malt1) and 
Plcg1were also upregulated in inversin-depleted renal epithelial cells.  Overall, the 
upregulation of these genes can contribute to cell proliferation or hypertrophy, increase 
the expression and synthesis of extracellular matix proteins or elicit immune response 
that can contribute to renal fibrosis resulting in renal damage. 
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Table 27: Genes in the upregulated canonical signaling pathways in inversin-depleted 
renal epithelial cells 
Gene ID 
Gene 
Symbol Protein Name  
 Fold 
change/ 
NTC   P-value 
Genes common to EGF, Thrombin and GnRH signaling 
    
16439 Itpr2 inositol 1,4,5-triphosphate receptor 2 2.13 0 
18803 Plcg1 phospholipase C, gamma 1 1.95 0 
26416 Mapk14 mitogen-activated protein kinase 14 1.53 0 
29857 Mapk12 mitogen-activated protein kinase 12 1.72 0 
20662 Sos1 son of sevenless homolog 1  1.63 1.00E-04 
72508 Rps6kb1 ribosomal protein S6 kinase, 
polypeptide 1 
1.54 2.00E-04 
Renin-Angiotensin signaling    
16439 Itpr2 inositol 1,4,5-triphosphate receptor 2 2.13 0 
18803 Plcg1 phospholipase C, gamma 1 1.95 0 
29857 Mapk12 mitogen-activated protein kinase 12 1.72 0 
11512 Adcy6 adenylate cyclase 6 1.66 0 
20662 Sos1 son of sevenless homolog 1 1.63 1.00E-04 
26416 Mapk14 mitogen-activated protein kinase 14 1.53 0 
14083 Ptk2 PTK2 protein tyrosine kinase 2 1.48 0 
AMPK signaling       
22084 Tsc2 tuberous sclerosis 2 1.84 0 
93759 Sirt1 sirtuin 1 1.73 0 
29857 Mapk12 mitogen-activated protein kinase 12 1.72 0 
72508 Rps6kb1 ribosomal protein S6 kinase, 1 1.54 2.00E-04 
26416 Mapk14 mitogen-activated protein kinase 14 1.53 0 
15357 Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme 
A reductase 
-1.52 0 
Corticotropin releasing hormone signaling   
18803 Plcg1 phospholipase C, gamma 1 1.95 0 
29857 Mapk12 mitogen-activated protein kinase 12 1.72 0 
11512 Adcy6 adenylate cyclase 6 1.66 0 
26416 Mapk14 mitogen-activated protein kinase 14 1.53 0 
109880 Braf Braf transforming gene 1.48 0 
GnRH signaling       
12322 Camk2a calcium/calmodulin-dependent protein 
kinase II alpha 
1.97 0.0124 
11512 Adcy6 adenylate cyclase 6 1.66 0 
14083 Ptk2 PTK2 protein tyrosine kinase 2 1.48 0 
108058 Camk2d calcium/calmodulin-dependent protein 
kinase II, delta 
1.49 2.00E-04 
 
144 
 
Table 27 continued   
PI3 kinase signaling       
107503 Atf5 activating transcription factor 5 3.9 0 
16439 Itpr2 inositol 1,4,5-triphosphate receptor 2 2.13 0 
12322 Camk2a calcium/calmodulin-dependent protein 
kinase II alpha 
1.97 0.0124 
18803 Plcg1 phospholipase C, gamma 1 1.95 0 
223922 Atf7 activating transcription factor 7 1.71 0.0161 
12915 Atf6b activating transcription factor 6 beta 1.66 0 
240354 Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
1.58 7.00E-04 
108058 Camk2d calcium/calmodulin-dependent protein 
kinase II, delta 
1.49 2.00E-04 
PKA signaling      
16439 Itpr2 inositol 1,4,5-triphosphate receptor 2 2.13 0 
12322 Camk2a calcium/calmodulin-dependent protein 
kinase II alpha 
1.97 0.0124 
18803 Plcg1 phospholipase C, gamma 1 1.95 0 
11512 Adcy6 adenylate cyclase 6 1.66 0 
108058 Camk2d calcium/calmodulin-dependent protein 
kinase II, delta 
1.49 2.00E-04 
109880 Braf Braf transforming gene 1.48 0 
14083 Ptk2 PTK2 protein tyrosine kinase 2 1.48 0 
12530 Cdc25a cell division cycle 25A -1.63 5.00E-04 
19272 Ptprk protein tyrosine phosphatase, receptor 
type, K 
-1.74 0 
72391 Cdkn3 cyclin-dependent kinase inhibitor 3 -2.03 0.0167 
14677 Gnai1 guanine nucleotide binding protein (G 
protein), alpha inhibiting 1 
-2.63 0 
19274 Ptprm protein tyrosine phosphatase, receptor 
type, M 
-3.52 0 
Thrombin signaling       
17904 Myl6 myosin, light polypeptide 6, alkali, 
smooth muscle and non-muscle 
2.24 0 
12322 Camk2a calcium/calmodulin-dependent protein 
kinase II alpha 
1.97 0.0124 
11512 Adcy6 adenylate cyclase 6 1.66 0 
16800 Arhgef2 rho/rac guanine nucleotide exchange 
factor (GEF) 2 
1.62 0 
108058 Camk2d calcium/calmodulin-dependent protein 
kinase II, delta 
1.49 2.00E-04 
14083 Ptk2 PTK2 protein tyrosine kinase 2 1.48 0 
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Genes affecting ion transport are altered in inversin-depleted renal epithelial 
cells:  Several genes that affect ion transport including sodium reabsorption were altered 
in inversin-depleted renal epithelial cells (Table 28).  Neural precursor expressed 
developmentally downregulated gene 4-like (Nedd4l), a negative regulator of epithelial 
sodium channel (ENaC) activity was upregulated whereas, serine threonine kinase 39 
(Stk39/Spak), a positive regulator of ENaC (Ahmed et al, 2015) was downregulated in 
inversin-depleted renal epithelial cells.  Overall, these two findings suggest that loss of 
inversin decreased sodium transport in renal epithelial cells consistent with the findings 
in inv/inv mice kidneys and in inversin-depleted mouse cortical collecting duct cells. 
Calcium/calmodulin-dependent kinase 2 delta (Camk2d), one of the protein kinases that 
can phosphorylate aquaporin-2, a water channel in the collecting duct, was upregulated in 
inversin-depleted renal epithelial cells. Members of the solute carrier (Slc) family were 
differentially regulated in inversin-depleted renal epithelial cells that included 
monocarboxylic acid transporters Slc16a6 (upregulated) and Slc16a12 (downregulated); 
mitochondrial transport members such as Slc25a12/aralar, Slc25a27/Ucp4 (uncoupling 
protein 4), Slc25a53, a mitochondrial carrier triple repeat 6 (Mcart6) were upregulated.  
In addition, some of the upregulated solute carrier members included Slc7a5, an L-type 
amino acid transporter (Lat1), Slc46a1, a proton-coupled folate transporter (Pcft) and 
Slc30a10, a zinc transporter (Znt10).  Interestingly, Slc29a2, a nucleoside transporter that 
mediates reabsorption of nucleosides from lumen to blood driven by Na
+
 currents was 
upregulated in inversin-depleted renal epithelial cells. Slc4a3/Ae3 (an anion exchanger 
3), a Cl
-
/bicarbonate exchanger and Slc4a8, a Na
+
-coupled bicarbonate co-transporter 
(Nbc3) were also upregulated. 
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Table 28: Genes involved in ion transport altered in inversin-depleted renal epithelial 
cells 
Gene 
ID 
Gene 
Symbol Protein Name 
Fold 
change/ 
NTC P-value 
Na
+
 transport    
83814 Nedd4l neural precursor cell expressed, 
developmentally down-regulated gene 
4-like 
2.37 0 
108058 Camk2d calcium/calmodulin-dependent protein 
kinase II, delta 
1.49 2.00E-04 
53416 Stk39 serine/threonine kinase 39 -3.61 0 
59033 Slc4a8 solute carrier family 4 (anion 
exchanger), member 8 
1.48 0.0131 
Others     
104681 Slc16a6 solute carrier family 16 
(monocarboxylic acid transporters), 
member 6 
3.21 0 
20539 Slc7a5 solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 5 
1.92 0 
52466 Slc46a1 solute carrier family 46, member 1 1.89 0 
78830 Slc25a12 solute carrier family 25 (mitochondrial 
carrier, Aralar), member 12 
1.79 1.00E-04 
74011 Slc25a27 solute carrier family 25, member 27 1.75 6.00E-04 
67062 Slc25a53 solute carrier family 25, member 53 1.72 0 
13340 Slc29a2 solute carrier family 29 (nucleoside 
transporters), member 2 
1.62 1.00E-04 
226781 Slc30a10 solute carrier family 30, member 10 1.55 0 
73836 Slc35b2 solute carrier family 35, member B2 1.51 0.0041 
242585 Slc35d1 solute carrier family 35 (UDP-
glucuronic acid/UDP-N-
acetylgalactosamine dual transporter), 
member D1 
1.49 2.00E-04 
20536 Slc4a3 solute carrier family 4 (anion 
exchanger), member 3 
1.46 7.00E-04 
229782 Slc35a3 solute carrier family 35 (UDP-N-
acetylglucosamine (UDP-GlcNAc) 
transporter), member 3 
-1.47 0 
240638 Slc16a12 solute carrier family 16 
(monocarboxylic acid transporters), 
member 12 
-3.71 0 
210027 Slc35f3 solute carrier family 35, member F3 -4.83 0 
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Genes implicated in renal fibrosis were altered in inversin-depleted renal 
epithelial cells:  Kidney failure, a disease category identified in IPA

 analysis 
comprising of glomerular injury and renal fibrosis was altered in inversin-depleted renal 
epithelial cells.  Key genes in this category included budding uninhibited by 
benzimidazole 1 (Bub1b), a mitotic regulator, matrix metalloproteinase 14 (Mmp14), 
metallothionein 2 (Mt2), a metal-binding protein, stanniocalcin1 (Stc1), tumor necrosis 
factor superfamily 1b (Tnfrsf1b) were downregulated in inversin-depleted renal epithelial 
cells compared to control.  Additionally, certain genes implicated in glomerulosclerosis 
such as thymidine kinase (Tk1), a gene in pyrimidine nucleotide salvage pathway 
(Dobrovolsky et al, 2003) and secreted phosphoprotein (Spp1/osteopontin), were also 
downregulated in inversin-depleted renal epithelial cells (Table 29). 
 
Table 29: Genes affecting renal fibrosis altered in inversin-depleted renal epithelial cells 
Gene 
ID 
Gene 
Symbol Protein Name  
 
Fold 
change/ 
NTC 
  
P-value 
12236 Bub1b budding uninhibited by benzimidazoles 1 
homolog, beta (S. cerevisiae) 
-3.13 0.0037 
20855 Stc1 stanniocalcin 1 -1.96 3.00E-04 
17750 Mt2 metallothionein 2 -1.77 2.00E-04 
17387 Mmp14 matrix metallopeptidase 14 (membrane-
inserted) 
-1.67 0 
21938 Tnfrsf1b tumor necrosis factor receptor superfamily, 
member 1b 
-1.97 0 
21877 Tk1 thymidine kinase 1 -5.08 0.0045 
20750 Spp1 secreted phosphoprotein 1 -2.95 0 
 
 
148 
 
Overall, some of the key biological processes that were altered in inversin-
depleted renal epithelial cells included transcription, regulation of RNA biosynthetic 
process and apoptosis.  Some of the cellular and molecular functions that were affected 
upon inversin loss in renal epithelial cells include cell cycle, cellular assembly and 
organization, DNA replication, recombination and repair, cellular development, cell 
growth and proliferation and ion transport. The key signaling pathways that were 
upregulated were EGF, AMPK, PI3K, renin-angiotensin that may contribute to 
mitogenesis, cytoskeletal changes or renal fibrosis.  The key downregulated pathway 
included cell cycle regulation.  Loss of inversin decreased cell number as a function of 
time in renal epithelial cells indicating a decreased cell proliferation. 
 
Comparison of transcriptome data from inv/inv mice cystic kidneys and 
inversin-depleted renal epithelial cells:  Gene array data showed a total of 646 genes that 
were differentially expressed in inv/inv mice cystic kidneys compared to the wild-type 
controls (Appendix, Tables 31 and 32).  A total of 738 genes were differentially 
expressed in inversin-depleted renal epithelial cells compared to control cells (Appendix, 
Tables 33 and 34).  Comparison of the gene array from inv/inv mice kidneys and 
inversin-depleted renal epithelial cell cultures are shown in Table 30.  A total of 38 genes 
were common to both data sets and altered in the same direction.   Of the 38 common 
genes 28 were upregulated and 10 were downregulated.  As expected, inversin was 
downregulated in both inv/inv mice kidneys as well as in inversin-depleted renal 
epithelial cells.   Furthermore, these 38 common differentially expressed genes were 
further subjected to pathway analysis in IPA.  Two functional categories that were 
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significantly altered were a decrease in organismal death (increased survival) and the 
other one is increase in body size. 
Out of 38 genes that were common between the two data sets 16 genes were 
represented in the organismal death category, of which 12 genes were upregulated and 4 
were downregulated (Figure 22).  Genes such as, sprouty-related EVH1 domain 
containing 2 (spred2), cysteine rich transmembrane BMP regulator 1 (Crim1) which is a 
developmentally expressed transmembrane protein, neural precursor cell expressed 
developmentally down-regulated 4-like (Nedd4l), an E3 ubiquitin ligase that 
ubiquitinates ENaC,  A kinase (PRKA) anchor protein 13 (Akap13), baculoviral IAP 
repeat-containing 6 (Birc6), Braf transforming gene (Braf), strawberry notch homolog 2 
(Sbno2) which is a DExD/H helicase family corepressor, Erbb2 interacting protein 
(Erbb2ip), kruppel-like factor 6 (Klf6), a zinc finger domain transcription factor, methyl-
CpG binding domain protein 5 (Mbd5), muscleblind-like (Mbnl1) and nuclear receptor 
corepressor 1 (Ncor1), an activating subunit of chromatin modifying enzyme histone 
decetylase (Hdac3) were upregulated in both data sets.  On the other hand, caspase 3 
(Casp3), cytochrome P450 family 51a1 (Cyp51), GA binding protein beta 1 (Gabpb1) 
and hepatocyte growth factor activator (Hgfac) were downregulated in both data sets.  
Overall, the differential regulation of these genes may contribute to decreased organismal 
death (increased survival) as a compensatory mechanism to maintain homeostasis since 
the inv/inv mice have a short lifespan (Yokoyama et al, 1993).  
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Table 30:  Altered genes common to inversin-depleted renal epithelial cells and inv/inv 
mice cystic kidneys  
Gene 
ID 
Gene 
Symbol Protein Name  
Fold 
change  
/NTC-
Inversin-
depleted 
cells 
Fold 
change 
(inv
-/-
/wild-
type) Family 
Upregulated genes         
214150 Ago3 argonaute RISC catalytic 
subunit 3 
1.68 1.90 translational 
regulator 
75547 Akap13 A kinase (PRKA) anchor 
protein 13 
1.82 1.52 protein kinase 
scaffold  
106585 Ankrd12 ankyrin repeat domain 12 1.83 1.53 other 
12211 Birc6 baculoviral IAP repeat-
containing 6 
1.48 1.80 ubiquitin 
ligase 
109880 Braf Braf transforming gene 1.48 1.52 kinase 
268936 Brpf3 bromodomain and PHD finger 
containing, 3 
1.55 1.95 other 
66371 Chmp4c charged multivesicular body 
protein 4C 
1.46 3.03 other 
50766 Crim1 cysteine rich transmembrane 
BMP regulator 1 (chordin like) 
1.79 1.60 kinase 
70686 Dusp16 dual specificity phosphatase 16 1.54 1.59 phosphatase 
18218 Dusp8 dual specificity phosphatase 8 1.62 1.85 phosphatase 
59079 Erbb2ip Erbb2 interacting protein 1.46 1.49 other 
58180 Hic2 hypermethylated in cancer 2 2.68 2.15 other 
63830 Kcnq1ot
1 
KCNQ1 overlapping transcript 
1 
2.15 3.86 other 
23849 Klf6 Kruppel-like factor 6 1.47 2.15 transcriptional 
regulator 
14924 Magi1 membrane associated 
guanylate kinase, WW and 
PDZ domain containing 1 
1.51 1.61 guanylate 
kinase 
109241 Mbd5 methyl-CpG binding domain 
protein 5 
1.59 1.53 other 
56758 Mbnl1 muscleblind-like 1 
(Drosophila) 
1.49 1.79 other 
20185 Ncor1 nuclear receptor co-repressor 1 1.67 1.57 transcriptional 
regulator 
            
83814 Nedd4l neural precursor cell expressed, 
developmentally down-
regulated gene 4-like 
2.37 1.68 ubiquitin 
ligase 
71175 Nipbl Nipped-B homolog 
(Drosophila) 
1.48 1.50 transcriptional 
regulator 
22038 Plscr1 phospholipid scramblase 1 1.71 2.04 enzyme 
216161 Sbno2 strawberry notch homolog 2 
(Drosophila) 
1.46 1.45 other 
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Table 30: continued    
59009 Sh3rf1 
SH3 domain containing ring 
finger 1 1.45 1.59 other 
114716 Spred2 
sprouty-related, EVH1 domain 
containing 2 1.58 1.96 cytokine 
75956 Srrm2 
serine/arginine repetitive 
matrix 2 1.61 1.93 other 
24132 Zfp53 zinc finger protein 53 2.02 2.04 other 
69020 Zfp707 zinc finger protein 707 1.58 1.48 other 
Downregulated genes       
12367 Casp3 caspase 3 -2.06 -1.55 peptidase 
13121 Cyp51 cytochrome P450, family 51 -1.65 -1.49 enzyme 
14391 Gabpb1 
GA repeat binding protein, 
beta 1 -1.45 -1.64 
transcriptional 
regulator 
54426 Hgfac 
hepatocyte growth factor 
activator -1.52 -2.06 
serine 
protease 
110920 Hspa13 
heat shock protein 70 family, 
member 13 -2.29 -1.45 other 
16348 Invs inversin -2.70 -3.10 transcriptional 
regulator/ 
protein 
binding 
18451 P4ha1 procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 
1 polypeptide 
-1.61 -2.03 enzyme 
225845 Pla2g16 phospholipase A2, group XVI -1.51 -1.86 enzyme 
80914 Uck2 uridine-cytidine kinase 2 -1.61 -1.53 kinase 
224454 Zdhhc14 
zinc finger, DHHC domain 
containing 14 -1.56 -1.68 enzyme 
 
  
152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F 
 
 
Figure 22:  IPA analysis of genes common to inv/inv mice cystic kidneys and 
inversin-depleted renal epithelial cells predicted decrease in organismal death (shaded in 
blue in the center) category to be increased with an activation Z score of -2.05.  Shaded in 
red are the genes that are upregulated and shaded in green are downregulated genes in the 
dataset.  The direction of change in the gene expression of 12 out of 16 genes in the 
category was predicted to increase body size.   Blue dotted arrow indicates a decrease in 
organismal death.  Yellow dotted lines indicate genes where the direction of change in 
gene expression (downregulation) is predicted to increase organismal death. 
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Interestingly, a subset of genes from the organismal death category was also 
represented in the body size functional category.  As shown in Figure 23, genes that were 
predicted to affect the body size included Mbd5, Mbnl, a RNA-processing factor, Ncor1, 
Sbno2, KCNQ1 overlapping transcript 1 (Kcnq1ot1), an imprinting gene and Kruppel-
like factor 6 (Klf6) were upregulated in both data sets.  Since the gene expression data are 
from kidney and renal epithelial cells, these findings indicate that these genes may 
contribute to increased kidney size observed in inv/inv mice (Phillips et al, 2004; 
Yokoyama et al, 1993). 
 
Decreased caspase 3 activity in inversin-depleted renal epithelial cells:  Caspase 
3 was one of the genes common to both inv/inv mice cystic kidneys and inversin-depleted 
renal epithelial cells.  To determine if the decrease in the expression of caspase 3 has an 
effect on its activity, caspase 3/7 activity was evaluated in inversin-depleted renal 
epithelial cells.  As shown in Figure 24, loss of inversin decreased caspase 3/7 activity as 
a function of time in inversin-depleted cells compared to controls.  These data suggest 
that loss of inversin may result in decreased apoptosis in inv/inv mice kidneys and in 
renal epithelial cells that may contribute to kidneys. 
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Figure 23:  IPA analysis of genes common to inv/inv mice cystic kidneys and 
inversin-depleted renal epithelial cells predicted increased body size (shaded in orange in 
the center) category to be increased with an activation Z score of 1.46.  Shaded in red are 
the genes that are upregulated and shaded in green are downregulated genes in the data 
set.  The direction of change in the gene expression of 5 out of 7 genes in the category 
was predicted to increase body size.   Red dotted arrow indicates an increase in the size of 
body.  Grey arrow indicates the effect of Ncor1 affects body size but the direction of 
change is not known. Yellow dotted lines indicate gene where the direction of change in 
gene expression is not consistent with findings on downstream effects. 
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Figure 24:  Assessment of caspase 3/7 activity in inversin-depleted renal epithelial 
cells.  Cells with inversin knockdown (clone 440-2) and the control were plated at a 
density of 2x10
4 
cells per well in a 96-well plate.  Following incubation at the indicated 
time points, 200 µl of the Caspase-Glo 3/7

 reagent was added directly to the cells in 96-
well plates, mixed well and incubated at room temperature for 90 min. Luminescence 
(relative light units, RLU) was recorded using Wallac Victor 2

 1420 multilabel counter.  
Values are mean  SD; n=5, *P < 0.05 vs NTC.  NTC, non-targeting control 
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Discussion 
In kidneys, the cortical collecting duct is the final site of regulation of sodium, 
potassium, acid or base and water excretion.  The major hormonal factors that positively 
control sodium reabsorption in the collecting duct are aldosterone and vasopressin 
(Feraille & Doucet, 2001).  A decrease in vasopressin-stimulated amiloride-sensitive Na
+
 
transport was observed in inversin-depleted renal epithelial cells by electrophysiology.  
To better understand inversin function, transcriptome analysis was performed in inversin-
depleted renal epithelial cells isolated from mouse collecting duct.  The key transcription 
profiles that were altered in pathway analysis included cell cycle progression, cellular 
assembly and organization, DNA replication, recombination and repair, cellular 
development, cell growth and proliferation and ion transport.  
In the collecting duct cells, main actions of vasopressin, an anti-diuretic hormone 
is to permeabilize the apical membrane to water through increased expression of 
aquaporin 2 (Aqp2), sodium reabsorption and potassium secretion (Kwon et al, 2013).  
Although Aqp2 was not altered in inversin-depleted renal epithelial cells, AMP kinase 
(AMPK), a metabolic sensor known to inhibit Aqp2 function in kidney principal cells 
(Al-Bataineh et al, 2016) was upregulated indicating that water reabsorption may be 
affected upon inversin loss.  Stk39/Spak, a serine threonine kinase, participates in renal 
salt excretion through the regulation of NaCl and Na(+), K(+), 2Cl(-) cotransport was 
downregulated in inversin-depleted renal cells.  Coexpression of Stk39 in ENaC 
expressing oocytes increased the amiloride sensitive current indicating ENaC activity 
(Ahmed et al, 2015).  Nedd4l, an ubiquitin ligase that ubiquitinates ENaC and inhibits its 
activity was upregulated in inversin-depleted renal cells.  Interestingly, the 
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downregulation of Stk39 (a positive regulator of ENaC) and upregulation of Nedd4l (a 
negative regulator of ENaC) decreases overall Na
+
 transport in inversin-depleted renal 
epithelial cells.  Regulation of Na
+
 balance is a crucial factor to maintain blood volume 
and dysregulation of sodium excretion results in altered intravascular volume resulting in 
hypertension (Guyton, 1991) or natriuresis due to decreased reabsorption (Granger et al, 
2002).  Na
+
 reabsorption can also occur via Na
+
-dependent Cl
-
/HCO3
-
 exchanger 
(Slc4a8), and Na
+
-independent transporters Cl
-
/HCO3
-
 exchanger (Slc26a4) in collecting 
duct cells (Leviel et al, 2010).  Interestingly, Slc4a8 and Slc4a3, also a Cl
-
/HCO3
-
 
exchangers, were upregulated in inversin-depleted renal epithelial cells suggesting a 
compensatory mechanism to maintain Na
+
 balance in these cells.  
Solute carrier 25 family of mitochondrial carriers (MC) provide a link between 
metabolic reactions occurring in the cytosol and mitochondrial matrix by catalyzing the 
translocation of solutes across the membrane and MCs are involved in many metabolic 
pathways (Palmieri, 2013). Upregulation of mitochondrial transporters Slc25a12/aralar 
(aspartate/glutamate carrier), Slc25a27/Ucp4 and Slc25a53/Mcart6 in inversin-depleted 
cells may increase aspartate/glutamate transport and maintain energy homeostasis.  Renal 
handling of the nucleosides is a major determinant of their plasma levels and tissue 
availability (Elwi et al, 2006) and upregulation of Slc29a2, a nucleoside transporter in 
inversin-depleted renal epithelial cells may help in supply of nucleosides to maintain cell 
homeostasis. 
Certain genes implicated in renal fibrosis were altered in inversin-depleted renal 
epithelial cells.  Mice overexpressing Stanniocalcin 1 (Stc1), a connective tissue growth 
factor inhibits reactive oxygen species and protects from ischemia/reperfusion injury (Pan 
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et al, 2015) was downregulated in inversin-depleted renal epithelial cells.  Thymidine 
kinase (Tk1) knockout mice exhibit short lifespan, develop glomerulosclerosis and have 
abnormal immune system (Dobrovolsky et al, 2003) too was downregulated in inversin-
depleted renal cells. Bub1b /BubR1, a mitotic regulator decreases age-related interstitial 
fibrosis in mice (Baker et al, 2013) was also downregulated in inversin-depleted renal 
epithelial cells.  Taken together, these data suggest that loss of inversin may contribute to 
fibrosis via downregulation of certain genes implicated in renal fibrosis. 
To decipher similarities in the molecular and functional pathways affected in 
mouse cystic kidneys due to inversin loss, the transcriptome data from inv/inv mice cystic 
kidneys was compared to the gene array data from inversin-depleted renal epithelial cells.  
Interestingly, some of the gene expression changes observed in inv/inv mice cystic 
kidneys were recapitulated in inversin-depleted renal epithelial cells. Some of the several 
biological processeses common to both inv/inv mice cystic kidneys and inversin-depleted 
renal epithelial cells included, cell proliferation, apoptosis and ion transport.  A decrease 
in Na
+
 transport and cell cycle progression was evident in both data sets indicating the 
direct effects of inversin in inv/inv cystic kidneys as well as in inversin-depleted renal 
epithelial cells.  In addition, the genes represented in the functional categories of organ 
size and survival were common to both in vivo and in vitro data sets of inversin loss.  
Genes implicated in development and postnatal growth (Mbd5, Mbnl, Ncor1 and Nedd4l) 
in both in vitro and in vivo model of inversin loss suggests that inversin may contribute to 
organ size through regulation of these genes.  Mbd family of proteins has been shown to 
play central roles in transcriptional regulation and development (Fan & Hutnick, 2005; 
Razin, 1998) and Mbd5 was upregulated in both in vitro and in vivo models of inversin 
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loss data sets.  Loss of Mbd5
-/- 
mice has been shown to exhibit growth retardation, 
wasting and pre-weaning lethality (Du et al, 2012).   Mbnl, a RNA processing factor was 
also upregulated in both in vitro and in vivo models of inversin loss.  Enhanced 
expression of Mbnl can improve muscle function and increase lifespan in a Drosophila 
model of DM (Cerro-Herreros et al, 2016) whereas loss of Mbnl can cause myotonic 
dystrophy (DM) and reduced lifespan (Lee et al, 2013).  Ncor1, a nuclear receptor 
corepressor was also upregulated in both the in vitro and in vivo data sets of inversin loss. 
Ncor1 plays crucial role in development and Ncor1
-/-
 embryos exhibit decreased size 
compared to wild type controls (Jepsen et al, 2000). Overall, the upregulation of these 
various transcriptional regulators suggests that these players may contribute to enlarged 
kidneys in inv/inv mice or could play a compensatory role to maintain homeostasis and 
improve survival.   
Transcription factor Klf-6, a zinc finger protein was upregulated in both inversin-
depleted renal epithelial cells and inv/inv mice cystic kidneys. Klf-6 has been shown to be 
an essential regulator of mitochondrial function in podocyte apoptosis and increased 
survival (Mallipattu et al, 2015).  Braf, a signaling factor and suppressor of apoptosis, and 
Birc6, an inhibitor of apoptosis were also upregulated in inversin-depleted renal cells.  
Mice with targeted disruption of Braf gene, has been shown to promote apoptotic death 
of differentiated endothelial cells (Wojnowski et al, 1997).   Increased expression of Braf 
and Birc6, an inhibitor of apoptosis in inversin-depleted renal epithelial cells may 
contribute to decreased apoptosis.  Another gene Nedd4l, an ubiquitin ligase and a 
negative regulator of ENaC was also upregulated in both the in vitro and in vivo data sets 
of inversin loss. Nedd4l
-/-
 mice exhibit perinatal lethality due to increased ENaC activity 
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(Boase et al, 2011).  Members of the cysteine aspartic acid-specific protease (caspase) 
family play key effector roles in apoptosis in mammalian cells.  Interestingly, caspase 3 
(Casp3), an inducer of apoptosis was downregulated in both in vitro and in vivo models 
of inversin loss.   Overall, the genes common to both inversin-depleted cells and inv/inv 
mice cystic kidneys represented an increase in survival and decreased apoptosis and these 
mechansims may contribute to enlarged kidneys. 
 In summary, transcriptome analysis revealed some of the key molecular and 
cellular functions that were altered upon inversin-depletion in an isolated renal cell type.   
Pathways implicated in cell cycle, cellular assembly and organization, DNA replication, 
recombination and repair, cellular development, cell growth and proliferation and ion 
transport were altered in inversin-depleted cells as compared to controls.  Loss of inversin 
upregulated the pathways associated with mitogenesis, cytoskeletal changes, migration 
and inflammation/immune response.  On the other hand, pathways involved in cell cycle 
progression and proliferation were downregulated in inversin-depleted cells. Loss of 
inversin also decreased cell number as function of time in renal epithelial cells indicating 
a decreased cell proliferation.  The in vitro transcriptome data showing a decrease in the 
expression of cell cycle and an increase in survival genes was in concordance with the in 
vivo array data from inv/inv mice kidneys. Additionally, the gene array data from 
inversin-depleted renal epithelial cells in vitro was compared with the array data from 
inv/inv mice cystic kidneys.  The common pathways that were altered in both inv/inv 
mice cystic kidneys and inversin-depleted renal epithelial cells included survival, ion 
transport, cell cycle, and inflammatory/immune response suggesting that these 
mechanisms may be a direct effect of inversin loss. Interestingly, genes that were 
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common between in vitro and in vivo data sets represented categories of organism 
survival and organ size suggesting that the regulation of common genes may contribute to 
cyst growth and expansion in inv/inv kidneys. 
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CONCLUSIONS 
Type II nephronophthisis (NPHP2), a renal cystic disease occurs in infants and 
progresses rapidly leading to end stage renal disease by 2-5 years of age. It is caused by 
mutations in the Inversin (INVS) gene that encodes inversin protein.  NPHP2 has 
overlapping features with PKD and other forms of NPH.  In human PKD and in murine 
models of PKD the mechanism of cyst growth and expansion is relatively well 
understood compared to NPHP2.  To better understand inversin function, transcriptome 
analysis in the kidneys of inversin knockout mice was carried out.  Pathway analysis 
showed that inversin exerts its effect on kidneys, at least in part through transcriptional 
regulation of genes involved in inflammation or immune response, cellular metabolism, 
cell cycle, and ion transport.  A decrease in the expression of cell cycle and apoptosis 
genes and an increase in the expression of inflammation/immune response in this study 
suggest dysregulated cell proliferation that might affect proper formation of renal tubules.  
In addition, a decrease in the expression of ion transport genes may contribute to fluid 
accumulation in inversin knockout mice.   
Functional consequence of inversin depletion on transepithelial ion transport was 
evaluated in an isolated renal cell line using electrophysiological techniques.  Loss of 
inversin decreased vasopressin-induced Na
+
 absorption but did not alter Cl
-
 secretion 
compared to control cells suggesting that inversin may play a role in Na
+ 
reabsorption 
and its loss could lead to fluid accumulation contributing to the enlarged kidneys in 
inversin knockout mice.     
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The control of organ size in multicellular organisms is mediated by the balance 
between cell proliferation, differentiation and apoptosis.  Inversin is a complex protein 
with multiple functional domains that can interact with several proteins and can affect 
various cellular processes.  To elucidate inversin function in an isolated renal cell type 
(mouse cortical collecting duct cells, mCCD), transcriptome analysis was performed in 
inversin-depleted versus control cells.  Some of the key molecular and cellular functions 
that were affected upon inversin loss included cell cycle, cellular assembly and 
organization, DNA replication, recombination and repair, cellular development, cell 
growth and proliferation and ion transport indicating the role of inversin in various 
celluar processes in this isolated renal cell type.  Gene expression profiling showed that 
loss of inversin decreased the expression of cell cycle genes indicating a delay in cell 
cycle progression.  Additionally, cell number, a measure of cell proliferation and caspase 
3/7 activity, a measure of apoptosis was decreased as a function of time in inversin-
depleted cells.   
The kidney is a complex organ comprising multiple cell types and in addition 
circulating cells also infiltrate the tissue. To ascertain the direct effects of inversin in 
renal cells, the gene array data from inversin-depleted renal epithelial cells in vitro were 
compared with the array data from inv/inv mice cystic kidneys.  Gene expression changes 
observed in vitro in isolated renal cells were recapitulated in vivo.  Interestingly, genes 
that were common between in vitro and in vivo data sets represented apoptotic, ion 
transport, cell cycle, inflammatory pathways.  A decrease in the expression of cell cycle 
and apoptotic genes along with genes affecting Na
+
 transport accompanied by an increase 
164 
 
in the inflammatory or immune response genes may be a direct effect of inversin loss in 
renal cells contributing to cyst growth and expansion in inv/inv kidneys. 
In summary, current research helped to further understand the role of inversin in renal 
epithelial cells.  There are several factors that contribute to cyst growth and expansion in 
NPHP2.  Loss of inversin may cause a delay in cell cycle progression that can lead to  
perturbation of renal tubular geometry.  Also, a decrease in Na
+
 reabsorption together 
with differential regulation of other transporters can result in altered ion transport.  
Additionally, activation of immune or inflammatory pathways may drive disease 
progression contributing to cystogenesis, cyst growth, fluid accumulation and cyst 
expansion in NPHP2 (Figure 25).  
 
 
 
 
 
Figure 25:  Proposed model of cyst growth and expansion in NPHP2 
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APPENDIX 
Table 31: Upregulated genes inv/inv mice cystic kidneys 
Gene ID 
Gene 
Symbol Protein Name  
Fold change 
(inv-/-/wild-
type) P-value 
22436 Xdh xanthine dehydrogenase 40.19 1.30E-03 
70673 Prdm16 PR domain containing 16 7.91 2.00E-04 
235320 Zbtb16 zinc finger and BTB domain containing 16 7.67 2.30E-03 
76282 Gpt glutamic pyruvic transaminase, soluble 6.12 9.40E-03 
18787 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, 
member 1 
5.91 0.00E+00 
77794 Adamtsl2 ADAMTS-like 2 5.87 1.00E-04 
17133 Maff v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein F (avian) 
5.85 0.00E+00 
12795 Plk3 polo-like kinase 3 (Drosophila) 5.67 3.00E-04 
226040 Tmem252 Transmembrane protein 252 5.54 6.80E-03 
18124 Nr4a3 nuclear receptor subfamily 4, group A, member 3 5 0.00E+00 
240672 Dusp5 dual specificity phosphatase 5 4.67 2.90E-03 
74392 Specc1l sperm antigen with calponin homology and coiled-coil 
domains 1-like 
4.51 2.00E-04 
20773 Sptlc2 serine palmitoyltransferase, long chain base subunit 2 4.5 0.00E+00 
12062 Bdkrb2 bradykinin receptor, beta 2 4.01 0.00E+00 
63830 Kcnq1ot1 potassium voltage-gated channel, subfamily Q, member 
1 
3.86 1.10E-03 
18414 Osmr oncostatin M receptor 3.78 0.00E+00 
15959 Ifit3 interferon-induced protein with tetratricopeptide repeats 
3 
3.61 6.00E-04 
18491 Pappa pregnancy-associated plasma protein A 3.08 0.00E+00 
215418 Csrnp1 cysteine-serine-rich nuclear protein 1 3.05 0.00E+00 
63913 Fam129a family with sequence similarity 129, member A 3.04 2.60E-03 
66371 Chmp4c charged multivesicular body protein 4C 3.03 1.01E-02 
239719 Mkl2 MKL/myocardin-like 2 3.02 0.00E+00 
12010 B2m beta-2 microglobulin 2.9 2.40E-03 
12609 Cebpd CCAAT/enhancer binding protein (C/EBP), delta 2.88 1.30E-03 
14219 Ctgf connective tissue growth factor 2.83 0.00E+00 
80890 Trim2 tripartite motif-containing 2 2.81 1.00E-04 
384783 Irs2 insulin receptor substrate 2 2.77 1.00E-04 
74155 Errfi1 ERBB receptor feedback inhibitor 1 2.64 1.70E-03 
74486 Osbpl10 oxysterol binding protein-like 10 2.64 9.30E-03 
14313 Fst Follistatin 2.6 2.70E-03 
16194 Il6ra interleukin 6 receptor, alpha 2.59 0.00E+00 
12608 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 2.56 0.00E+00 
19120 Prm3 protamine 3 2.54 8.90E-03 
68774 Ms4a6d membrane-spanning 4-domains, subfamily A, member 
6D 
2.47 4.00E-04 
57915 Tbc1d1 TBC1 domain family, member 1 2.42 1.00E-03 
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20308 Ccl9 chemokine (C-C motif) ligand 9 2.41 5.10E-03 
69640 Fam83g family with sequence similarity 83, member G 2.41 6.90E-03 
68354 Plekhd1os pleckstrin homology domain containing, family D (with 
coiled-coil domains) member 1, opposite strand 
2.41 6.20E-03 
381605 Tbc1d2 similar to TBC1 domain family, member 2 2.38 1.60E-03 
225372 Apbb3 amyloid beta (A4) precursor protein-binding, family B, 
member 3 
2.37 2.00E-04 
20411 Sorbs1 sorbin and SH3 domain containing 1 2.37 0.00E+00 
11699 Ambp alpha 1 microglobulin/bikunin 2.36 1.02E-02 
23886 Gdf15 growth differentiation factor 15 2.33 0.00E+00 
70574 Cpm carboxypeptidase M 2.33 6.70E-03 
27279 Tnfrsf12a tumor necrosis factor receptor superfamily, member 
12a 
2.31 9.00E-04 
14579 Gem GTP binding protein (gene overexpressed in skeletal 
muscle) 
2.3 8.50E-03 
16007 Cyr61 cysteine rich protein 61 2.29 0.00E+00 
23882 Gadd45g growth arrest and DNA-damage-inducible 45 gamma 2.29 0.00E+00 
18113 Nnmt nicotinamide N-methyltransferase 2.24 3.80E-03 
17135 Mafk v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein K (avian) 
2.21 8.00E-03 
26943 Serinc3 serine incorporator 3 2.21 2.50E-03 
74716 Wbp2nl WBP2 N-terminal like 2.2 2.90E-03 
68691 Kansl1l KAT8 regulatory NSL complex subunit 1-like 2.2 1.00E-04 
13614 Edn1 endothelin 1 2.2 0.00E+00 
53417 Hif3a hypoxia inducible factor 3, alpha subunit 2.18 2.90E-03 
75750 Slc10a6 solute carrier family 10, member 6 2.17 5.30E-03 
93671 Cd163 CD163 antigen 2.16 7.00E-04 
107765 Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 2.16 6.00E-04 
18034 Nfkb2 nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 2, p49/p100 
2.16 4.00E-04 
16502 Kcnc1 potassium voltage gated channel, Shaw-related 
subfamily, member 1 
2.15 4.50E-03 
23849 Klf6 Kruppel-like factor 6 2.15 2.00E-04 
58180 Hic2 hypermethylated in cancer 2 2.15 1.03E-02 
18626 Per1 period homolog 1 (Drosophila) 2.14 2.60E-03 
16477 Junb Jun-B oncogene 2.13 0.00E+00 
18712 Pim1 proviral integration site 1 2.13 1.00E-04 
14229 Fkbp5 FK506 binding protein 5 2.12 5.90E-03 
11847 Arg2 arginase type II 2.1 2.30E-03 
230796 Wdtc1 WD and tetratricopeptide repeats 1 2.06 2.90E-03 
16601 Klf9 Kruppel-like factor 9 2.06 6.80E-03 
74646 Spsb1 splA/ryanodine receptor domain and SOCS box 
containing 1 
2.05 8.00E-04 
24132 Zfp53 zinc finger protein 53 2.04 1.00E-04 
12702 Socs3 suppressor of cytokine signaling 3 2.04 0.00E+00 
22038 Plscr1 phospholipid scramblase 1 2.04 1.90E-03 
242202 Pde5a Phosphodiesterase 5A 2.03 1.03E-02 
104831 Ptpn23 protein tyrosine phosphatase, non-receptor type 23 2.02 0.00E+00 
286940 Flnb filamin, beta 2.01 2.00E-04 
     
206 
 
Table 31 continued  
20848 Stat3 signal transducer and activator of transcription 3 2 0.00E+00 
433022 Plcxd2 phosphatidylinositol-specific phospholipase C, X 
domain containing 2 
2 5.90E-03 
14284 Fosl2 similar to fos-like antigen 2; fos-like antigen 2 2 0.00E+00 
13653 Egr1 early growth response 1 1.96 0.00E+00 
114716 Spred2 sprouty-related, EVH1 domain containing 2 1.96 3.20E-03 
56620 Clec4n C-type lectin domain family 4, member n 1.95 0.00E+00 
238871 Pde4d phosphodiesterase 4D, cAMP specific 1.95 0.00E+00 
268936 Brpf3 bromodomain and PHD finger containing, 3 1.95 6.20E-03 
16400 Itga3 integrin alpha 3 1.94 1.40E-03 
80859 Nfkbiz nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, zeta 
1.93 0.00E+00 
75956 Srrm2 serine/arginine repetitive matrix 2 1.93 6.00E-04 
19252 Dusp1 dual specificity phosphatase 1 1.93 1.00E-04 
109620 Dsp desmoplakin 1.92 1.00E-04 
17873 Gadd45b growth arrest and DNA-damage-inducible 45 beta 1.92 3.00E-04 
108664 Atp6v1h ATPase, H+ transporting, lysosomal V1 subunit H 1.92 6.00E-04 
381199 Tmem151a transmembrane protein 151A 1.91 3.40E-03 
20698 Sphk1 sphingosine kinase 1 1.91 0.00E+00 
214150 Ago3 eukaryotic translation initiation factor 2C, 3 1.9 7.00E-04 
338367 Myo1d myosin ID 1.9 8.00E-04 
17196 Mbp myelin basic protein 1.88 2.00E-04 
13655 Egr3 early growth response 3 1.88 0.00E+00 
13198 Ddit3 DNA-damage inducible transcript 3 1.88 3.70E-03 
194231 Cnksr1 connector enhancer of kinase suppressor of Ras 1 1.88 1.90E-03 
26564 Ror2 expressed sequence AL024213 1.88 0.00E+00 
94332 Cadm3 cell adhesion molecule 3 1.87 9.40E-03 
11303 Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 1.87 1.60E-03 
21366 Slc6a6 solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 
1.87 2.50E-03 
18218 Dusp8 dual specificity phosphatase 8 1.85 2.50E-03 
19878 Rock2 Rho-associated coiled-coil containing protein kinase 2 1.84 7.00E-04 
18810 Plec plectin 1 1.82 1.10E-03 
20525 Slc2a1 solute carrier family 2 (facilitated glucose transporter), 
member 1 
1.81 5.00E-04 
23792 Adam23 a disintegrin and metallopeptidase domain 23; similar 
to ADAM23 
1.81 2.20E-03 
67072 Cdc37l1 cell division cycle 37 homolog (S. cerevisiae)-like 1 1.8 1.10E-03 
12211 Birc6 baculoviral IAP repeat-containing 6 1.8 1.00E-04 
19324 Rab1 RAB1, member RAS oncogene family 1.8 8.30E-03 
329152 Hecw2 HECT, C2 and WW domain containing E3 ubiquitin 
protein ligase 2 
1.8 6.20E-03 
11551 Adra2a adrenergic receptor, alpha 2a 1.79 3.20E-03 
56758 Mbnl1 muscleblind-like 1 (Drosophila) 1.79 3.10E-03 
18739 Pitpnm1 phosphatidylinositol transfer protein, membrane-
associated 1 
1.78 1.10E-03 
11307 Abcg1 ATP-binding cassette, sub-family G (WHITE), member 
1 
1.78 5.00E-03 
68112 Sdccag3 serologically defined colon cancer antigen 3 1.78 9.20E-03 
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12740 Cldn4 claudin 4 1.77 0.00E+00 
52440 Tax1bp1 Tax1 (human T-cell leukemia virus type I) binding 
protein 1 
1.77 0.00E+00 
74173 Rab10os RIKEN cDNA 1700012B15 gene 1.77 1.00E-04 
106052 Fbxo4 F-box protein 4 1.76 0.00E+00 
56417 Adar adenosine deaminase, RNA-specific 1.76 2.00E-04 
217708 Lin52 lin-52 homolog (C. elegans); predicted gene 7020 1.76 4.30E-03 
63955 Cables1 CDK5 and Abl enzyme substrate 1 1.76 4.00E-04 
58865 Tdh L-threonine dehydrogenase; predicted gene 13929 1.75 4.60E-03 
15370 Nr4a1 nuclear receptor subfamily 4, group A, member 1 1.74 0.00E+00 
208104 Mlxip MLX interacting protein 1.73 1.00E-04 
68703 Rere arginine glutamic acid dipeptide (RE) repeats 1.73 4.00E-04 
21923 Tnc tenascin C 1.73 2.70E-03 
105732 Fam83h family with sequence similarity 83, member H 1.72 5.60E-03 
1.01E+08 Gdap10 ganglioside-induced differentiation-associated-protein 
10 
1.71 0.00E+00 
12260 C1qb complement component 1, q subcomponent, beta 
polypeptide 
1.71 0.00E+00 
235587 Parp3 poly (ADP-ribose) polymerase family, member 3 1.71 5.00E-04 
12259 C1qa complement component 1, q subcomponent, alpha 
polypeptide 
1.7 0.00E+00 
56386 B4galt6 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, 
polypeptide 6 
1.7 0.00E+00 
233011 Itpkc inositol 1,4,5-trisphosphate 3-kinase C 1.7 1.00E-04 
80981 Arl4d ADP-ribosylation factor-like 4D; hypothetical protein 
LOC100044157 
1.69 1.00E-04 
13649 Egfr epidermal growth factor receptor 1.69 2.00E-04 
17886 Myh9 myosin, heavy polypeptide 9, non-muscle 1.69 8.00E-04 
104445 Cdc42ep1 CDC42 effector protein (Rho GTPase binding) 1 1.69 6.00E-04 
73569 Vgll3 vestigial like 3 (Drosophila) 1.68 2.00E-04 
71738 Mamdc2 MAM domain containing 2 1.68 2.80E-03 
83814 Nedd4l neural precursor cell expressed, developmentally down-
regulated gene 4-like 
1.68 0.00E+00 
14825 Cxcl1 chemokine (C-X-C motif) ligand 1 1.68 1.00E-04 
56421 Pfkp phosphofructokinase, platelet 1.67 3.70E-03 
12817 Col13a1 collagen, type XIII, alpha 1 1.67 5.90E-03 
77733 Rnf170 ring finger protein 170 1.67 0.00E+00 
170638 Hpcal4 hippocalcin-like 4 1.67 0.00E+00 
98496 Pid1 prior incubation determinant 1 1.67 8.90E-03 
16668 Krt18 keratin 18 1.67 9.00E-04 
16177 Il1r1 interleukin 1 receptor, type I 1.67 7.80E-03 
108123 Napg N-ethylmaleimide sensitive fusion protein attachment 
protein gamma 
1.66 1.80E-03 
12660 Chka choline kinase alpha 1.66 0.00E+00 
226551 Suco expressed sequence AI848100 1.66 2.00E-03 
233789 Smg1 SMG1 homolog, phosphatidylinositol 3-kinase-related 
kinase (C. elegans) 
1.66 0.00E+00 
12495 Entpd1 ectonucleoside triphosphate diphosphohydrolase 1 1.65 3.00E-04 
242481 Palm2 A kinase (PRKA) anchor protein 2; paralemmin 2 1.65 5.00E-04 
14066 F3 coagulation factor III 1.64 1.00E-04 
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77087 Ankrd11 ankyrin repeat domain 11 1.64 8.00E-03 
18035 Nfkbia nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, alpha 
1.64 0.00E+00 
18030 Nfil3 similar to NFIL3/E4BP4 transcription factor; nuclear 
factor, interleukin 3, regulated 
1.63 4.10E-03 
50794 Klf13 RIKEN cDNA 9430029L20 gene 1.63 0.00E+00 
16430 Stt3a STT3, subunit of the oligosaccharyltransferase 
complex, homolog A (S. cerevisiae) 
1.63 1.00E-04 
225028 Map4k3 mitogen-activated protein kinase kinase kinase kinase 
3; similar to mitogen-activated protein kinase kinase 
kinase kinase 3 
1.63 8.00E-04 
12642 Ch25h cholesterol 25-hydroxylase 1.63 0.00E+00 
12575 Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 1.62 7.90E-03 
69562 Cdk13 cell division cycle 2-like 5 (cholinesterase-related cell 
division controller) 
1.62 0.00E+00 
73167 Arhgap8 Rho GTPase activating protein 8; proline rich 5 (renal) 1.62 0.00E+00 
14538 Gcnt2 glucosaminyl (N-acetyl) transferase 2, I-branching 
enzyme 
1.61 8.10E-03 
252837 Ackr4 chemokine (C-C motif) receptor-like 1 1.61 5.80E-03 
70675 Vcpip1 valosin containing protein (p97)/p47 complex 
interacting protein 1 
1.61 2.60E-03 
14063 F2rl1 coagulation factor II (thrombin) receptor-like 1 1.61 6.00E-04 
14924 Magi1 membrane associated guanylate kinase, WW and PDZ 
domain containing 1 
1.61 2.00E-04 
78892 Crispld2 cysteine-rich secretory protein LCCL domain 
containing 2 
1.61 1.00E-04 
56722 Litaf LPS-induced TN factor 1.6 2.00E-04 
50766 Crim1 cysteine rich transmembrane BMP regulator 1 (chordin 
like) 
1.6 5.00E-03 
218811 Sec24c Sec24 related gene family, member C (S. cerevisiae) 1.6 7.70E-03 
230088 Fam214b RIKEN cDNA B230312A22 gene 1.6 5.00E-04 
14055 Ezh1 enhancer of zeste homolog 1 (Drosophila) 1.6 0.00E+00 
17533 Mrc1 mannose receptor, C type 1 1.6 3.90E-03 
338372 Map3k9 mitogen-activated protein kinase kinase kinase 9 1.6 3.00E-04 
70686 Dusp16 dual specificity phosphatase 16 1.59 0.00E+00 
11669 Aldh2 aldehyde dehydrogenase 2, mitochondrial 1.59 3.00E-03 
72296 Rusc1 RUN and SH3 domain containing 1 1.59 5.30E-03 
66713 Actr2 ARP2 actin-related protein 2 homolog (yeast); 
predicted gene 6828 
1.59 1.00E-04 
12262 C1qc complement component 1, q subcomponent, C chain 1.59 0.00E+00 
59009 Sh3rf1 SH3 domain containing ring finger 1 1.59 6.00E-04 
19155 Npepps aminopeptidase puromycin sensitive 1.58 5.40E-03 
1E+08 Hrct1 histidine rich carboxyl terminus 1 1.58 1.40E-03 
78797 Ndor1 NADPH dependent diflavin oxidoreductase 1 1.58 6.00E-04 
319817 Rc3h2 ring finger and CCCH-type zinc finger domains 2 1.58 0.00E+00 
50776 Polg2 polymerase (DNA directed), gamma 2, accessory 
subunit 
1.58 7.00E-04 
77864 Ypel2 yippee-like 2 (Drosophila) 1.58 0.00E+00 
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20352 Sema4b sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4B 
1.58 3.40E-03 
11975 Atp6v0a1 ATPase, H+ transporting, lysosomal V0 subunit A1 1.57 1.00E-04 
20185 Ncor1 nuclear receptor co-repressor 1 1.57 5.50E-03 
19290 Pura RIKEN cDNA 6330403M23 gene 1.57 1.40E-03 
13025 Ctla2b cytotoxic T lymphocyte-associated protein 2 beta 1.57 4.30E-03 
66853 Pnpla2 patatin-like phospholipase domain containing 2 1.56 9.70E-03 
101488 Slco2b1 solute carrier organic anion transporter family, member 
2b1 
1.56 0.00E+00 
231207 Cpeb2 cytoplasmic polyadenylation element binding protein 2 1.56 8.60E-03 
108735 Sft2d2 SFT2 domain containing 2 1.56 1.00E-04 
99526 Usp53 ubiquitin specific peptidase 53 1.56 0.00E+00 
20288 Msr1 macrophage scavenger receptor 1 1.56 5.70E-03 
67150 Rnf141 predicted gene 10179; ring finger protein 141 1.55 4.40E-03 
12273 C5ar1 complement component 5a receptor 1 1.55 2.40E-03 
12226 Btg1 B-cell translocation gene 1, anti-proliferative; similar to 
myocardial vascular inhibition factor 
1.55 5.80E-03 
66053 Ppil2 peptidylprolyl isomerase (cyclophilin)-like 2 1.55 7.00E-04 
76901 Jade2 PHD finger protein 15 1.55 0.00E+00 
20361 Sema7a sema domain, immunoglobulin domain (Ig), and GPI 
membrane anchor, (semaphorin) 7A 
1.55 6.80E-03 
26930 Ppnr per-pentamer repeat gene 1.54 3.10E-03 
72674 Adipor1 adiponectin receptor 1 1.54 0.00E+00 
77963 Hook1 hook homolog 1 (Drosophila) 1.54 2.00E-04 
66369 Dus2 dihydrouridine synthase 2-like (SMM1, S. cerevisiae) 1.54 4.20E-03 
11982 Atp10a ATPase, class V, type 10A 1.54 0.00E+00 
80888 Hspb8 heat shock protein 8 1.53 0.00E+00 
19106 Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 1.53 4.40E-03 
15507 Hspb1 heat shock protein 1 1.53 5.70E-03 
223649 Nrbp2 nuclear receptor binding protein 2 1.53 1.00E-04 
232431 Gprc5a G protein-coupled receptor, family C, group 5, member 
A 
1.53 0.00E+00 
109241 Mbd5 methyl-CpG binding domain protein 5 1.53 0.00E+00 
106585 Ankrd12 ankyrin repeat domain 12; similar to Ankrd12 protein 1.53 8.50E-03 
317717 Sec22a SEC22 vesicle trafficking protein homologe A (S. 
cerevisiae) 
1.53 4.40E-03 
12227 Btg2 B-cell translocation gene 2, anti-proliferative 1.53 0.00E+00 
66395 Ahnak AHNAK nucleoprotein (desmoyokin) 1.53 8.50E-03 
75547 Akap13 A kinase (PRKA) anchor protein 13 1.52 2.30E-03 
12725 Clcn3 chloride channel 3 1.52 3.00E-04 
225358 Fam13b family with sequence similarity 13, member B 1.52 1.10E-03 
69863 Ttc39b tetratricopeptide repeat domain 39B 1.52 0.00E+00 
109880 Braf Braf transforming gene 1.52 6.00E-04 
66083 Setd6 SET domain containing 6 1.52 1.40E-03 
57294 Rps27  ribosomal protein S27 1.52 4.00E-03 
72388 Ripk4 receptor-interacting serine-threonine kinase 4 1.51 8.70E-03 
15894 Icam1 intercellular adhesion molecule 1 1.51 0.00E+00 
76527 Il34 interleukin 34 1.51 7.00E-04 
328365 Zmiz1 zinc finger, MIZ-type containing 1 1.51 4.10E-03 
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66404 Rtfdc1 Replication termination factor domain containing 1 1.51 1.00E-04 
18806 Pld2 phospholipase D2 1.5 0.00E+00 
226252 Fam160b1 family with sequence similarity 160, member B1 1.5 3.00E-04 
263803 Pkn3 protein kinase N3 1.5 9.10E-03 
71175 Nipbl Nipped-B homolog (Drosophila) 1.5 5.60E-03 
72429 Dnajc25 DnaJ (Hsp40) homolog, subfamily C, member 25 1.5 1.90E-03 
217069 Trim25 tripartite motif-containing 25 1.49 2.90E-03 
16396 Itch itchy, E3 ubiquitin protein ligase 1.49 0.00E+00 
16337 Insr insulin receptor 1.49 9.00E-04 
217866 Cdc42bpb CDC42 binding protein kinase beta 1.49 0.00E+00 
14268 Fn1 fibronectin 1 1.49 5.00E-04 
282619 Sbsn suprabasin 1.49 3.80E-03 
59079 Erbb2ip Erbb2 interacting protein 1.49 3.00E-04 
77446 Heg1 HEG homolog 1 (zebrafish) 1.49 2.40E-03 
14131 Fcgr3 Fc receptor, IgG, low affinity III 1.49 9.10E-03 
72349 Dusp3 dual specificity phosphatase 3 (vaccinia virus 
phosphatase VH1-related) 
1.49 3.00E-04 
270162 Elmod1 ELMO domain containing 1 1.48 9.30E-03 
76199 Med13l mediator complex subunit 13-like 1.48 7.00E-03 
69020 Zfp707 zinc finger protein 707 1.48 5.00E-04 
108829 Jmjd1c jumonji domain containing 1C 1.48 3.50E-03 
14254 Flt1 FMS-like tyrosine kinase 1 1.48 7.00E-04 
20239 Atxn2 similar to ataxin 2 1.48 6.00E-03 
19263 Ptprb protein tyrosine phosphatase, receptor type, B 1.47 9.00E-04 
16599 Klf3 Kruppel-like factor 3 (basic); similar to BKLF 1.47 3.00E-03 
12916 Crem cAMP responsive element modulator 1.46 2.70E-03 
70497 Arhgap17 Rho GTPase activating protein 17 1.46 0.00E+00 
16905 Lmna lamin A 1.45 5.00E-04 
246696 Slc25a28 solute carrier family 25, member 28 1.45 8.80E-03 
64652 Nisch nischarin 1.45 7.60E-03 
108655 Foxp1 forkhead box P1 1.45 1.70E-03 
18583 Pde7a phosphodiesterase 7A 1.45 1.20E-03 
103537 Mbtd1 mbt domain containing 1 1.45 6.00E-04 
212391 Lcor ligand dependent nuclear receptor corepressor 1.45 2.00E-04 
381290 Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 1.45 8.40E-03 
14718 Got1 glutamate oxaloacetate transaminase 1, soluble 1.45 3.10E-03 
11987 Slc7a1 solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 1 
1.45 0.00E+00 
17210 Mcl1 similar to myeloid cell leukemia sequence 1; myeloid 
cell leukemia sequence 1 
1.45 6.00E-04 
216161 Sbno2 strawberry notch homolog 2 (Drosophila) 1.45 0.00E+00 
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Table 32:  Downregulated genes in inv/inv mice cystic kidneys 
Gene ID 
Gene 
Symbol Protein Name  
Fold change 
(inv-/-/wild-
type) P-value 
210463 Slc22a22 solute carrier family 22 (organic cation transporter), 
member 22 
-12.58 0.00E+00 
72160 Tmem163 transmembrane protein 163 -8.27 0.00E+00 
56727 Miox myo-inositol oxygenase -8.12 1.00E-04 
68352 Aspdh aspartate dehydrogenase domain containing -6.49 0.00E+00 
246700 Defb19 defensin beta 19 -5.57 9.80E-03 
18478 Pah phenylalanine hydroxylase -5.04 5.60E-03 
16612 Klk1 kallikrein 1 -4.33 1.40E-03 
192113 Atp12a ATPase, H+/K+ transporting, nongastric, alpha 
polypeptide 
-3.99 5.80E-03 
112417 Ugt2b37 UDP glucuronosyltransferase 2 family, polypeptide 
B37 
-3.99 3.90E-03 
67092 Gatm glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
-3.94 2.00E-04 
14060 F13b coagulation factor XIII, beta subunit -3.88 4.10E-03 
15186 Hdc histidine decarboxylase -3.67 8.00E-03 
77462 Tmem116 transmembrane protein 116 -3.66 5.00E-04 
12350 Car3 carbonic anhydrase 3 -3.54 0.00E+00 
74129 Dmgdh dimethylglycine dehydrogenase precursor -3.54 4.50E-03 
19879 Slc22a8 solute carrier family 22 (organic anion transporter), 
member 8 
-3.4 3.60E-03 
114644 Slc13a3 solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 3 
-3.3 5.80E-03 
28254 Slco1a6 solute carrier organic anion transporter family, member 
1a6 
-3.28 4.10E-03 
109901 Cela1 chymotrypsin-like elastase family, member 1 -3.21 0.00E+00 
22034 Traf6 TNF receptor-associated factor 6 -3.16 0.00E+00 
66116 Cml1 N-acetyltransferase 8B; camello-like 1 -3.11 0.00E+00 
16348 Invs inversin -3.1 2.00E-03 
12425 Cckar cholecystokinin A receptor -3.08 0.00E+00 
20518 Slc22a2 solute carrier family 22 (organic cation transporter), 
member 2 
-2.98 1.30E-03 
216225 Slc5a8 solute carrier family 5 (iodide transporter), member 8 -2.95 6.50E-03 
102570 Slc22a13 solute carrier family 22 (organic cation transporter), 
member 13 
-2.94 5.00E-04 
234564 Ces1f carboxylesterase 1F -2.94 4.10E-03 
69123 Eci3 enoyl-Coenzyme A delta isomerase 3 -2.92 0.00E+00 
268782 Agxt2 alanine-glyoxylate aminotransferase 2 -2.88 0.00E+00 
20521 Slc22a12 solute carrier family 22 (organic anion/cation 
transporter), member 12 
-2.87 1.00E-04 
232984 B3gnt8 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 8 
-2.85 4.20E-03 
20505 Slc34a1 solute carrier family 34 (sodium phosphate), member 1 -2.81 9.30E-03 
109246 Tspan9 tetraspanin 9 -2.8 2.40E-03 
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229699 Slc16a4 solute carrier family 16 (monocarboxylic acid 
transporters), member 4 
-2.79 1.00E-03 
16483 Kap kidney androgen regulated protein -2.77 3.90E-03 
13837 Epha3 Eph receptor A3 -2.75 0.00E+00 
14261 Fmo1 flavin containing monooxygenase 1 -2.73 1.40E-03 
113854 Vmn1r44 vomeronasal 1 receptor, B4 -2.72 7.20E-03 
64918 Bhmt2 betaine-homocysteine methyltransferase 2 -2.71 9.30E-03 
68680 Fitm1 fat storage-inducing transmembrane protein 1 -2.67 6.00E-04 
17229 Tpsb2 tryptase beta 2 -2.66 7.10E-03 
18399 Slc22a6 solute carrier family 22 (organic anion transporter), 
member 6 
-2.63 1.20E-03 
109342 Slc5a10 solute carrier family 5 (sodium/glucose cotransporter), 
member 10 
-2.62 2.30E-03 
94223 Dgcr8 DiGeorge syndrome critical region gene 8 -2.58 1.00E-04 
105355 Slc17a3 solute carrier family 17 (sodium phosphate), member 3 -2.56 2.60E-03 
17071 Ly6f lymphocyte antigen 6 complex, locus F -2.53 0.00E+00 
108114 Slc22a7 solute carrier family 22 (organic anion transporter), 
member 7 
-2.53 4.10E-03 
239133 Dleu7 deleted in lymphocytic leukemia, 7 -2.51 6.00E-04 
58176 Rhbg Rhesus blood group-associated B glycoprotein -2.48 1.10E-03 
22599 Slc6a20b solute carrier family 6 (neurotransmitter transporter), 
member 20B 
-2.47 8.20E-03 
74087 Slc7a13 solute carrier family 7, (cationic amino acid transporter, 
y+ system) member 13 
-2.46 1.60E-03 
18008 Nes nestin -2.43 0.00E+00 
20493 Slc10a1 solute carrier family 10 (sodium/bile acid cotransporter 
family), member 1 
-2.42 1.60E-03 
320678 Iffo1 intermediate filament family orphan 1 -2.42 2.00E-04 
106389 Eaf2 ELL associated factor 2 -2.41 4.40E-03 
19212 Pter phosphotriesterase related -2.39 7.70E-03 
84112 Sucnr1 succinate receptor 1 -2.39 5.60E-03 
14048 Eya1 eyes absent 1 homolog (Drosophila) -2.39 6.00E-04 
50498 Ebi3 Epstein-Barr virus induced gene 3 -2.38 2.20E-03 
234267 Gpm6a glycoprotein m6a -2.37 3.80E-03 
18563 Pcx pyruvate carboxylase -2.36 3.80E-03 
13109 Cyp2j5 cytochrome P450, family 2, subfamily j, polypeptide 5 -2.35 9.20E-03 
18080 Nin ninein -2.35 6.00E-04 
208665 Akr1d1 aldo-keto reductase family 1, member D1 -2.35 7.40E-03 
22239 Ugt8a UDP galactosyltransferase 8A -2.33 9.60E-03 
212442 Lactb2 lactamase, beta 2 -2.32 0.00E+00 
244954 Prss35 protease, serine, 35 -2.32 1.60E-03 
20522 Slc23a1 solute carrier family 23 (nucleobase transporters), 
member 1 
-2.32 5.90E-03 
11639 Ak4 adenylate kinase 3-like 1 -2.25 3.00E-04 
170952 Prima1 proline rich membrane anchor 1 -2.25 1.90E-03 
232078 Thnsl2 threonine synthase-like 2 (bacterial) -2.25 0.00E+00 
27392 Pign phosphatidylinositol glycan anchor biosynthesis, class 
N 
-2.24 1.30E-03 
12763 Cmah cytidine monophospho-N-acetylneuraminic acid 
hydroxylase 
-2.23 8.00E-04 
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69454 Clic3 chloride intracellular channel 3 -2.22 5.90E-03 
319800 Slc22a30 solute carrier family 22, member -2.22 1.30E-03 
20377 Sfrp1 secreted frizzled-related protein 1 -2.22 6.60E-03 
13482 Dpp4 dipeptidylpeptidase 4 -2.21 0.00E+00 
50490 Nox4 NADPH oxidase 4 -2.21 6.90E-03 
319922 Vwc2 von Willebrand factor C domain containing 2 -2.2 4.50E-03 
223774 Alg12 asparagine-linked glycosylation 12 homolog  -2.19 0.00E+00 
74717 Spata17 spermatogenesis associated 17 -2.19 0.00E+00 
19293 Pvalb parvalbumin -2.16 7.50E-03 
101202 Hepacam2 HEPACAM family member 2 -2.15 4.70E-03 
69923 Agk acylglycerol kinase -2.13 7.00E-04 
13822 Epb4.1l2 erythrocyte protein band 4.1-like 2 -2.12 0.00E+00 
72685 Dnajc6 DnaJ (Hsp40) homolog, subfamily C, member 6 -2.12 0.00E+00 
212190 Ubxn10 UBX domain protein 10 -2.11 9.00E-04 
21338 Tacr3 tachykinin receptor 3 -2.1 6.60E-03 
54426 Hgfac hepatocyte growth factor activator -2.06 4.10E-03 
224079 Atp13a4 ATPase type 13A4 -2.05 2.00E-03 
16508 Kcnd2 potassium voltage-gated channel, Shal-related family, 
member 2 
-2.03 1.90E-03 
18451 P4ha1 procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 1 polypeptide 
-2.03 9.30E-03 
330657 Prss53 protease, serine 53 -2.03 1.00E-03 
207683 Igsf11 immunoglobulin superfamily, member 11 -2.02 5.00E-04 
14255 Flt3 FMS-like tyrosine kinase 3 -2.01 7.20E-03 
235674 Acaa1b acetyl-Coenzyme A acyltransferase 1A -2.01 3.90E-03 
231842 Amz1 archaelysin family metallopeptidase 1 -2.01 3.40E-03 
72039 Mccc1 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) -1.97 4.90E-03 
12950 Hapln1 hyaluronan and proteoglycan link protein 1 -1.97 0.00E+00 
67375 Qprt quinolinate phosphoribosyltransferase -1.95 1.00E-03 
99543 Olfml3 olfactomedin-like 3 -1.94 8.60E-03 
75578 Fggy FGGY carbohydrate kinase domain containing -1.94 2.70E-03 
329421 Myo3b myosin IIIB -1.94 1.90E-03 
51813 Ccnc cyclin C -1.93 1.00E-04 
66696 Snx31 sorting nexin 31 -1.9 1.00E-02 
102448 Xylb xylulokinase homolog (H. influenzae) -1.89 0.00E+00 
76459 Car12 carbonic anyhydrase 12 -1.89 1.60E-03 
20322 Sord sorbitol dehydrogenase -1.89 0.00E+00 
217371 Rab40b Rab40b, member RAS oncogene family -1.88 1.20E-03 
27401 Skp2 S-phase kinase-associated protein 2 (p45) -1.87 7.00E-04 
14675 Gna14 guanine nucleotide binding protein, alpha 14 -1.87 0.00E+00 
66469 Fam213b family with sequence similarity 213, member b -1.86 1.00E-04 
78832 Cacul1 CDK2 associated, cullin domain 1 -1.86 1.00E-04 
225845 Pla2g16 phospholipase A2, group XVI -1.86 3.00E-04 
225913 Dak dihydroxyacetone kinase 2 homolog (yeast) -1.85 0.00E+00 
56794 Hacl1 2-hydroxyacyl-CoA lyase 1 -1.85 1.00E-04 
22411 Wnt11 wingless-related MMTV integration site 11 -1.84 3.60E-03 
320840 Negr1 neuronal growth regulator 1 -1.84 1.60E-03 
12865 Cox7a1 cytochrome c oxidase, subunit VIIa 1 -1.83 0.00E+00 
17762 Mapt microtubule-associated protein tau -1.83 3.00E-03 
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59020 Pdzk1 PDZ domain containing 1 -1.82 1.60E-03 
235386 Hykk hydroxylysine kinase 1 -1.82 4.90E-03 
20346 Sema3a semaphorin 3A -1.82 3.70E-03 
56175 Bace2 beta-site APP-cleaving enzyme 2 -1.81 4.00E-04 
76426 Fam209 family with sequence similarity 209 -1.8 3.90E-03 
64074 Smoc2 SPARC related modular calcium binding 2 -1.8 0.00E+00 
242667 Dlgap3 discs, large (Drosophila) homolog-associated protein 3 -1.79 1.00E-04 
17117 Amacr alpha-methylacyl-CoA racemase -1.78 2.00E-03 
16019 Ighm immunoglobulin heavy chain 6 (heavy chain of IgM) -1.78 1.00E-04 
71974 Prmt3 protein arginine N-methyltransferase 3 -1.78 2.00E-04 
20209 Saa2 serum amyloid A 2 -1.78 9.30E-03 
11834 Aqr aquarius -1.78 3.00E-04 
60525 Acss2 acyl-CoA synthetase short-chain family member 2 -1.77 4.30E-03 
56403 Syncrip synaptotagmin binding, cytoplasmic RNA interacting 
protein 
-1.77 1.00E-04 
15251 Hif1a hypoxia inducible factor 1, alpha subunit -1.77 1.50E-03 
226791 Lyplal1 lysophospholipase-like 1 -1.77 5.00E-04 
59008 Anapc5 anaphase-promoting complex subunit 5 -1.77 3.70E-03 
22341 Vegfc vascular endothelial growth factor C -1.76 2.40E-03 
73910 Arhgap18 Rho GTPase activating protein 18 -1.76 0.00E+00 
100952 Emilin1 elastin microfibril interfacer 1 -1.76 1.02E-02 
11484 Aspa aspartoacylase -1.75 6.10E-03 
11489 Adam12 a disintegrin and metallopeptidase domain 12 (meltrin 
alpha) 
-1.75 1.10E-03 
14782 Gsr similar to Glutathione reductase, mitochondrial 
precursor (GR) (GRase); glutathione reductase 
-1.75 0.00E+00 
14810 Grin1 glutamate receptor, ionotropic, NMDA1 (zeta 1) -1.75 7.20E-03 
67923 Tceb1 transcription elongation factor B (SIII), polypeptide 1 -1.75 3.80E-03 
80718 Rab27b RAB27b, member RAS oncogene family -1.74 3.00E-04 
20686 Spa17 sperm autoantigenic protein 17 -1.74 1.30E-03 
12167 Bmpr1b bone morphogenetic protein receptor, type 1B -1.74 0.00E+00 
57754 Cend1 cell cycle exit and neuronal differentiation 1 -1.74 3.70E-03 
232086 Tmem150a transmembrane protein 150 -1.74 0.00E+00 
70789 Kynu kynureninase (L-kynurenine hydrolase) -1.74 0.00E+00 
14431 Gamt guanidinoacetate methyltransferase -1.73 0.00E+00 
227059 Slc39a10 solute carrier family 39 (zinc transporter), member 10 -1.73 2.00E-03 
217449 Trappc12 tetratricopeptide repeat domain 15 -1.73 4.90E-03 
23964 Tenm2 odd Oz/ten-m homolog 2 (Drosophila) -1.73 8.00E-04 
67840 Mrpl57 mitochondrial ribosomal protein 63 -1.73 3.00E-04 
64934 Pes1 pescadillo homolog 1, containing BRCT domain -1.72 5.30E-03 
13132 Dab2 disabled homolog 2 (Drosophila) -1.72 0.00E+00 
280662 Afm Afamin -1.72 7.00E-03 
75847 Ispd isoprenoid synthase domain containing -1.72 0.00E+00 
214058 Megf11 multiple EGF-like-domains 11 -1.72 0.00E+00 
13034 Ctse cathepsin E -1.71 2.70E-03 
68044 Chac2 ChaC, cation transport regulator homolog 2 (E. coli) -1.71 7.40E-03 
58194 Sh3kbp1 SH3-domain kinase binding protein 1 -1.71 3.70E-03 
108653 Rimklb ribosomal modification protein rimK-like family 
member B 
-1.71 0.00E+00 
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1.01E+08 Ccdc13 coiled-coil domain containing 13 -1.71 0.00E+00 
193385 Fam65b family with sequence similarity 65, member B -1.71 8.30E-03 
30959 Ddx25 DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 -1.7 1.10E-03 
22174 Tyro3 TYRO3 protein tyrosine kinase 3 -1.7 0.00E+00 
104183 Chil4 chitinase 3-like 4 -1.7 1.00E-04 
241226 Itga8 integrin alpha 8 -1.7 4.80E-03 
224454 Zdhhc14 zinc finger, DHHC domain containing 14 -1.68 1.70E-03 
270076 Gcdh glutaryl-Coenzyme A dehydrogenase -1.68 7.00E-04 
109019 Nabp1 oligonucleotide/oligosaccharide-binding fold 
containing 2A 
-1.67 8.90E-03 
208643 Eif4g1 eukaryotic translation initiation factor 4, gamma 1 -1.67 0.00E+00 
16370 Irs4 insulin receptor substrate 4 -1.66 1.60E-03 
19691 Recql RecQ protein-like -1.66 8.00E-04 
69358 Lrrc51 leucine rich repeat containing 51 -1.66 4.10E-03 
234889 Gucy1a2 guanylate cyclase 1, soluble, alpha 2 -1.66 4.60E-03 
67109 Zfp787 zinc finger protein 787 -1.66 2.00E-04 
14802 Gria4 glutamate receptor, ionotropic, AMPA4 (alpha 4) -1.66 7.80E-03 
22247 Umps uridine monophosphate synthetase -1.66 4.30E-03 
103136 Pwp1 PWP1 homolog (S. cerevisiae) -1.66 6.80E-03 
17222 Anapc1 anaphase promoting complex subunit 1 -1.65 0.00E+00 
26879 B3galnt1 UDP-GalNAc:betaGlcNAc beta 1,3-
galactosaminyltransferase, polypeptide 1 
-1.65 9.00E-04 
74197 Gtf2e1 general transcription factor II E, polypeptide 1 (alpha 
subunit) 
-1.65 3.90E-03 
234407 Glt25d1 glycosyltransferase 25 domain containing 1 -1.65 0.00E+00 
192216 Tmem47 transmembrane protein 47 -1.65 3.80E-03 
68539 Tmem109 transmembrane protein 109 -1.64 5.00E-04 
14105 Srsf10 serine/arginine-rich splicing factor 10 -1.64 3.60E-03 
14391 Gabpb1 GA repeat binding protein, beta 1 -1.64 1.00E-04 
11608 Agtr1b angiotensin II receptor, type 1b -1.64 4.70E-03 
71760 Etnppl alanine-glyoxylate aminotransferase 2-like 1 -1.64 4.30E-03 
69309 Slc16a13 solute carrier family 16 (monocarboxylic acid 
transporters), member 13 
-1.64 1.90E-03 
67455 Klhl13 kelch-like 13 (Drosophila) -1.63 0.00E+00 
110639 Prps2 phosphoribosyl pyrophosphate synthetase 2 -1.63 4.70E-03 
99011 Pomt1 protein-O-mannosyltransferase 1 -1.63 4.60E-03 
66950 Tmem206 transmembrane protein 206 -1.63 2.00E-04 
17986 Ndp Norrie disease (pseudoglioma) (human) -1.63 7.10E-03 
11602 Angpt4 angiopoietin 4 -1.63 3.00E-04 
16000 Igf1 insulin-like growth factor 1 -1.63 7.30E-03 
229211 Acad9 acyl-Coenzyme A dehydrogenase family, member 9 -1.63 3.70E-03 
22017 Tpmt thiopurine methyltransferase -1.63 0.00E+00 
12290 Cacna1e calcium channel, voltage-dependent, R type, alpha 1E 
subunit 
-1.62 7.80E-03 
56189 Prodh2 proline dehydrogenase (oxidase) 2 -1.62 0.00E+00 
243537 Uroc1 urocanase domain containing 1 -1.62 1.20E-03 
11831 Aqp6 aquaporin 6 -1.62 6.00E-04 
21391 Tbxas1 thromboxane A synthase 1, platelet -1.61 2.00E-03 
66183 Sptssb serine palmitoyltransferase, small subunit b -1.61 4.60E-03 
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19288 Ptx3 pentraxin related gene -1.61 3.00E-04 
21401 Tcea3 transcription elongation factor A (SII), 3 -1.61 0.00E+00 
93961 B3galt5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 5 
-1.61 0.00E+00 
14586 Gfra2 glial cell line derived neurotrophic factor family 
receptor alpha 2 
-1.61 3.60E-03 
18391 Sigmar1 sigma non-opioid intracellular receptor 1 -1.61 1.00E-04 
110809 Srsf1 serine/arginine-rich splicing factor 10 -1.61 5.10E-03 
18767 Pkia protein kinase inhibitor, alpha -1.6 1.00E-04 
18768 Pkib protein kinase inhibitor beta, cAMP dependent, testis 
specific 
-1.6 4.40E-03 
68916 Cdkal1 CDK5 regulatory subunit associated protein 1-like 1 -1.6 0.00E+00 
68021 Bphl biphenyl hydrolase-like (serine hydrolase, breast 
epithelial mucin-associated antigen) 
-1.6 1.00E-04 
22200 Uba3 ubiquitin-like modifier activating enzyme 3 -1.6 1.00E-04 
75590 Dusp9 dual specificity phosphatase 9 -1.6 5.80E-03 
22652 Mkrn3 makorin, ring finger protein, 3 -1.59 9.00E-03 
75572 Acyp2 acylphosphatase 2, muscle type; similar to 
acylphosphatase 2, muscle type 
-1.59 6.30E-03 
56367 Scoc short coiled-coil protein -1.59 6.00E-04 
67333 Stk35 serine/threonine kinase 35 -1.59 5.40E-03 
68126 Fahd2a fumarylacetoacetate hydrolase domain containing 2A -1.59 2.00E-04 
110175 Ggct gamma-glutamyl cyclotransferase -1.59 0.00E+00 
170718 Idh3b isocitrate dehydrogenase 3 (NAD+) beta -1.59 2.70E-03 
66648 Tpgs2 tubulin polyglutamylase complex subunit 2 -1.59 5.30E-03 
13048 Cux2 cut-like homeobox 2 -1.59 6.00E-04 
16593 Klc1 kinesin light chain 1; similar to Kinesin light chain 1 -1.59 8.40E-03 
56790 Supt20 suppressor of Ty 20 -1.59 0.00E+00 
108100 Baiap2 brain-specific angiogenesis inhibitor 1-associated 
protein 2 
-1.59 1.80E-03 
66106 Smpx small muscle protein, X-linked -1.58 0.00E+00 
66650 Nepn nephrocan -1.58 0.00E+00 
26434 Prnd prion protein dublet -1.58 5.20E-03 
80985 Trim44 tripartite motif-containing 44 -1.58 6.00E-04 
241118 Asic4 amiloride-sensitive cation channel 4, pituitary -1.58 5.10E-03 
68472 Tmem126b transmembrane protein 126B -1.58 3.80E-03 
13638 Efna3 ephrin A3 -1.58 5.30E-03 
13732 Emp3 epithelial membrane protein 3 -1.57 4.00E-04 
76238 Grhpr glyoxylate reductase/hydroxypyruvate reductase -1.57 0.00E+00 
21789 Tfpi2 tissue factor pathway inhibitor 2 -1.57 1.40E-03 
14852 Gspt1 G1 to S phase transition 1 -1.57 1.40E-03 
12818 Col14a1 collagen, type XIV, alpha 1 -1.57 8.00E-03 
11428 Aco1 aconitase 1 -1.57 1.00E-03 
20541 Slc8a1 solute carrier family 8 (sodium/calcium exchanger), 
member 1 
-1.56 1.40E-03 
60596 Gucy1a3 guanylate cyclase 1, soluble, alpha 3 -1.56 6.20E-03 
68385 Tlcd1 TLC domain containing 1 -1.56 3.80E-03 
209584 Tyw3 tRNA-yW synthesizing protein 3 homolog (S. 
cerevisiae) 
-1.56 1.00E-04 
14609 Gja1 gap junction protein, alpha 1 -1.55 9.90E-03 
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54140 Avpr1a arginine vasopressin receptor 1A -1.55 7.30E-03 
64008 Aqp9 aquaporin 9 -1.55 9.00E-03 
12367 Casp3 caspase 3 -1.55 4.90E-03 
70620 Ube2v2 ubiquitin-conjugating enzyme E2 variant 2 -1.55 1.00E-04 
209456 Trp53bp2 transformation related protein 53 binding protein 2 -1.55 1.40E-03 
239435 Aard alanine and arginine rich domain containing protein -1.55 2.90E-03 
23831 Car14 carbonic anhydrase 14 -1.55 4.90E-03 
268670 Zfp759 zinc finger protein 759 -1.55 0.00E+00 
69090 Ascc1 activating signal cointegrator 1 complex subunit 1 -1.55 0.00E+00 
15931 Ids iduronate 2-sulfatase -1.54 5.30E-03 
14874 Gstz1 glutathione transferase zeta 1 (maleylacetoacetate 
isomerase) 
-1.54 6.60E-03 
242736 Pramef8 PRAME family member 8 -1.54 5.40E-03 
13178 Dck deoxycytidine kinase -1.54 4.20E-03 
16431 Itm2a integral membrane protein 2A -1.54 7.10E-03 
13057 Cyba cytochrome b-245, alpha polypeptide -1.54 5.00E-03 
58238 Fam181b family with sequence similarity 181, member B -1.53 0.00E+00 
66948 Acad8 acyl-Coenzyme A dehydrogenase family, member 8 -1.53 9.10E-03 
66204 Acyp1 acylphosphatase 1, erythrocyte (common) type -1.53 0.00E+00 
12729 Clns1a chloride channel, nucleotide-sensitive, 1A -1.53 1.60E-03 
13170 Dbp D site albumin promoter binding protein -1.53 5.00E-04 
27364 Srr serine racemase -1.53 7.00E-04 
75104 Mmd2 monocyte to macrophage differentiation-associated 2 -1.53 6.00E-03 
80914 Uck2 uridine-cytidine kinase 2 -1.53 6.80E-03 
22762 Zfpm2 zinc finger protein, multitype 2 -1.53 3.20E-03 
70998 Phf6 PHD finger protein 6 -1.53 2.60E-03 
66834 Acot13 acyl-CoA thioesterase 13 -1.52 9.70E-03 
13180 Pcbd1 pterin 4 alpha carbinolamine dehydratase/dimerization 
cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 1 
-1.52 1.00E-04 
65973 Asph aspartate-beta-hydroxylase -1.52 1.00E-04 
11416 Slc33a1 solute carrier family 33 (acetyl-CoA transporter), 
member 1 
-1.52 3.40E-03 
319953 Ttll1 tubulin tyrosine ligase-like 1 -1.52 1.30E-03 
71767 Tysnd1 trypsin domain containing 1 -1.52 1.00E-04 
66291 Smim8 small integral membrane protein 8 -1.52 2.00E-04 
24058 Sigirr single immunoglobulin and toll-interleukin 1 receptor 
(TIR) domain 
-1.52 4.00E-04 
209018 Vps8 vacuolar protein sorting 8 homolog (S. cerevisiae) -1.52 0.00E+00 
242125 Mab21l3 mab-21-like 3 (C. elegans) -1.52 3.80E-03 
56046 Uqcc1 ubiquinol-cytochrome c reductase complex chaperone, 
CBP3 homolog (yeast 
-1.51 0.00E+00 
19057 Ppp3cc protein phosphatase 3, catalytic subunit, gamma 
isoform 
-1.51 0.00E+00 
118451 Mrps2 mitochondrial ribosomal protein S2 -1.51 3.40E-03 
108105 B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 
-1.51 1.00E-04 
20444 St3gal2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 -1.51 1.10E-03 
227580 C1ql3 C1q-like 3 -1.51 0.00E+00 
27494 Amot angiomotin -1.51 7.70E-03 
26466 Zfp260 zinc finger protein 260 -1.51 9.10E-03 
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67429 Nudcd1 NudC domain containing 1 -1.51 6.50E-03 
327747 Mettl24 methyltransferase like 24 -1.51 2.00E-04 
27386 Npas3 neuronal PAS domain protein 3 -1.51 0.00E+00 
27052 Aoah acyloxyacyl hydrolase -1.51 1.50E-03 
70357 Kcnip1 Kv channel-interacting protein 1 -1.5 6.30E-03 
17068 Ly6d lymphocyte antigen 6 complex, locus D -1.5 6.30E-03 
109077 Ints5 integrator complex subunit 5 -1.5 5.00E-04 
68038 Chid1 chitinase domain containing 1 -1.5 1.10E-03 
13616 Edn3 endothelin 3 -1.5 4.20E-03 
19335 Rab23 RAB23, member RAS oncogene family -1.5 6.90E-03 
78802 Ttc30a1 tetratricopeptide repeat domain 30A1 -1.5 4.10E-03 
21843 Tial1 Tia1 cytotoxic granule-associated RNA binding 
protein-like 1 
-1.5 2.00E-04 
11836 Araf v-raf murine sarcoma 3611 viral oncogene homolog -1.5 0.00E+00 
73296 Rhobtb3 Rho-related BTB domain containing 3 -1.5 6.00E-04 
11441 Chrna7 cholinergic receptor, nicotinic, alpha polypeptide 7 -1.5 3.90E-03 
74254 Gpn1 GPN-loop GTPase 1 -1.5 2.10E-03 
72899 Macrod2 MACRO domain containing 2 -1.5 1.60E-03 
74013 Rftn2 raftlin family member 2 -1.5 9.00E-04 
78689 Naa35 MAK10 homolog, amino-acid N-acetyltransferase 
subunit, (S. cerevisiae) 
-1.5 3.00E-04 
55943 Stx8 syntaxin 8 -1.5 0.00E+00 
102182 Prmt10 protein arginine methyltransferase 10 (putative) -1.5 0.00E+00 
13593 Ebf3 early B-cell factor 3 -1.5 3.20E-03 
52163 Camk1 calcium/calmodulin-dependent protein kinase I -1.49 2.00E-04 
170728 Rtn4ip1 reticulon 4 interacting protein 1 -1.49 0.00E+00 
56305 Pitpnb phosphatidylinositol transfer protein, beta -1.49 2.80E-03 
13121 Cyp51 cytochrome P450, family 51 -1.49 8.40E-03 
67405 Nts neurotensin -1.49 2.70E-03 
11610 Agtrap angiotensin II, type I receptor-associated protein -1.49 3.40E-03 
252864 Dusp15 dual specificity phosphatase-like 15 -1.49 3.00E-04 
71902 Cand1 cullin associated and neddylation disassociated 1 -1.49 4.90E-03 
12444 Ccnd2 cyclin D2 -1.49 1.10E-03 
654824 Ankrd37 ankyrin repeat domain 37 -1.49 5.30E-03 
15374 Hn1 hematological and neurological expressed sequence 1 -1.49 9.20E-03 
51810 Hnrnpu heterogeneous nuclear ribonucleoprotein U -1.49 2.00E-03 
12972 Cryz crystallin, zeta -1.49 9.40E-03 
27385 Magel2 melanoma antigen, family L, 2 -1.48 1.60E-03 
54711 Plagl2 pleiomorphic adenoma gene-like 2 -1.48 0.00E+00 
12567 Cdk4 Cyclin-dependent kinase 4 -1.48 4.30E-03 
233799 Acsm2 acyl-CoA synthetase medium-chain family member 2 -1.48 4.20E-03 
14702 Gng2 guanine nucleotide binding protein (G protein), gamma 
2 
-1.48 3.90E-03 
407790 Ndufa4l2 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4-like 2 
-1.48 4.00E-04 
68554 Cebpzos CCAAT/enhancer binding protein (C/EBP), zeta, 
opposite strand 
-1.48 0.00E+00 
111175 Pecr peroxisomal trans-2-enoyl-CoA reductase -1.48 1.00E-04 
12593 Cdyl chromodomain protein, Y chromosome-like -1.48 5.00E-04 
66882 Bzw1 basic leucine zipper and W2 domains 1 -1.48 3.10E-03 
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218454 Lhfpl2 lipoma HMGIC fusion partner-like 2 -1.48 6.40E-03 
14886 Gtf2i general transcription factor II I -1.48 6.90E-03 
268566 Gphn gephyrin -1.47 6.00E-04 
22059 Trp53 transformation related protein 53 -1.47 1.40E-03 
13990 Smarcad1 SWI/SNF-related, matrix-associated actin-dependent 
regulator of chromatin, subfamily a, containing 
DEAD/H box 1 
-1.47 3.00E-04 
12447 Ccne1 cyclin E1 -1.47 8.50E-03 
66249 Pno1 partner of NOB1 homolog (S. cerevisiae) -1.47 3.00E-04 
545428 Ccdc141 coiled-coil domain containing 141 -1.47 0.00E+00 
19076 Prim2 DNA primase, p58 subunit -1.46 2.50E-03 
66870 Serbp1 serpine1 mRNA binding protein 1 -1.46 9.60E-03 
12663 Chml choroideremia-like -1.46 0.00E+00 
171170 Mbnl3 muscleblind-like 3 (Drosophila) -1.46 5.00E-04 
66614 Gpatch4 G patch domain containing 4 -1.46 7.10E-03 
105670 Rcbtb2 regulator of chromosome condensation (RCC1) and 
BTB (POZ) domain containing protein 2 
-1.46 0.00E+00 
72135 Pygo1 pygopus 1 -1.46 9.70E-03 
13612 Edil3 EGF-like repeats and discoidin I-like domains 3 -1.46 9.00E-04 
12715 Ckm creatine kinase, muscle -1.46 2.00E-04 
57264 Retn resistin -1.46 7.00E-03 
621603 Aldh3b2 aldehyde dehydrogenase 3 family -1.46 9.90E-03 
108011 Ap4e1 adaptor-related protein complex AP-4, epsilon 1 -1.46 0.00E+00 
67669 l7Rn6 lethal, Chr 7, Rinchik 6 -1.45 1.30E-03 
18559 Pctp phosphatidylcholine transfer protein -1.45 1.90E-03 
67005 Polr3k polymerase (RNA) III (DNA directed) polypeptide K -1.45 5.00E-04 
69792 Med6 mediator of RNA polymerase II transcription, subunit 6 
homolog (yeast) 
-1.45 3.10E-03 
50493 Txnrd1 thioredoxin reductase 1 -1.45 7.00E-04 
12393 Runx2 runt related transcription factor 2 -1.45 2.50E-03 
74782 Glt8d2 glycosyltransferase 8 domain containing 2 -1.45 9.80E-03 
110920 Hspa13 heat shock protein 70 family, member 13 -1.45 2.10E-03 
58244 Stx6 syntaxin 6 -1.45 8.90E-03 
20204 Prrx2 paired related homeobox 2 -1.45 3.00E-04 
109006 Ciapin1 cytokine induced apoptosis inhibitor 1 -1.45 1.50E-03 
50530 Mfap5 microfibrillar associated protein 5 -1.45 2.20E-03 
12180 Smyd1 SET and MYND domain containing 1 -1.45 9.00E-04 
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Table 33:  Upregulated genes in inversin-depleted renal epithelial cells 
Gene 
ID 
Gene  
Symbol Protein Name  
 Fold 
change/ 
NTC   P-value 
72948 Tppp tubulin polymerization promoting protein 21.78 0 
20652 Soat1 sterol O-acyltransferase 1 7.6 0 
68528 Smim6 small integral membrane protein 6 5.71 0 
16840 Lect1 leukocyte cell derived chemotaxin 1 5.37 0 
56863 Cldn9 claudin 9 5.19 0 
75320 Etnk1 ethanolamine kinase 1 4.31 0 
68236 Gtsf1l gametocyte specific factor 1-like 3.91 0.0034 
107503 Atf5 activating transcription factor 5 3.9 0 
104681 Slc16a6 solute carrier family 16 (monocarboxylic acid 
transporters), member 6 
3.21 0 
74096 Hvcn1 hydrogen voltage-gated channel 1 3.2 0 
1E+08 Six3os1 SIX homeobox 3, opposite strand 1 3.06 0.0143 
14755 Pigq phosphatidylinositol glycan anchor biosynthesis, class Q 2.94 0 
80797 Clca2 chloride channel calcium activated 2 2.91 0 
237847 Rtn4rl1 reticulon 4 receptor-like 1 2.89 0 
67269 Agtpbp1 ATP/GTP binding protein 1 2.86 0.0299 
67859 Cysrt1 cysteine rich tail 1 2.85 0.0135 
224813 Lrrc73 leucine rich repeat containing 73 2.83 0.0213 
12978 Csf1r colony stimulating factor 1 receptor 2.76 0 
23967 Osr1 odd-skipped related 1 (Drosophila) 2.76 0 
58180 Hic2 hypermethylated in cancer 2 2.68 0 
18104 Nqo1 NAD(P)H dehydrogenase, quinone 1 2.49 0 
17470 Cd200 CD200 antigen 2.44 0.0013 
23956 Neu2 neuraminidase 2 2.41 0 
22762 Zfpm2 zinc finger protein, multitype 2 2.4 0 
83814 Nedd4l neural precursor cell expressed, developmentally down-
regulated gene 4-like 
2.37 0 
53868 Rab25 RAB25, member RAS oncogene family 2.37 0 
16581 Kifc2 kinesin family member C2 2.36 0.0014 
210789 Tbc1d4 TBC1 domain family, member 4 2.3 0 
52906 Ahi1 Abelson helper integration site 1 2.29 0 
27494 Amot angiomotin 2.28 0 
19201 Pstpip2 proline-serine-threonine phosphatase-interacting protein 
2 
2.28 0.0343 
246277 Csad cysteine sulfinic acid decarboxylase 2.27 0 
225187 Ankrd29 ankyrin repeat domain 29 2.26 3.00E-04 
214505 Gnptg N-acetylglucosamine-1-phosphotransferase, gamma 
subunit 
2.26 0 
53951 Gpatch11 G patch domain containing 11 2.26 0.0074 
13423 Dnase2a deoxyribonuclease II alpha 2.25 0 
210982 Gltscr1l GLTSCR1-like 2.24 0 
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17904 Myl6 myosin, light polypeptide 6, alkali, smooth muscle and 
non-muscle 
2.24 0 
68877 Maf1 MAF1 homolog (S. cerevisiae) 2.23 0.0049 
54393 Gabbr1 gamma-aminobutyric acid (GABA) B receptor, 1 2.21 0 
226751 Cdc42bpa CDC42 binding protein kinase alpha 2.18 0.0013 
83679 Pde4dip phosphodiesterase 4D interacting protein (myomegalin) 2.17 0 
108075 Ltbp4 latent transforming growth factor beta binding protein 4 2.16 0 
71687 Tmem25 transmembrane protein 25 2.16 0.0084 
63830 Kcnq1ot1 KCNQ1 overlapping transcript 1 2.15 0 
105638 Dnph1 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 2.14 0 
16439 Itpr2 inositol 1,4,5-triphosphate receptor 2 2.13 0 
16598 Klf2 Kruppel-like factor 2 (lung) 2.13 0 
237930 Ttll6 tubulin tyrosine ligase-like family, member 6 2.13 0 
67516 Kctd4 potassium channel tetramerisation domain containing 4 2.11 0.0052 
14670 Gnl1 guanine nucleotide binding protein-like 1 2.09 0 
74309 Osbp2 oxysterol binding protein 2 2.09 0.0057 
109689 Arrb1 arrestin, beta 1 2.08 0 
16600 Klf4 Kruppel-like factor 4 (gut) 2.07 0 
66237 Atp6v1g2 ATPase, H+ transporting, lysosomal V1 subunit G2 2.05 0 
237860 Ssh2 slingshot homolog 2 (Drosophila) 2.04 0 
24132 Zfp53 zinc finger protein 53 2.02 0 
68597 Ccdc167 coiled-coil domain containing 167 2.01 1.00E-04 
13518 Dst dystonin 2.01 0 
68614 Letmd1 LETM1 domain containing 1 1.99 0 
64657 Mrps10 mitochondrial ribosomal protein S10 1.99 0.0268 
216445 Arhgap9 Rho GTPase activating protein 9 1.98 0.0285 
17299 Mettl1 methyltransferase like 1 1.98 0 
237336 Tbpl1 TATA box binding protein-like 1 1.98 0 
12322 Camk2a calcium/calmodulin-dependent protein kinase II alpha 1.97 0.0124 
214854 Neurl3 neuralized homolog 3 homolog (Drosophila) 1.97 0 
242022 Frem2 Fras1 related extracellular matrix protein 2 1.96 0 
76071 Jakmip1 janus kinase and microtubule interacting protein 1 1.96 0 
53627 Porcn porcupine homolog (Drosophila) 1.96 0 
224826 Ubr2 ubiquitin protein ligase E3 component n-recognin 2 1.96 0 
22700 Zfp40 zinc finger protein 40 1.96 0 
329165 Abi2 abl-interactor 2 1.95 0 
64898 Lpin2 lipin 2 1.95 0 
18803 Plcg1 phospholipase C, gamma 1 1.95 0 
52830 Pnrc2 proline-rich nuclear receptor coactivator 2 1.95 0.029 
71567 Mcm9 minichromosome maintenance complex component 9 1.94 0 
81630 Zbtb22 zinc finger and BTB domain containing 22 1.94 0 
110532 Adarb1 adenosine deaminase, RNA-specific, B1 1.93 0 
11980 Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, 
type 8A, member 1 
1.93 0 
12364 Casp12 caspase 12 1.93 0 
58231 Stmnd1 stathmin domain containing 1 1.93 0.0029 
215690 Nav1 neuron navigator 1 1.92 0 
20539 Slc7a5 solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 5 
1.92 0 
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108995 Tbc1d10c TBC1 domain family, member 10c 1.92 6.00E-04 
71718 Telo2 TEL2, telomere maintenance 2, homolog (S. cerevisiae) 1.92 0 
73822 Mfsd12 major facilitator superfamily domain containing 12 1.91 0 
72886 Ccdc94 coiled-coil domain containing 94 1.9 0 
19725 Rfx2 regulatory factor X, 2 (influences HLA class II 
expression) 
1.89 0 
52466 Slc46a1 solute carrier family 46, member 1 1.89 0 
99681 Tchh trichohyalin 1.87 0 
16529 Kcnk5 potassium channel, subfamily K, member 5 1.86 0 
269610 Chd5 chromodomain helicase DNA binding protein 5 1.85 2.00E-04 
53621 Cnot4 CCR4-NOT transcription complex, subunit 4 1.85 0 
20425 Shmt1 serine hydroxymethyltransferase 1 (soluble) 1.85 0 
73582 Camkmt calmodulin-lysine N-methyltransferase 1.84 0 
15081 H3f3b H3 histone, family 3B 1.84 1.00E-04 
76137 Mcur1 mitochondrial calcium uniporter regulator 1 1.84 0 
381695 N4bp2l2 NEDD4 binding protein 2-like 2 1.84 0.0053 
241289 Ppp1r26 protein phosphatase 1, regulatory subunit 26 1.84 0 
22084 Tsc2 tuberous sclerosis 2 1.84 0 
106585 Ankrd12 ankyrin repeat domain 12 1.83 0 
97112 Nmd3 NMD3 homolog (S. cerevisiae) 1.83 1.00E-04 
20743 Sptbn2 spectrin beta, non-erythrocytic 2 1.83 0 
75547 Akap13 A kinase (PRKA) anchor protein 13 1.82 0 
223527 Eny2 enhancer of yellow 2 homolog (Drosophila) 1.82 0 
72039 Mccc1 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 1.82 0 
233066 Syne4 spectrin repeat containing, nuclear envelope family 
member 4 
1.82 2.00E-04 
104806 Fancm Fanconi anemia, complementation group M 1.81 0.0098 
18011 Neurl1a neuralized homolog 1A (Drosophila) 1.81 0.0071 
53320 Folh1 folate hydrolase 1 1.8 0 
78656 Brd8 bromodomain containing 8 1.79 5.00E-04 
50766 Crim1 cysteine rich transmembrane BMP regulator 1 (chordin 
like) 
1.79 2.00E-04 
170755 Sgk3 serum/glucocorticoid regulated kinase 3 1.79 0 
78830 Slc25a12 solute carrier family 25 (mitochondrial carrier, Aralar), 
member 12 
1.79 1.00E-04 
52430 Echdc2 enoyl Coenzyme A hydratase domain containing 2 1.78 0 
16993 Lta4h leukotriene A4 hydrolase 1.78 8.00E-04 
72462 Rrp1b ribosomal RNA processing 1 homolog B (S. cerevisiae) 1.78 0 
74741 C2cd5 C2 calcium-dependent domain containing 5 1.77 0 
12722 Clca1 chloride channel calcium activated 1 1.77 4.00E-04 
240041 Zfp945 zinc finger protein 945 1.77 0 
105504 Exoc5 exocyst complex component 5 1.76 0 
330671 B4galnt4 beta-1,4-N-acetyl-galactosaminyl transferase 4 1.75 0 
19647 Rbbp6 retinoblastoma binding protein 6 1.75 0 
74011 Slc25a27 solute carrier family 25, member 27 1.75 6.00E-04 
94089 Trim7 tripartite motif-containing 7 1.75 0 
105785 Kdelr3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 3 
1.74 0.0022 
14536 Nr6a1 nuclear receptor subfamily 6, group A, member 1 1.74 0 
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68799 Rgmb repulsive guidance molecule family member B 1.74 0 
320226 Ccdc171 coiled-coil domain containing 171 1.73 7.00E-04 
76917 Flywch2 FLYWCH family member 2 1.73 0 
76500 Ip6k2 inositol hexaphosphate kinase 2 1.73 0 
101706 Numa1 nuclear mitotic apparatus protein 1 1.73 1.00E-04 
93759 Sirt1 sirtuin 1 1.73 0 
224648 Uhrf1bp1 UHRF1 (ICBP90) binding protein 1 1.73 2.00E-04 
80892 Zfhx4 zinc finger homeodomain 4 1.73 0 
103406 Zfr2 zinc finger RNA binding protein 2 1.73 0 
76863 Dcun1d5 DCN1, defective in cullin neddylation 1, domain 
containing 5 (S. cerevisiae) 
1.72 0 
29857 Mapk12 mitogen-activated protein kinase 12 1.72 0 
106583 Scaf8 SR-related CTD-associated factor 8 1.72 0 
67062 Slc25a53 solute carrier family 25, member 53 1.72 0 
223922 Atf7 activating transcription factor 7 1.71 0.0161 
26889 Cln8 ceroid-lipofuscinosis, neuronal 8 1.71 0.0084 
72514 Fgfbp3 fibroblast growth factor binding protein 3 1.71 0 
22038 Plscr1 phospholipid scramblase 1 1.71 8.00E-04 
18845 Plxna2 plexin A2 1.71 1.00E-04 
56468 Socs5 suppressor of cytokine signaling 5 1.71 0 
12005 Axin1 axin 1 1.7 0 
70772 Ggnbp1 gametogenetin binding protein 1 1.7 0.0281 
66467 Gtf2h5 general transcription factor IIH, polypeptide 5 1.7 0 
76781 Mettl4 methyltransferase like 4 1.7 0 
338367 Myo1d myosin ID 1.7 0 
70439 Taf15 TAF15 RNA polymerase II, TATA box binding protein 
(TBP)-associated factor 
1.7 0 
11727 Ang angiogenin, ribonuclease, RNase A family, 5 1.69 0 
72029 Cnpy3 canopy 3 homolog (zebrafish) 1.69 0 
50758 Fbxl17 F-box and leucine-rich repeat protein 17 1.69 3.00E-04 
56516 Rbms2 RNA binding motif, single stranded interacting protein 2 1.69 0 
100201 Tmem64 transmembrane protein 64 1.69 0 
217333 Trim47 tripartite motif-containing 47 1.69 0 
68789 Trmt61b tRNA methyltransferase 61B 1.69 0 
214150 Ago3 argonaute RISC catalytic subunit 3 1.68 0.00E+0
0 
238123 Cog5 component of oligomeric golgi complex 5 1.68 0 
20463 Cox7a2l cytochrome c oxidase subunit VIIa polypeptide 2-like 1.68 0 
12946 Cr1l complement component (3b/4b) receptor 1-like 1.68 1.00E-04 
211446 Exoc3 exocyst complex component 3 1.68 0 
109801 Glo1 glyoxalase 1 1.68 0 
22196 Ube2i ubiquitin-conjugating enzyme E2I 1.68 0 
77048 Cep83 centrosomal protein 83 1.67 0 
70291 Mkrn2os makorin, ring finger protein 2, opposite strand 1.67 0 
20185 Ncor1 nuclear receptor co-repressor 1 1.67 0 
72057 Phf10 PHD finger protein 10 1.67 0 
51796 Srrm1 serine/arginine repetitive matrix 1 1.67 0.0035 
69539 Trnp1 TMF1-regulated nuclear protein 1 1.67 0 
11512 Adcy6 adenylate cyclase 6 1.66 0 
 
224 
 
Table 33 continued 
11842 Arf3 ADP-ribosylation factor 3 1.66 0.0072 
12915 Atf6b Activating transcription factor 6 beta 1.66 0 
73739 Cby1 chibby homolog 1 (Drosophila) 1.66 1.00E-04 
56149 Grasp GRP1 (general receptor for phosphoinositides 1)-
associated scaffold protein 
1.66 0 
19250 Ptpn14 protein tyrosine phosphatase, non-receptor type 14 1.66 0 
225027 Srsf7 serine/arginine-rich splicing factor 7 1.66 0 
97503 Vwa7 von Willebrand factor A domain containing 7 1.66 0.0184 
432486 Gnptab N-acetylglucosamine-1-phosphate transferase, alpha and 
beta subunits 
1.65 0 
68537 Mrpl13 mitochondrial ribosomal protein L13 1.65 0 
72193 Scaf11 SR-related CTD-associated factor 11 1.65 0 
57908 Zfp318 zinc finger protein 318 1.65 0 
193742 Abhd16a abhydrolase domain containing 16A 1.64 0 
67723 Cep83os centrosomal protein 83, opposite strand 1.64 0 
66978 Luc7l Luc7 homolog (S. cerevisiae)-like 1.64 0 
216154 Med16 mediator complex subunit 16 1.64 0 
56716 Mlst8 MTOR associated protein, LST8 homolog (S. 
cerevisiae) 
1.64 0 
100273 Osbpl9 oxysterol binding protein-like 9 1.64 0 
170719 Oxr1 oxidation resistance 1 1.64 0 
22643 Zfp101 zinc finger protein 101 1.64 5.00E-04 
240120 Zfp119b zinc finger protein 119b 1.64 0 
66548 Adamtsl5 ADAMTS-like 5 1.63 0.0026 
233115 Dpy19l3 dpy-19-like 3 (C. elegans) 1.63 0 
71436 Flrt3 fibronectin leucine rich transmembrane protein 3 1.63 0.0013 
259277 Klk8 kallikrein related-peptidase 8 1.63 0 
17356 Mllt4 myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 4 
1.63 0 
56409 Nudt3 nudix (nucleotide diphosphate linked moiety X)-type 
motif 3 
1.63 0 
19326 Rab11b RAB11B, member RAS oncogene family 1.63 0 
20662 Sos1 son of sevenless homolog 1 (Drosophila) 1.63 1.00E-04 
22687 Zpr1 ZPR1 zinc finger 1.63 0.0014 
16800 Arhgef2 rho/rac guanine nucleotide exchange factor (GEF) 2 1.62 0 
18218 Dusp8 dual specificity phosphatase 8 1.62 0.0044 
225055 Fbxo11 F-box protein 11 1.62 0 
14910 Gt(ROSA)2
6Sor 
gene trap ROSA 26, Philippe Soriano 1.62 0 
16576 Kif7 kinesin family member 7 1.62 0.0051 
17762 Mapt microtubule-associated protein tau 1.62 0 
13340 Slc29a2 solute carrier family 29 (nucleoside transporters), 
member 2 
1.62 1.00E-04 
12268 C4b complement component 4B (Chido blood group) 1.61 0.0011 
218210 Nup153 nucleoporin 153 1.61 6.00E-04 
70335 Reep6 receptor accessory protein 6 1.61 0 
66353 Riiad1 regulatory subunit of type II PKA R-subunit (RIIa) 
domain containing 1 
1.61 0.0145 
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74355 Smchd1 SMC hinge domain containing 1 1.61 0 
75956 Srrm2 serine/arginine repetitive matrix 2 1.61 0 
11736 Ankfy1 ankyrin repeat and FYVE domain containing 1 1.6 0.0069 
320162 Cep95 centrosomal protein 95 1.6 0.0014 
224907 Dus3l dihydrouridine synthase 3-like (S. cerevisiae) 1.6 0 
16855 Lgals4 lectin, galactose binding, soluble 4 1.6 9.00E-04 
17760 Map6 microtubule-associated protein 6 1.6 0.0022 
240087 Mdc1 mediator of DNA damage checkpoint 1 1.6 0 
18854 Pml promyelocytic leukemia 1.6 0.0013 
208292 Zfp871 zinc finger protein 871 1.6 0 
229776 Cdc14a CDC14 cell division cycle 14A 1.59 0 
14885 Gtf2h4 general transcription factor II H, polypeptide 4 1.59 0 
109241 Mbd5 methyl-CpG binding domain protein 5 1.59 0.0042 
239985 Arid1b AT rich interactive domain 1B (SWI-like) 1.58 0 
12611 Cebpg CCAAT/enhancer binding protein (C/EBP), gamma 1.58 0 
319158 Hist1h4i histone cluster 1, H4i 1.58 0 
67042 Ift27 intraflagellar transport 27 1.58 0 
240354 Malt1 mucosa associated lymphoid tissue lymphoma 
translocation gene 1 
1.58 7.00E-04 
320878 Mical2 microtubule associated monooxygenase, calponin and 
LIM domain containing 2 
1.58 0.0081 
114716 Spred2 sprouty-related, EVH1 domain containing 2 1.58 1.00E-04 
69020 Zfp707 zinc finger protein 707 1.58 0.0031 
67006 Cisd2 CDGSH iron sulfur domain 2 1.57 1.00E-04 
224897 Dpp9 dipeptidylpeptidase 9 1.57 0 
98053 Gtf2f1 general transcription factor IIF, polypeptide 1 1.57 0 
67429 Nudcd1 NudC domain containing 1 1.57 0.0038 
71365 Pdss2 prenyl (solanesyl) diphosphate synthase, subunit 2 1.57 0.0163 
224893 Zfp959 zinc finger protein 959 1.57 2.00E-04 
71361 Aifm2 apoptosis-inducing factor, mitochondrion-associated 2 1.56 0 
11772 Ap2a2 adaptor-related protein complex 2, alpha 2 subunit 1.56 0 
56724 Cript cysteine-rich PDZ-binding protein 1.56 0 
66590 Farsa phenylalanyl-tRNA synthetase, alpha subunit 1.56 0.0063 
11692 Gfer growth factor, erv1 (S. cerevisiae)-like (augmenter of 
liver regeneration) 
1.56 0 
68304 Kdelc2 KDEL (Lys-Asp-Glu-Leu) containing 2 1.56 0 
213760 Prepl prolyl endopeptidase-like 1.56 0 
56438 Rbx1 ring-box 1 1.56 1.00E-04 
20194 S100a10 S100 calcium binding protein A10 (calpactin) 1.56 0 
109552 Sri sorcin 1.56 0 
30056 Timm9 translocase of inner mitochondrial membrane 9 1.56 0 
224836 Usp49 ubiquitin specific peptidase 49 1.56 0 
106618 Wdr90 WD repeat domain 90 1.56 2.00E-04 
78795 Armc9 armadillo repeat containing 9 1.55 0 
268936 Brpf3 bromodomain and PHD finger containing, 3 1.55 0 
384009 Glipr2 GLI pathogenesis-related 2 1.55 0.0111 
80718 Rab27b RAB27B, member RAS oncogene family 1.55 0 
226781 Slc30a10 solute carrier family 30, member 10 1.55 0 
68166 Spire1 spire homolog 1 (Drosophila) 1.55 1.00E-04 
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20383 Srsf3 serine/arginine-rich splicing factor 3 1.55 0 
72322 Xpo5 exportin 5 1.55 0 
233058 Zfp420 zinc finger protein 420 1.55 9.00E-04 
226747 Ahctf1 AT hook containing transcription factor 1 1.54 0 
73242 Atat1 alpha tubulin acetyltransferase 1 1.54 0 
70686 Dusp16 dual specificity phosphatase 16 1.54 0.0065 
72508 Rps6kb1 ribosomal protein S6 kinase, polypeptide 1 1.54 2.00E-04 
63856 Taf8 TAF8 RNA polymerase II, TATA box binding protein 
(TBP)-associated factorq 
1.54 0 
110960 Tars threonyl-tRNA synthetase 1.54 0 
211660 Cspp1 centrosome and spindle pole associated protein 1 1.53 2.00E-04 
239667 Dip2b DIP2 disco-interacting protein 2 homolog B 
(Drosophila) 
1.53 0.0171 
75219 Dusp18 dual specificity phosphatase 18 1.53 0 
246179 Fktn fukutin 1.53 0 
77480 Kidins220 kinase D-interacting substrate 220 1.53 1.00E-04 
26416 Mapk14 mitogen-activated protein kinase 14 1.53 0 
17181 Matn2 matrilin 2 1.53 0.0038 
214742 Rcor3 REST corepressor 3 1.53 0 
21843 Tial1 Tia1 cytotoxic granule-associated RNA binding protein-
like 1 
1.53 0 
72515 Wdr43 WD repeat domain 43 1.53 0 
15458 Hpx hemopexin 1.52 0.0072 
67733 Itgb3bp integrin beta 3 binding protein (beta3-endonexin) 1.52 0.0171 
74127 Krt80 keratin 80 1.52 0 
382793 Mtx3 metaxin 3 1.52 0 
330260 Pon2 paraoxonase 2 1.52 0.0071 
19386 Ranbp2 RAN binding protein 2 1.52 0 
66855 Tcf25 transcription factor 25 (basic helix-loop-helix) 1.52 3.00E-04 
102791 Tcta T cell leukemia translocation altered gene 1.52 0 
68915 Vars2 valyl-tRNA synthetase 2, mitochondrial (putative) 1.52 0 
21769 Zfand3 zinc finger, AN1-type domain 3 1.52 0 
66136 Znrd1 zinc ribbon domain containing, 1 1.52 0 
215748 Cnksr3 Cnksr family member 3 1.51 0 
55936 Ctps2 cytidine 5'-triphosphate synthase 2 1.51 2.00E-04 
13110 Cyp2j6 cytochrome P450, family 2, subfamily j, polypeptide 6 1.51 2.00E-04 
56809 Gmeb1 glucocorticoid modulatory element binding protein 1 1.51 0.0031 
15193 Hdgfrp2 hepatoma-derived growth factor, related protein 2 1.51 0 
93730 Lztfl1 leucine zipper transcription factor-like 1 1.51 0 
14924 Magi1 membrane associated guanylate kinase, WW and PDZ 
domain containing 1 
1.51 0 
18207 Nthl1 nth (endonuclease III)-like 1 (E.coli) 1.51 3.00E-04 
214968 Sema6d sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D 
1.51 0.02 
72895 Setd5 SET domain containing 5 1.51 0 
73836 Slc35b2 solute carrier family 35, member B2 1.51 0.0041 
20744 Strbp spermatid perinuclear RNA binding protein 1.51 1.00E-04 
109115 Supt3 suppressor of Ty 3 1.51 0 
60532 Wtap Wilms tumour 1-associating protein 1.51 0 
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68270 Dnaaf1 dynein, axonemal assembly factor 1 1.5 0.0399 
74559 Elovl7 ELOVL family member 7, elongation of long chain fatty 
acids (yeast) 
1.5 0 
71927 Itfg1 integrin alpha FG-GAP repeat containing 1 1.5 1.00E-04 
80877 Lrba LPS-responsive beige-like anchor 1.5 0 
17776 Mast2 microtubule associated serine/threonine kinase 2 1.5 1.00E-04 
56462 Mtch1 mitochondrial carrier homolog 1 (C. elegans) 1.5 0 
20683 Sp1 trans-acting transcription factor 1 1.5 0 
72726 Tbcc tubulin-specific chaperone C 1.5 0.0017 
79263 Trim39 tripartite motif-containing 39 1.5 0 
68767 Wash WAS protein family homolog 1.5 0.0038 
268933 Wdr24 WD repeat domain 24 1.5 0 
77264 Zfp142 zinc finger protein 142 1.5 0.0278 
240064 Zfp799 zinc finger protein 799 1.5 0 
108058 Camk2d calcium/calmodulin-dependent protein kinase II, delta 1.49 2.00E-04 
13640 Efna5 ephrin A5 1.49 0 
78878 Ftx Ftx transcript, Xist regulator (non-protein coding) 1.49 0.0101 
94353 Hmgn3 high mobility group nucleosomal binding domain 3 1.49 0 
15382 Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1 1.49 5.00E-04 
16661 Krt10 keratin 10 1.49 0 
56758 Mbnl1 muscleblind-like 1 (Drosophila) 1.49 0.0288 
17685 Msh2 mutS homolog 2 (E. coli) 1.49 6.00E-04 
320111 Prr18 proline rich 18 1.49 0.0252 
19296 Pvt1 plasmacytoma variant translocation 1 1.49 0 
215445 Rab11fip3 RAB11 family interacting protein 3 (class II) 1.49 4.00E-04 
242585 Slc35d1 solute carrier family 35 (UDP-glucuronic acid/UDP-N-
acetylgalactosamine dual transporter), member D1 
1.49 2.00E-04 
68268 Zdhhc21 zinc finger, DHHC domain containing 21 1.49 0 
27410 Abca3 ATP-binding cassette, sub-family A (ABC1), member 3 1.48 0 
11855 Arhgap5 Rho GTPase activating protein 5 1.48 1.00E-04 
12211 Birc6 baculoviral IAP repeat-containing 6 1.48 0 
109880 Braf Braf transforming gene 1.48 0 
12607 Cebpz CCAAT/enhancer binding protein zeta 1.48 0 
432508 Cpsf6 cleavage and polyadenylation specific factor 6 1.48 7.00E-04 
70069 H1fnt H1 histone family, member N, testis-specific 1.48 0.0045 
78651 Lsm6 LSM6 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
1.48 0 
66414 Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 12 
1.48 2.00E-04 
18027 Nfia nuclear factor I/A 1.48 0.0088 
71175 Nipbl Nipped-B homolog (Drosophila) 1.48 0 
18195 Nsf N-ethylmaleimide sensitive fusion protein 1.48 0.013 
18515 Pbx2 pre B cell leukemia homeobox 2 1.48 0 
319518 Pdpr pyruvate dehydrogenase phosphatase regulatory subunit 1.48 0.0161 
14083 Ptk2 PTK2 protein tyrosine kinase 2 1.48 0 
380714 Rph3al rabphilin 3A-like (without C2 domains) 1.48 0 
20084 Rps18 ribosomal protein S18 1.48 2.00E-04 
108077 Skiv2l superkiller viralicidic activity 2-like (S. cerevisiae) 1.48 0 
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59033 Slc4a8 solute carrier family 4 (anion exchanger), member 8 1.48 0.0131 
69434 Snhg10 small nucleolar RNA host gene 10 1.48 0 
67023 Use1 unconventional SNARE in the ER 1 homolog (S. 
cerevisiae) 
1.48 0.0111 
237898 Usp32 ubiquitin specific peptidase 32 1.48 9.00E-04 
54194 Akap8l A kinase (PRKA) anchor protein 8-like 1.47 1.00E-04 
75415 Arhgap12 Rho GTPase activating protein 12 1.47 0 
102545 Cmtm7 CKLF-like MARVEL transmembrane domain 
containing 7 
1.47 0.0011 
77996 Cutal cutA divalent cation tolerance homolog-like 1.47 0 
13367 Diap1 diaphanous homolog 1 (Drosophila) 1.47 2.00E-04 
71916 Dus4l dihydrouridine synthase 4-like (S. cerevisiae) 1.47 1.00E-04 
107508 Eprs glutamyl-prolyl-tRNA synthetase 1.47 0.0027 
12695 Inadl InaD-like (Drosophila) 1.47 0 
23849 Klf6 Kruppel-like factor 6 1.47 0.0019 
76890 Memo1 mediator of cell motility 1 1.47 7.00E-04 
18771 Pknox1 Pbx/knotted 1 homeobox 1.47 4.00E-04 
20907 Stx1a syntaxin 1A (brain) 1.47 0 
237500 Tmtc3 transmembrane and tetratricopeptide repeat containing 3 1.47 0 
22215 Ube3a ubiquitin protein ligase E3A 1.47 8.00E-04 
235574 Atp2c1 ATPase, Ca++-sequestering 1.46 0 
66371 Chmp4c charged multivesicular body protein 4C 1.46 1.00E-04 
59079 Erbb2ip Erbb2 interacting protein 1.46 1.00E-04 
67529 Fgfr1op2 FGFR1 oncogene partner 2 1.46 0 
53618 Fut8 fucosyltransferase 8 1.46 1.00E-04 
328329 Mast4 microtubule associated serine/threonine kinase family 
member 4 
1.46 1.00E-04 
67245 Peli1 pellino 1 1.46 4.00E-04 
83946 Phip pleckstrin homology domain interacting protein 1.46 0 
56194 Prpf40a PRP40 pre-mRNA processing factor 40 homolog A 
(yeast) 
1.46 0.0051 
77300 Raph1 Ras association (RalGDS/AF-6) and pleckstrin 
homology domains 1 
1.46 0.0012 
71340 Riok1 RIO kinase 1 (yeast) 1.46 1.00E-04 
216161 Sbno2 strawberry notch homolog 2 (Drosophila) 1.46 0 
72198 Skiv2l2 superkiller viralicidic activity 2-like 2 (S. cerevisiae) 1.46 0.0078 
20536 Slc4a3 solute carrier family 4 (anion exchanger), member 3 1.46 7.00E-04 
72238 Tbc1d5 TBC1 domain family, member 5 1.46 0 
194388 Tet3 tet methylcytosine dioxygenase 3 1.46 0.039 
216810 Tom1l2 target of myb1-like 2 (chicken) 1.46 0.0019 
22409 Wnt10a wingless-type MMTV integration site family, member 
10A 
1.46 0 
66894 Wwp2 WW domain containing E3 ubiquitin protein ligase 2 1.46 7.00E-04 
22666 Zbtb14 zinc finger and BTB domain containing 14 1.46 3.00E-04 
231866 Zfp12 zinc finger protein 12 1.46 4.00E-04 
105841 Dennd3 DENN/MADD domain containing 3 1.45 0 
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14073 Faah fatty acid amide hydrolase 1.45 0 
76522 Lsm8 LSM8 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
1.45 0 
67045 Riok2 RIO kinase 2 (yeast) 1.45 0 
59009 Sh3rf1 SH3 domain containing ring finger 1 1.45 0 
329584 Slc2a4rg-ps Slc2a4 regulator, pseudogene 1.45 0 
213773 Tbl3 transducin (beta)-like 3 1.45 1.00E-04 
67226 Tmem19 transmembrane protein 19 1.45 8.00E-04 
68327 Tsr3 TSR3 20S rRNA accumulation 1.45 1.00E-04 
225049 Ttc7 tetratricopeptide repeat domain 7 1.45 0 
218914 Wapal wings apart-like homolog (Drosophila) 1.45 0 
328801 Zfp414 zinc finger protein 414 1.45 7.00E-04 
224691 Zfp472 zinc finger protein 472 1.45 0 
77652 Zfp955a zinc finger protein 955A 1.45 0 
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Table 34:  Downregulated genes in inversin-depleted renal epithelial cells 
Gene 
ID 
Gene 
Symbol Protein Name  
 Fold 
change/ 
NTC   P-value 
105638 Dph3 diphthamine biosynthesis 3 -1.45 0 
67456 Ergic2 ERGIC and golgi 2 -1.45 0 
14391 Gabpb1 GA repeat binding protein, beta 1 -1.45 0 
225887 Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 -1.45 2.00E-04 
21679 Tead4 TEA domain family member 4 -1.45 0.0011 
21898 Tlr4 toll-like receptor 4 -1.45 0 
66058 Tmem176a transmembrane protein 176A -1.45 0 
56224 Tspan5 tetraspanin 5 -1.45 0.0234 
109711 Actn1 actinin, alpha 1 -1.46 0 
12443 Ccnd1 cyclin D1 -1.46 0 
13636 Efna1 ephrin A1 -1.46 0 
14872 Gstt2 glutathione S-transferase, theta 2 -1.46 4.00E-04 
15510 Hspd1 heat shock protein 1 (chaperonin) -1.46 0 
19139 Prps1 phosphoribosyl pyrophosphate synthetase 1 -1.46 0 
226043 Cbwd1 COBW domain containing 1 -1.47 2.00E-04 
211151 Churc1 churchill domain containing 1 -1.47 0 
66573 Dzip1 DAZ interacting protein 1 -1.47 2.00E-04 
20135 Rrm2 ribonucleotide reductase M2 -1.47 0.0077 
229782 Slc35a3 solute carrier family 35 (UDP-N-acetylglucosamine 
(UDP-GlcNAc) transporter), member 3 
-1.47 0 
387524 Znrf2 zinc and ring finger 2 -1.47 0 
50883 Chek2 checkpoint kinase 2 -1.48 1.00E-04 
17951 Naip5 NLR family, apoptosis inhibitory protein 5 -1.48 0 
244668 Sipa1l2 signal-induced proliferation-associated 1 like 2 -1.48 0.0178 
66757 Adat2 adenosine deaminase, tRNA-specific 2 -1.49 0 
26905 Eif2s3x eukaryotic translation initiation factor 2, subunit 3, 
structural gene X-linked 
-1.49 6.00E-04 
69270 Gins1 GINS complex subunit 1 (Psf1 homolog) -1.49 0.003 
67441 Isoc2b isochorismatase domain containing 2b -1.49 0.0056 
17304 Mfge8 milk fat globule-EGF factor 8 protein -1.49 0 
18472 Pafah1b1 platelet-activating factor acetylhydrolase, isoform 
1b, subunit 1 
-1.49 0 
219189 Vwa8 von Willebrand factor A domain containing 8 -1.49 0.0033 
320924 Ccbe1 collagen and calcium binding EGF domains 1 -1.5 1.00E-04 
106143 Cggbp1 CGG triplet repeat binding protein 1 -1.5 1.00E-04 
69605 Lnp limb and neural patterns -1.5 2.00E-04 
68043 N6amt2 N-6 adenine-specific DNA methyltransferase 2 
(putative) 
-1.5 0 
67916 Ppap2b phosphatidic acid phosphatase type 2B -1.5 0 
57259 Tob2 transducer of ERBB2, 2 -1.5 0.0086 
66622 Ubr7 ubiquitin protein ligase E3 component n-recognin 7 
(putative) 
-1.5 2.00E-04 
66884 Appbp2 amyloid beta precursor protein (cytoplasmic tail) 
binding protein 2 
-1.51 1.00E-04 
70640 Dcp2 DCP2 decapping enzyme homolog (S. cerevisiae) -1.51 0.008 
16400 Itga3 integrin alpha 3 -1.51 0.0037 
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14489 Mtpn Myotrophin -1.51 0 
17919 Myo5b myosin VB -1.51 0 
66566 Ntpcr nucleoside-triphosphatase, cancer-related -1.51 0 
70974 Pgm2l1 phosphoglucomutase 2-like 1 -1.51 0 
225845 Pla2g16 phospholipase A2, group XVI -1.51 0.0352 
59069 Tpm3 tropomyosin 3, gamma -1.51 0 
20402 Zfp106 zinc finger protein 106 -1.51 0 
11975 Atp6v0a1 ATPase, H+ transporting, lysosomal V0 subunit 
A1 
-1.52 0 
66121 Chchd1 coiled-coil-helix-coiled-coil-helix domain 
containing 1 
-1.52 0 
12848 Cops2 COP9 (constitutive photomorphogenic) homolog, 
subunit 2 (Arabidopsis thaliana) 
-1.52 0 
14423 Galnt1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 1 
-1.52 1.00E-04 
54426 Hgfac hepatocyte growth factor activator -1.52 0 
15357 Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase 
-1.52 0 
56428 Mtch2 mitochondrial carrier homolog 2 (C. elegans) -1.52 0.0089 
17777 Mttp microsomal triglyceride transfer protein -1.52 0.0063 
56309 Mycbp c-myc binding protein -1.52 0.0032 
18187 Nrp2 neuropilin 2 -1.52 1.00E-04 
109785 Pgm3 phosphoglucomutase 3 -1.52 1.00E-04 
19712 Rest RE1-silencing transcription factor -1.52 0 
319322 Sf3b2 splicing factor 3b, subunit 2 -1.52 0 
236920 Stard8 START domain containing 8 -1.52 0 
110208 Pgd phosphogluconate dehydrogenase -1.53 0.0044 
13555 E2f1 E2F transcription factor 1 -1.54 0.0378 
74386 Rmi1 RMI1, RecQ mediated genome instability 1, 
homolog (S. cerevisiae) 
-1.54 0 
20778 Scarb1 scavenger receptor class B, member 1 -1.54 0 
15205 Hes1 hairy and enhancer of split 1 (Drosophila) -1.55 0 
20350 Sema3f sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3F 
-1.55 3.00E-04 
53413 Exoc7 exocyst complex component 7 -1.56 0 
27418 Mkln1 muskelin 1, intracellular mediator containing kelch 
motifs 
-1.56 0 
68095 Ociad1 OCIA domain containing 1 -1.56 9.00E-04 
224454 Zdhhc14 zinc finger, DHHC domain containing 14 -1.56 0 
112407 Egln3 egl-9 family hypoxia-inducible factor 3 -1.57 0 
17873 Gadd45b growth arrest and DNA-damage-inducible 45 beta -1.57 0 
57342 Parva parvin, alpha -1.57 0.0141 
67010 Rbm7 RNA binding motif protein 7 -1.57 0 
209773 Dennd2a DENN/MADD domain containing 2A -1.58 0 
66234 Msmo1 methylsterol monoxygenase 1 -1.58 0 
72333 Palld palladin, cytoskeletal associated protein -1.58 0.0092 
69178 Snx5 sorting nexin 5 -1.58 0 
59025 Usp14 ubiquitin specific peptidase 14 -1.58 0 
21452 Tcn2 transcobalamin 2 -1.58 6.00E-04 
229900 Gbp7 guanylate binding protein 7 -1.59 0.0196 
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52014 Nus1 nuclear undecaprenyl pyrophosphate synthase 1 
homolog (S. cerevisiae) 
-1.59 0 
76073 Pcgf5 polycomb group ring finger 5 -1.59 0 
21752 Tert telomerase reverse transcriptase -1.59 0.0113 
54343 Atf7ip activating transcription factor 7 interacting protein -1.6 0 
18616 Peg3 paternally expressed 3 -1.6 2.00E-04 
80890 Trim2 tripartite motif-containing 2 -1.6 0.0091 
12448 Ccne2 cyclin E2 -1.61 0.0011 
13433 Dnmt1 DNA methyltransferase (cytosine-5) 1 -1.61 0.0013 
320878 Mis18bp1 MIS18 binding protein 1 -1.61 8.00E-04 
18451 P4ha1 procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 1 polypeptide 
-1.61 0 
64009 Syne1 spectrin repeat containing, nuclear envelope 1 -1.61 0 
114606 Tle6 transducin-like enhancer of split 6, homolog of 
Drosophila E(spl) 
-1.61 0.0039 
80914 Uck2 uridine-cytidine kinase 2 -1.61 0 
108000 Cenpf centromere protein F -1.62 0.0042 
14569 Gdi2 guanosine diphosphate (GDP) dissociation inhibitor 
2 
-1.62 0 
14873 Gsto1 glutathione S-transferase omega 1 -1.62 0 
20973 Syngr2 synaptogyrin 2 -1.62 0 
170938 Zfp617 zinc finger protein 617 -1.62 0 
12331 Cap1 CAP, adenylate cyclase-associated protein 1 (yeast) -1.63 0 
12530 Cdc25a cell division cycle 25A -1.63 5.00E-04 
13361 Dhfr dihydrofolate reductase -1.63 1.00E-04 
207781 C2cd2 C2 calcium-dependent domain containing 2 -1.64 0.0198 
108645 Mat2b methionine adenosyltransferase II, beta -1.64 0 
17535 Mre11a meiotic recombination 11 homolog A (S. cerevisiae) -1.64 0 
52615 Suz12 suppressor of zeste 12 homolog (Drosophila) -1.64 0 
13121 Cyp51 cytochrome P450, family 51 -1.65 0 
16881 Lig1 ligase I, DNA, ATP-dependent -1.65 0 
14156 Fen1 flap structure specific endonuclease 1 -1.66 0 
16151 Ikbkg inhibitor of kappaB kinase gamma -1.66 0.0023 
57296 Psmd8 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 8 
-1.66 0 
17387 Mmp14 matrix metallopeptidase 14 (membrane-inserted) -1.67 0 
20439 Siah2 seven in absentia 2 -1.67 0.0018 
20911 Stxbp2 syntaxin binding protein 2 -1.67 0 
241525 Ypel4 yippee-like 4 (Drosophila) -1.67 0.0067 
54447 Asah2 N-acylsphingosine amidohydrolase 2 -1.68 0 
52276 Cdca8 cell division cycle associated 8 -1.68 0.0066 
237082 Nxt2 nuclear transport factor 2-like export factor 2 -1.68 0 
12633 Cflar CASP8 and FADD-like apoptosis regulator -1.69 0 
23881 G3bp2 GTPase activating protein (SH3 domain) binding 
protein 2 
-1.69 0 
14841 Gsg2 germ cell-specific gene 2 -1.69 0.0022 
229317 Eif2a eukaryotic translation initiation factor 2A -1.7 0 
234593 Ndrg4 N-myc downstream regulated gene 4 -1.7 0 
114643 Oas1c 2'-5' oligoadenylate synthetase 1C -1.7 0 
20873 Plk4 polo-like kinase 4 -1.7 1.00E-04 
67771 Arpc5 actin related protein 2/3 complex, subunit 5 -1.71 0 
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231999 Plekha8 pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 8 
-1.71 0.0024 
64929 Scel Sciellin -1.71 0 
56524 Mpp6 membrane protein, palmitoylated 6 (MAGUK p55 
subfamily member 6) 
-1.72 0 
21335 Tacc3 transforming, acidic coiled-coil containing protein 3 -1.72 0.0058 
66805 Tspan1 tetraspanin 1 -1.72 0 
16835 Ldlr low density lipoprotein receptor -1.73 0 
19272 Ptprk protein tyrosine phosphatase, receptor type, K -1.74 0 
20133 Rrm1 ribonucleotide reductase M1 -1.74 1.00E-04 
76044 Ncapg2 non-SMC condensin II complex, subunit G2 -1.75 5.00E-04 
67963 Npc2 Niemann-Pick type C2 -1.75 0.0016 
72065 Rap2c RAP2C, member of RAS oncogene family -1.75 0 
108912 Cdca2 cell division cycle associated 2 -1.76 0.0097 
58186 Rad18 RAD18 homolog (S. cerevisiae) -1.76 2.00E-04 
66309 Tmem128 transmembrane protein 128 -1.76 0 
229841 Cenpe centromere protein E -1.77 0.0049 
13116 Cyp46a1 cytochrome P450, family 46, subfamily a, 
polypeptide 1 
-1.77 0.0204 
26384 Gnpda1 glucosamine-6-phosphate deaminase 1 -1.77 0 
17750 Mt2 metallothionein 2 -1.77 2.00E-04 
107358 Tm9sf3 transmembrane 9 superfamily member 3 -1.77 0 
74747 Ddit4 DNA-damage-inducible transcript 4 -1.78 0 
68735 Mrps18c mitochondrial ribosomal protein S18C -1.78 0 
94190 Ophn1 oligophrenin 1 -1.78 0 
66395 Ahnak AHNAK nucleoprotein (desmoyokin) -1.79 0 
236930 Ercc6l excision repair cross-complementing rodent repair 
deficiency complementation group 6 like 
-1.79 0.0017 
53381 Prdx4 peroxiredoxin 4 -1.79 0 
100678 Psph phosphoserine phosphatase -1.79 0 
17436 Me1 malic enzyme 1, NADP(+)-dependent, cytosolic -1.8 0 
94219 Cnnm2 cyclin M2 -1.81 0 
70355 Gprc5c G protein-coupled receptor, family C, group 5, 
member C 
-1.81 1.00E-04 
71978 Ppp2r2a protein phosphatase 2, regulatory subunit B, alpha -1.81 0 
12649 Chek1 checkpoint kinase 1 -1.82 1.00E-04 
14200 Fhl2 four and a half LIM domains 2 -1.82 0 
66387 Nudt8 nudix (nucleoside diphosphate linked moiety X)-
type motif 8 
-1.82 0 
21384 Tbx15 T-box 15 -1.82 0.0013 
66929 Asf1b anti-silencing function 1B histone chaperone -1.84 0.005 
23834 Cdc6 cell division cycle 6 -1.84 5.00E-04 
66197 Cks2 CDC28 protein kinase regulatory subunit 2 -1.84 0 
69823 Fyttd1 forty-two-three domain containing 1 -1.84 0 
15366 Hmmr hyaluronan mediated motility receptor (RHAMM) -1.84 0.026 
404710 Iqgap3 IQ motif containing GTPase activating protein 3 -1.84 8.00E-04 
53322 Nucb2 nucleobindin 2 -1.84 0 
18974 Pole2 polymerase (DNA directed), epsilon 2 (p59 subunit) -1.84 1.00E-04 
70472 Atad2 ATPase family, AAA domain containing 2 -1.85 0 
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97484 Cog8 component of oligomeric golgi complex 8 -1.85 0.0262 
224014 Fgd4 FYVE, RhoGEF and PH domain containing 4 -1.86 7.00E-04 
56349 Net1 neuroepithelial cell transforming gene 1 -1.86 0 
20878 Aurka aurora kinase A -1.87 0.0071 
15945 Cxcl10 chemokine (C-X-C motif) ligand 10 -1.87 0.0111 
13360 Dhcr7 7-dehydrocholesterol reductase -1.87 0 
15525 Hspa4 heat shock protein 4 -1.87 0 
68332 Sdhaf1 succinate dehydrogenase complex assembly factor 1 -1.87 0 
71703 Armcx3 armadillo repeat containing, X-linked 3 -1.88 0 
18140 Uhrf1 ubiquitin-like, containing PHD and RING finger 
domains, 1 
-1.88 0.004 
192156 Mvd mevalonate (diphospho) decarboxylase -1.89 0 
72584 Cul4b cullin 4B -1.9 0 
101401 Adamts9 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 9 
-1.91 0 
68631 Cryl1 crystallin, lambda 1 -1.91 0 
67608 Narf nuclear prelamin A recognition factor -1.91 0 
93732 Acox2 acyl-Coenzyme A oxidase 2, branched chain -1.92 0 
26886 Cenph centromere protein H -1.93 2.00E-04 
80986 Ckap2 cytoskeleton associated protein 2 -1.93 0.0073 
140486 Igf2bp1 insulin-like growth factor 2 mRNA binding protein 1 -1.93 1.00E-04 
66442 Spc25 SPC25, NDC80 kinetochore complex component, 
homolog (S. cerevisiae) 
-1.93 0.008 
170459 Stard4 StAR-related lipid transfer (START) domain 
containing 4 
-1.93 0 
18186 Nrp1 neuropilin 1 -1.94 0 
20460 Stil Scl/Tal1 interrupting locus -1.94 8.00E-04 
100637 N4bp2l1 NEDD4 binding protein 2-like 1 -1.96 0 
18611 Pea15a phosphoprotein enriched in astrocytes 15A -1.96 0 
20855 Stc1 stanniocalcin 1 -1.96 3.00E-04 
14793 Cdca3 cell division cycle associated 3 -1.97 0.0072 
237436 Gas2l3 growth arrest-specific 2 like 3 -1.97 0.0073 
15958 Ifit2 interferon-induced protein with tetratricopeptide 
repeats 2 
-1.97 0 
21938 Tnfrsf1b tumor necrosis factor receptor superfamily, member 
1b 
-1.97 0 
319554 Idi1 isopentenyl-diphosphate delta isomerase -1.98 0 
433904 Ociad2 OCIA domain containing 2 -1.98 0 
18107 Nmt1 N-myristoyltransferase 1 -1.99 0 
217325 Llgl2 lethal giant larvae homolog 2 (Drosophila) -2.01 0 
68209 Rnaseh2c ribonuclease H2, subunit C -2.02 0 
20877 Aurkb aurora kinase B -2.03 0.0018 
72391 Cdkn3 cyclin-dependent kinase inhibitor 3 -2.03 0.0167 
58231 Stk4 serine/threonine kinase 4 -2.03 0 
107568 Wwp1 WW domain containing E3 ubiquitin protein ligase 1 -2.03 0.0013 
240641 Kif20b kinesin family member 20B -2.04 0 
11306 Abcb7 ATP-binding cassette, sub-family B (MDR/TAP), 
member 7 
-2.05 0 
12367 Casp3 caspase 3 -2.06 0 
12450 Ccng1 cyclin G1 -2.06 0 
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60530 Fignl1 fidgetin-like 1 -2.06 0 
12534 Cdk1 cyclin-dependent kinase 1 -2.07 7.00E-04 
272551 Gins2 GINS complex subunit 2 (Psf2 homolog) -2.07 0.001 
68014 Zwilch zwilch kinetochore protein -2.07 3.00E-04 
22256 Ung uracil DNA glycosylase -2.08 0 
231070 Insig1 insulin induced gene 1 -2.09 0 
12189 Brca1 breast cancer 1 -2.1 0.0016 
60411 Cenpk centromere protein K -2.11 2.00E-04 
15901 Id1 inhibitor of DNA binding 1 -2.12 0 
68298 Ncapd2 non-SMC condensin I complex, subunit D2 -2.12 5.00E-04 
19361 Rad51 RAD51 homolog -2.12 0 
77630 Prdm8 PR domain containing 8 -2.15 0 
20197 S100a3 S100 calcium binding protein A3 -2.15 0.007 
14137 Fdft1 farnesyl diphosphate farnesyl transferase 1 -2.16 0 
20198 S100a4 S100 calcium binding protein A4 -2.16 0.0097 
11777 Ap3s1 adaptor-related protein complex 3, sigma 1 subunit -2.17 0 
17217 Mcm4 minichromosome maintenance deficient 4 homolog 
(S. cerevisiae) 
-2.17 0 
277414 Trp53i11 transformation related protein 53 inducible protein 
11 
-2.17 0 
230145 Galnt12 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 12 
-2.18 0 
18817 Plk1 polo-like kinase 1 -2.19 0.006 
67196 Ube2t ubiquitin-conjugating enzyme E2T (putative) -2.19 3.00E-04 
15201 Hells helicase, lymphoid specific -2.2 0 
52076 Tmem38b transmembrane protein 38B -2.2 0 
20893 Bhlhe40 basic helix-loop-helix family, member e40 -2.22 0 
67177 Cdt1 chromatin licensing and DNA replication factor 1 -2.22 0 
233406 Prc1 protein regulator of cytokinesis 1 -2.24 2.00E-04 
51944 Knstrn kinetochore-localized astrin/SPAG5 binding -2.25 0.0028 
74143 Opa1 optic atrophy 1 -2.25 0 
52033 Pbk PDZ binding kinase -2.25 2.00E-04 
67629 Spc24 SPC24, NDC80 kinetochore complex component, 
homolog (S. cerevisiae) 
-2.27 0.0019 
110920 Hspa13 heat shock protein 70 family, member 13 -2.29 0 
21973 Top2a topoisomerase (DNA) II alpha -2.29 4.00E-04 
73804 Kif2c kinesin family member 2C -2.31 0.0024 
12442 Ccnb2 cyclin B2 -2.32 0.0026 
20856 Stc2 stanniocalcin 2 -2.32 0.0066 
110196 Fdps farnesyl diphosphate synthetase -2.33 0 
20708 Serpinb6b serine (or cysteine) peptidase inhibitor, clade B, 
member 6b 
-2.33 0 
73710 Tubb2b tubulin, beta 2B class IIB -2.33 0 
224143 Poglut1 protein O-glucosyltransferase 1 -2.36 0 
224116 Muc20 mucin 20 -2.37 0 
76123 Gpsm2 G-protein signalling modulator 2 (AGS3-like, C. 
elegans) 
-2.4 0.0283 
16551 Kif11 kinesin family member 11 -2.4 0.0037 
21814 Tgfbr3 transforming growth factor, beta receptor III -2.44 0 
227929 Cytip cytohesin 1 interacting protein -2.45 0 
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72415 Sgol1 shugoshin-like 1 (S. pombe) -2.45 0.0057 
11799 Birc5 baculoviral IAP repeat-containing 5 -2.46 0.0124 
17279 Melk maternal embryonic leucine zipper kinase -2.47 0.0013 
219114 Ska3 spindle and kinetochore associated complex subunit 
3 
-2.47 0.0182 
56150 Mad2l1 MAD2 mitotic arrest deficient-like 1 -2.49 3.00E-04 
52570 Ccdc69 coiled-coil domain containing 69 -2.51 0.0025 
12615 Cenpa centromere protein A -2.54 0.0032 
14866 Gstm5 glutathione S-transferase, mu 5 -2.54 0 
18005 Nek2 NIMA (never in mitosis gene a)-related expressed 
kinase 2 
-2.55 0.0078 
54725 Cadm1 cell adhesion molecule 1 -2.56 0 
208628 Kntc1 kinetochore associated 1 -2.61 1.00E-04 
14677 Gnai1 guanine nucleotide binding protein (G protein), 
alpha inhibiting 1 
-2.63 0 
215387 Ncaph non-SMC condensin I complex, subunit H -2.63 5.00E-04 
106347 Ildr1 immunoglobulin-like domain containing receptor 1 -2.67 1.00E-04 
22418 Wnt5a wingless-type MMTV integration site family, 
member 5A 
-2.68 0 
12428 Ccna2 cyclin A2 -2.7 0 
16348 Invs Inversin -2.7 0 
72107 Dscc1 defective in sister chromatid cohesion 1 homolog (S. 
cerevisiae) 
-2.71 0 
14182 Fgfr1 fibroblast growth factor receptor 1 -2.71 0 
17829 Muc1 mucin 1, transmembrane -2.72 0 
70887 Dmrtc1a DMRT-like family C1a -2.76 0.0032 
72119 Tpx2 TPX2, microtubule-associated protein homolog 
(Xenopus laevis) 
-2.77 8.00E-04 
69706 Lrr1 leucine rich repeat protein 1 -2.8 2.00E-04 
17984 Ndn Necdin -2.8 0 
56742 Psrc1 proline/serine-rich coiled-coil 1 -2.81 0 
108907 Nusap1 nucleolar and spindle associated protein 1 -2.83 0.0012 
192193 Edem1 ER degradation enhancer, mannosidase alpha-like 1 -2.84 0 
54392 Ncapg non-SMC condensin I complex, subunit G -2.84 0.0137 
241230 St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 6 
-2.85 0 
17345 Mki67 antigen identified by monoclonal antibody Ki 67 -2.91 0.0173 
94040 Clmn Calmin -2.92 0.0028 
76843 Dtl denticleless homolog (Drosophila) -2.95 0 
20750 Spp1 secreted phosphoprotein 1 -2.95 0 
107995 Cdc20 cell division cycle 20 -2.97 0.0018 
74107 Cep55 centrosomal protein 55 -2.99 6.00E-04 
12728 Clcn5 chloride channel 5 -3.02 0 
15953 Ifi47 interferon gamma inducible protein 47 -3.06 1.00E-04 
66977 Nuf2 NUF2, NDC80 kinetochore complex component, 
homolog (S. cerevisiae) 
-3.12 0.0232 
26357 Abcg2 ATP-binding cassette, sub-family G (WHITE), 
member 2 
-3.13 0 
27384 Akr1c13 aldo-keto reductase family 1, member C13 -3.13 0 
12236 Bub1b budding uninhibited by benzimidazoles 1 homolog, 
beta (S. cerevisiae) 
-3.13 0.0037 
110033 Kif22 kinesin family member 22 -3.18 0.0013 
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12452 Ccng2 cyclin G2 -3.2 0 
17215 Mcm3 minichromosome maintenance deficient 3 (S. 
cerevisiae) 
-3.24 0 
20617 Snca synuclein, alpha -3.33 0 
17076 Ly75 lymphocyte antigen 75 -3.34 0 
17218 Mcm5 minichromosome maintenance deficient 5, cell 
division cycle 46 (S. cerevisiae) 
-3.41 0 
16477 Junb jun B proto-oncogene -3.46 0 
20419 Shcbp1 Shc SH2-domain binding protein 1 -3.49 1.00E-04 
19274 Ptprm protein tyrosine phosphatase, receptor type, M -3.52 0 
16420 Itgb6 integrin beta 6 -3.53 0 
20349 Sema3e sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3E 
-3.53 0 
21987 Tpd52l1 tumor protein D52-like 1 -3.53 0 
319468 Ppm1h protein phosphatase 1H (PP2C domain containing) -3.54 0.001 
76400 Pbp2 phosphatidylethanolamine binding protein 2 -3.55 1.00E-04 
67849 Cdca5 cell division cycle associated 5 -3.61 0 
53416 Stk39 serine/threonine kinase 39 -3.61 0 
12876 Cpe carboxypeptidase E -3.64 0 
240638 Slc16a12 solute carrier family 16 (monocarboxylic acid 
transporters), member 12 
-3.71 0 
68612 Ube2c ubiquitin-conjugating enzyme E2C -3.8 0.0065 
12235 Bub1 budding uninhibited by benzimidazoles 1 homolog 
(S. cerevisiae) 
-3.93 0.005 
353211 Prune2 prune homolog 2 (Drosophila) -3.94 0 
21853 Timeless timeless circadian clock 1 -4.13 7.00E-04 
235534 Pxylp1 2-phosphoxylose phosphatase 1 -4.21 0 
71778 Klhl5 kelch-like 5 -4.32 0 
76131 Depdc1a DEP domain containing 1a -4.53 0.0033 
219228 Pcdh17 protocadherin 17 -4.63 0 
19362 Rad51ap1 RAD51 associated protein 1 -4.79 0 
210027 Slc35f3 solute carrier family 35, member F3 -4.83 0 
21877 Tk1 thymidine kinase 1 -5.08 0.0045 
21825 Thbs1 thrombospondin 1 -5.31 0 
53614 Reck reversion-inducing-cysteine-rich protein with kazal 
motifs 
-5.51 0 
70385 Spdl1 spindle apparatus coiled-coil protein 1 -5.78 0.0034 
16574 Kif5c kinesin family member 5C -6.27 0 
16007 Cyr61 cysteine rich protein 61 -6.39 0 
18452 P4ha2 procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha II polypeptide 
-9.91 1.00E-04 
22634 Plagl1 pleiomorphic adenoma gene-like 1 -10.04 0 
18973 Pole polymerase (DNA directed), epsilon -11.57 0 
19876 Robo1 roundabout homolog 1 (Drosophila) -22.63 0 
18798 Plcb4 phospholipase C, beta 4 -32.41 0 
16979 Lrrn1 leucine rich repeat protein 1, neuronal -98.96 0 
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